HRP20171577T1 - Uporaba t stanica modificiranih himernim receptorom za antigen za liječenje karcinoma - Google Patents

Uporaba t stanica modificiranih himernim receptorom za antigen za liječenje karcinoma Download PDF

Info

Publication number
HRP20171577T1
HRP20171577T1 HRP20171577TT HRP20171577T HRP20171577T1 HR P20171577 T1 HRP20171577 T1 HR P20171577T1 HR P20171577T T HRP20171577T T HR P20171577TT HR P20171577 T HRP20171577 T HR P20171577T HR P20171577 T1 HRP20171577 T1 HR P20171577T1
Authority
HR
Croatia
Prior art keywords
cell
seq
months
use according
human
Prior art date
Application number
HRP20171577TT
Other languages
English (en)
Croatian (hr)
Inventor
Carl H. June
Bruce L. Levine
David L. Porter
Michael D. Kalos
Michael C. Milone
Original Assignee
The Trustees Of The University Of Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46207528&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20171577(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Trustees Of The University Of Pennsylvania filed Critical The Trustees Of The University Of Pennsylvania
Publication of HRP20171577T1 publication Critical patent/HRP20171577T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/075—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70507—CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Developmental Biology & Embryology (AREA)
HRP20171577TT 2010-12-09 2011-12-09 Uporaba t stanica modificiranih himernim receptorom za antigen za liječenje karcinoma HRP20171577T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US42147010P 2010-12-09 2010-12-09
US201161502649P 2011-06-29 2011-06-29
EP11846757.0A EP2649086B1 (en) 2010-12-09 2011-12-09 Use of chimeric antigen receptor-modified t cells to treat cancer
PCT/US2011/064191 WO2012079000A1 (en) 2010-12-09 2011-12-09 Use of chimeric antigen receptor-modified t cells to treat cancer

Publications (1)

Publication Number Publication Date
HRP20171577T1 true HRP20171577T1 (hr) 2017-12-01

Family

ID=46207528

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20171577TT HRP20171577T1 (hr) 2010-12-09 2011-12-09 Uporaba t stanica modificiranih himernim receptorom za antigen za liječenje karcinoma
HRP20182202TT HRP20182202T1 (hr) 2010-12-09 2018-12-31 Upotreba t stanica modificiranih himernim receptorom za antigen za liječenje raka

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20182202TT HRP20182202T1 (hr) 2010-12-09 2018-12-31 Upotreba t stanica modificiranih himernim receptorom za antigen za liječenje raka

Country Status (43)

Country Link
US (15) US9499629B2 (https=)
EP (4) EP3305798A1 (https=)
JP (7) JP5947311B2 (https=)
KR (6) KR102417796B1 (https=)
CN (5) CN108103085B (https=)
AP (1) AP2013006918A0 (https=)
AU (5) AU2011338200B2 (https=)
BR (3) BR122021026169B1 (https=)
CA (1) CA2820681C (https=)
CL (1) CL2013001645A1 (https=)
CO (1) CO6801633A2 (https=)
CR (1) CR20130269A (https=)
CY (3) CY1119760T1 (https=)
DK (2) DK3214091T3 (https=)
DO (1) DOP2013000128A (https=)
EA (2) EA027153B1 (https=)
EC (1) ECSP13012739A (https=)
ES (2) ES2641870T3 (https=)
FR (1) FR19C1006I2 (https=)
GT (1) GT201300150A (https=)
HK (2) HK1243082B (https=)
HR (2) HRP20171577T1 (https=)
HU (4) HUE036872T2 (https=)
IL (1) IL226694B (https=)
LT (4) LT3214091T (https=)
LU (1) LUC00104I2 (https=)
MA (1) MA34813B1 (https=)
MX (3) MX347078B (https=)
MY (2) MY169644A (https=)
NI (1) NI201300051A (https=)
NL (1) NL300967I2 (https=)
NO (2) NO2019007I1 (https=)
NZ (1) NZ612512A (https=)
PE (1) PE20140178A1 (https=)
PH (1) PH12013501201A1 (https=)
PL (2) PL2649086T3 (https=)
PT (2) PT2649086T (https=)
RS (2) RS58100B1 (https=)
SG (2) SG190997A1 (https=)
SI (2) SI3214091T1 (https=)
TR (1) TR201820015T4 (https=)
WO (1) WO2012079000A1 (https=)
ZA (1) ZA201304470B (https=)

Families Citing this family (1408)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2516320C (en) 2003-02-18 2015-05-26 Kevin Slawin Induced activation in dendritic cells
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
WO2008039874A2 (en) 2006-09-26 2008-04-03 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
WO2008039974A2 (en) 2006-09-28 2008-04-03 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
US8450112B2 (en) 2008-04-09 2013-05-28 Maxcyte, Inc. Engineering and delivery of therapeutic compositions of freshly isolated cells
PL2328923T3 (pl) 2008-09-02 2016-06-30 Cedars Sinai Medical Center Epitopy CD133
US8415150B2 (en) * 2009-02-24 2013-04-09 The Trustees Of The University Of Pennsylvania Methods for treating progressive multifocal leukoencephalopathy (PML)
US10426740B1 (en) 2010-08-18 2019-10-01 Avm Biotechnology, Llc Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
CA2815000C (en) 2010-10-22 2024-05-21 Dana-Farber Cancer Institute, Inc. Discovery of regulatory t cells programmed to suppress an immune response
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
ES2625288T3 (es) 2011-04-15 2017-07-19 The Johns Hopkins University Sistema de secuenciación segura
WO2013059593A1 (en) * 2011-10-20 2013-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd22 chimeric antigen receptors
WO2013063419A2 (en) * 2011-10-28 2013-05-02 The Trustees Of The University Of Pennsylvania A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
MX2014010185A (es) 2012-02-22 2014-11-14 Univ Pennsylvania Uso de dominio de señalizacion cd2 en receptores de antigeno quimericos de segunda generacion.
WO2013126712A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
PE20190658A1 (es) 2012-02-24 2019-05-08 Abbvie Stemcentrx Llc Moduladores y metodos de empleo novedosos
US9359447B2 (en) 2012-03-23 2016-06-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin chimeric antigen receptors
EA033110B1 (ru) 2012-04-11 2019-08-30 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерный рецептор антигена, направленный на антиген созревания b-клеток, кодирующая его нуклеиновая кислота, соответствующие экспрессионный вектор, клетка-хозяин, применения и способы
KR102437522B1 (ko) 2012-05-25 2022-08-26 셀렉티스 면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법
LT4461308T (lt) 2012-07-13 2025-06-10 The Trustees Of The University Of Pennsylvania Car priešnavikinio aktyvumo toksiškumo valdymas
KR20150029714A (ko) 2012-07-13 2015-03-18 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 이중특이적 항체의 공-도입에 의한 ｃａｒ 세포의 활성 증강
CN104507537A (zh) * 2012-07-13 2015-04-08 宾夕法尼亚大学董事会 用于调节car t细胞的组合物和方法
AU2013289979A1 (en) * 2012-07-13 2015-01-22 The Trustees Of The University Of Pennsylvania Methods of assessing the suitability of transduced T cells for administration
US20150290244A1 (en) * 2012-07-13 2015-10-15 The Trustees Of The University Of Pennsylvania Use of cart19 to deplete normal b cells to induce tolerance
US20160235787A1 (en) * 2012-07-13 2016-08-18 The Trustees Of The University Of Pennsylvania Epitope Spreading Associated with CAR T-Cells
CA2881981A1 (en) * 2012-08-20 2014-02-27 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
CN104769103B (zh) * 2012-09-04 2018-06-08 塞勒克提斯公司 多链嵌合抗原受体和其用途
CN104955845B (zh) * 2012-09-27 2018-11-16 美国政府(由卫生和人类服务部的部长所代表) 间皮素抗体和引起有效的抗肿瘤活性的方法
WO2014052545A2 (en) 2012-09-28 2014-04-03 Dana-Farber Cancer Institute, Inc. Targeted expansion of qa-1-peptide-specific regulatory cd8 t cells to ameliorate arthritis
WO2014055442A2 (en) * 2012-10-01 2014-04-10 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
US9598489B2 (en) 2012-10-05 2017-03-21 The Trustees Of The Univeristy Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
WO2014055657A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
CN104822705B (zh) 2012-10-24 2019-07-12 美国卫生和人力服务部 M971嵌合抗原受体
AU2013338393C1 (en) 2012-10-29 2024-07-25 The Johns Hopkins University Papanicolaou test for ovarian and endometrial cancers
AU2013204922B2 (en) * 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
AU2015210373B2 (en) * 2012-12-20 2017-04-06 Celgene Corporation Chimeric antigen receptors
EP2934532B1 (en) 2012-12-20 2019-10-23 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
SG11201507026WA (en) * 2013-02-06 2015-10-29 Anthrogenesis Corp Modified t lymphocytes having improved specificity
US10137182B2 (en) 2013-02-14 2018-11-27 Immunocellular Therapeutics, Ltd. Cancer vaccines and vaccination methods
EP4303232A3 (en) 2013-02-15 2024-04-17 The Regents of The University of California Chimeric antigen receptor and methods of use thereof
TW201446794A (zh) 2013-02-20 2014-12-16 Novartis Ag 利用抗－ｃｄ１２３嵌合抗原受體工程化ｔ細胞之初級人類白血病有效靶向
DK2958943T3 (da) 2013-02-20 2019-12-09 Univ Pennsylvania Behandling af cancer ved anvendelse af humaniseret anti-EGFRvIII kimær antigenreceptor
BR112015019909A2 (pt) 2013-02-22 2017-08-29 Abbvie Stemcentrx Llc Conjugados anticorpo-fármaco, composição farmacêutica, usos dos mesmos, e kit
PT2961831T (pt) 2013-02-26 2020-10-12 Memorial Sloan Kettering Cancer Center Composições e métodos para imunoterapêutica
EP3447072A3 (en) * 2013-03-05 2019-05-22 Baylor College of Medicine Engager cells comprising cd3 scfv and an antigen recognition domain that binds a tumor antigen for immunotherapy
US9587237B2 (en) 2013-03-14 2017-03-07 Elwha Llc Compositions, methods, and computer systems related to making and administering modified T cells
WO2014153114A1 (en) * 2013-03-14 2014-09-25 Fred Hutchinson Cancer Research Center Compositions and methods to modify cells for therapeutic objectives
US9499855B2 (en) * 2013-03-14 2016-11-22 Elwha Llc Compositions, methods, and computer systems related to making and administering modified T cells
WO2014151960A2 (en) * 2013-03-14 2014-09-25 Bellicum Pharmaceuticals, Inc. Methods for controlling t cell proliferation
US20150064153A1 (en) 2013-03-15 2015-03-05 The Trustees Of Princeton University High efficiency microfluidic purification of stem cells to improve transplants
EP3569313A1 (en) 2013-03-15 2019-11-20 GPB Scientific, LLC On-chip microfluidic processing of particles
AU2014240083C1 (en) * 2013-03-15 2019-10-24 Celgene Corporation Modified T lymphocytes
US9657105B2 (en) * 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
EP2970426B1 (en) 2013-03-15 2019-08-28 Michael C. Milone Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
US12590955B2 (en) 2013-03-15 2026-03-31 Zeon Corporation Methods and systems for processing particles
WO2015142314A1 (en) 2013-03-15 2015-09-24 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
EP3608022A1 (en) 2013-03-15 2020-02-12 The Trustees of Princeton University Methods and devices for high throughput purification
UY35468A (es) * 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
WO2014160627A1 (en) 2013-03-25 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd276 polypeptides, proteins, and chimeric antigen receptors
CN115028735A (zh) * 2013-05-03 2022-09-09 俄亥俄州创新基金会 Cs1-特异性嵌合抗原受体工程化的免疫效应细胞
US10260038B2 (en) 2013-05-10 2019-04-16 Whitehead Institute For Biomedical Research Protein modification of living cells using sortase
PL3546572T3 (pl) * 2013-05-13 2024-07-22 Cellectis Chimeryczny receptor antygenowy swoisty względem cd19 i jego zastosowania
US11077144B2 (en) 2013-05-13 2021-08-03 Cellectis CD19 specific chimeric antigen receptor and uses thereof
US11311575B2 (en) * 2013-05-13 2022-04-26 Cellectis Methods for engineering highly active T cell for immunotherapy
EP3783098A1 (en) 2013-05-14 2021-02-24 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
AU2014268364A1 (en) 2013-05-24 2015-12-10 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
ES2897579T3 (es) 2013-06-10 2022-03-01 Dana Farber Cancer Inst Inc Métodos y composiciones para reducir la inmunosupresión por células tumorales
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
AU2014312215B2 (en) 2013-08-28 2020-02-27 Abbvie Stemcentrx Llc Site-specific antibody conjugation methods and compositions
KR102271498B1 (ko) 2013-08-30 2021-07-05 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 종양 치료를 위한 키누레닌 고갈 효소의 투여
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
CN105813654B (zh) 2013-10-11 2019-05-31 美国政府(由卫生和人类服务部的部长所代表) Tem8抗体及其用途
KR102339240B1 (ko) 2013-10-15 2021-12-15 더 스크립스 리서치 인스티튜트 펩타이드 키메라 항원 수용체 t 세포 스위치 및 이의 용도
EP3057991B8 (en) * 2013-10-15 2019-09-04 The Scripps Research Institute Chimeric antigen receptor t cell switches and uses thereof
US10144770B2 (en) * 2013-10-17 2018-12-04 National University Of Singapore Chimeric receptors and uses thereof in immune therapy
EP3057986B1 (en) * 2013-10-17 2017-12-27 National University of Singapore Chimeric receptor that triggers antibody-dependent cell cytotoxicity against multiple tumors
CN104561069A (zh) * 2013-10-23 2015-04-29 深圳先进技术研究院 含重组嵌合抗原受体基因表达盒的微环dna重组母质粒、含该表达盒的微环dna及应用
WO2015069922A2 (en) 2013-11-06 2015-05-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Alk antibodies, conjugates, and chimeric antigen receptors, and their use
CN105899232A (zh) * 2013-11-13 2016-08-24 诺华股份有限公司 用于增强免疫应答的mTOR抑制剂
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
US10246505B2 (en) 2013-11-25 2019-04-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors to control HIV infection
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
JP6943568B2 (ja) 2013-12-06 2021-10-06 アメリカ合衆国 胸腺間質性リンパ球新生因子受容体特異的キメラ抗原受容体及びそれを使用する方法
ES2918501T3 (es) 2013-12-19 2022-07-18 Novartis Ag Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
US10287354B2 (en) 2013-12-20 2019-05-14 Novartis Ag Regulatable chimeric antigen receptor
EP3082853A2 (en) 2013-12-20 2016-10-26 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
CN113354744A (zh) 2013-12-20 2021-09-07 弗雷德哈钦森癌症研究中心 带标签的嵌合效应分子及其受体
WO2015092024A2 (en) * 2013-12-20 2015-06-25 Cellectis Method of engineering multi-input signal sensitive t cell for immunotherapy
WO2015103549A1 (en) 2014-01-03 2015-07-09 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
US20160333108A1 (en) * 2014-01-13 2016-11-17 Stephen J. Forman CHIMERIC ANTIGEN RECEPTORS (CARs) HAVING MUTATIONS IN THE FC SPACER REGION AND METHODS FOR THEIR USE
US11028143B2 (en) 2014-01-21 2021-06-08 Novartis Ag Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules
SG10201900002QA (en) 2014-01-24 2019-02-27 Dana Farber Cancer Institue Inc Antibody molecules to pd-1 and uses thereof
EP3099717B1 (en) 2014-01-31 2019-03-27 Novartis AG Antibody molecules to tim-3 and uses thereof
ES2792849T3 (es) * 2014-02-10 2020-11-12 Univ Emory Expresión de polipéptido químico con receptores de linfocitos variables en células inmunes y usos para tratar el cáncer
ES3063961T3 (en) * 2014-02-14 2026-04-21 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
EP3656864A1 (en) 2014-02-14 2020-05-27 Board of Regents, The University of Texas System Chimeric antigen receptors and methods of making
US10934346B2 (en) * 2014-02-14 2021-03-02 Bellicum Pharmaceuticals, Inc. Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12
CA2939093A1 (en) 2014-02-14 2015-08-20 Immune Design Corp. Immunotherapy of cancer through combination of local and systemic immune stimulation
US10196608B2 (en) 2014-02-21 2019-02-05 Cellectis Method for in situ inhibition of regulatory T cells
PE20161209A1 (es) 2014-02-21 2016-11-10 Abbvie Stemcentrx Llc Conjugados de anticuerpos anti-drosophila similar a delta 3 (anti-dll3) y medicamentos para usarse en el tratamiento contra melanoma
CN106279434B (zh) * 2014-02-24 2020-07-03 西比曼生物科技（上海）有限公司 工程化cd20靶向性的nkt细胞及其制备方法和应用
JP2017507950A (ja) 2014-02-27 2017-03-23 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ レチノイン酸受容体関連オーファン受容体ガンマのアゴニストを使用する養子細胞療法及び関連治療方法
CN104877028A (zh) * 2014-02-28 2015-09-02 百奥迈科生物技术有限公司 抗dota嵌合抗原受体修饰的t细胞及其抗肿瘤的应用
CN112094347A (zh) * 2014-03-05 2020-12-18 奥托路斯有限公司 具有针对T细胞受体beta恒定区的抗原结合域的嵌合抗原受体(CAR)
US20230027993A1 (en) 2014-03-05 2023-01-26 Autolus Limited Methods
US11385233B2 (en) 2015-03-05 2022-07-12 Autolus Limited Methods of depleting malignant T-cells
GB201403972D0 (en) 2014-03-06 2014-04-23 Ucl Business Plc Chimeric antigen receptor
US20150259420A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
WO2015143224A1 (en) * 2014-03-19 2015-09-24 Ambrx, Inc. Chimeric antigen receptor-modified t-cells
CA2943008C (en) * 2014-03-19 2021-03-30 Cellectis Cd123 specific chimeric antigen receptors for cancer immunotherapy
TWI731535B (zh) 2014-03-21 2021-06-21 美商艾伯維有限公司 抗-egfr抗體及抗體藥物結合物
EP3126390B2 (en) * 2014-04-03 2026-01-07 Cellectis Cd33 specific chimeric antigen receptors for cancer immunotherapy
AU2015244039B2 (en) 2014-04-07 2021-10-21 Novartis Ag Treatment of cancer using anti-CD19 chimeric antigen receptor
CN106414726A (zh) 2014-04-07 2017-02-15 米纳瓦生物技术公司 抗nme抗体
CA2945320A1 (en) 2014-04-10 2015-10-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Drug regulated transgene expression
WO2015158671A1 (en) * 2014-04-14 2015-10-22 Cellectis Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
RU2763795C2 (ru) 2014-04-23 2022-01-11 Джуно Терапьютикс, Инк. Способы выделения, культивирования и генетической инженерии популяций клеток иммунной системы для адоптивной терапии
NZ725201A (en) 2014-04-25 2018-05-25 Bluebird Bio Inc Improved methods for manufacturing adoptive cell therapies
US20170049819A1 (en) * 2014-04-25 2017-02-23 Bluebird Bio, Inc. Kappa/lambda chimeric antigen receptors
LT3134432T (lt) * 2014-04-25 2020-04-10 Bluebird Bio, Inc. Mnd promotorius chimerinių antigenų receptoriams
WO2015167766A1 (en) * 2014-04-29 2015-11-05 Seattle Children's Hospital (dba Seattle Children's Research Institute) Ccr5 disruption of cells expressing anti-hiv chimeric antigen receptor (car) derived from broadly neutralizing antibodies
DK3166968T3 (da) * 2014-05-02 2021-12-06 Univ Pennsylvania Sammensætninger og fremgangsmåder til kimæriske autoantistofreceptor-T-celler
GB201407852D0 (en) 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
CN106459173A (zh) 2014-05-02 2017-02-22 爱默蕾大学 人源化可变淋巴细胞受体（vlr）及其相关组合物和用途
JP6523337B2 (ja) 2014-05-05 2019-05-29 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγのアゴニストとしての使用及び疾患治療のためのベンゼンスルホンアミド及び関連化合物
US9896441B2 (en) 2014-05-05 2018-02-20 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
JP6682509B2 (ja) * 2014-05-14 2020-04-15 カースゲン セラピューティクス リミテッドＣａｒｓｇｅｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ キメラ抗原受容体タンパク質をコードする核酸およびキメラ抗原受容体タンパク質を発現するｔリンパ球
AU2015259877B2 (en) 2014-05-15 2021-02-25 National University Of Singapore Modified natural killer cells and uses thereof
US11041021B2 (en) 2014-05-23 2021-06-22 University Of Florida Research Foundation, Incorporated Car based immunotherapy
MX383150B (es) 2014-06-02 2025-03-13 Us Health Receptores quiméricos de antígeno que tienen como diana a cd-19.
SI3151672T1 (sl) 2014-06-06 2021-03-31 Bluebird Bio, Inc. Izboljšani T-celični sestavki
AU2015276131A1 (en) * 2014-06-17 2016-11-17 Cellectis CD123 specific multi-chain chimeric antigen receptor
GB201506423D0 (en) * 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
AU2015289644A1 (en) 2014-07-15 2017-02-02 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
KR20170037625A (ko) 2014-07-21 2017-04-04 노파르티스 아게 Cll-1 키메라 항원 수용체를 사용한 암의 치료
SG10201913765YA (en) 2014-07-21 2020-03-30 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
TWI750110B (zh) 2014-07-21 2021-12-21 瑞士商諾華公司 使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症
WO2016014530A1 (en) 2014-07-21 2016-01-28 Novartis Ag Combinations of low, immune enhancing. doses of mtor inhibitors and cars
MX2017001079A (es) 2014-07-24 2017-09-12 Bluebird Bio Inc Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma).
MX2017001229A (es) * 2014-07-29 2017-05-01 Pfizer Receptores de antigenos quimericos especificos de egfrviii para inmunoterapia de cancer.
KR102048855B1 (ko) * 2014-07-29 2019-11-26 셀렉티스 암 면역요법을 위한 ror1(ntrkr1) 특이적 키메라 항원 수용체
ES2781175T3 (es) 2014-07-31 2020-08-31 Novartis Ag Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico
JP2017522893A (ja) 2014-07-31 2017-08-17 セレクティスＣｅｌｌｅｃｔｉｓ Ｒｏｒ１特異的多重鎖キメラ抗原受容体
CA2958200A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using a gfr alpha-4 chimeric antigen receptor
ES2791248T3 (es) 2014-08-19 2020-11-03 Novartis Ag Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer
AU2015308899B2 (en) 2014-08-27 2020-05-28 Dana-Farber Cancer Institute, Inc. Intracellular osteopontin regulates the lineage commitment of lymphoid subsets
TWI805109B (zh) 2014-08-28 2023-06-11 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
EP2990416B1 (en) * 2014-08-29 2018-06-20 GEMoaB Monoclonals GmbH Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
JP7080053B2 (ja) 2014-08-29 2022-06-03 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 腫瘍の治療のための、キヌレニンを枯渇させる酵素の投与
US10888608B2 (en) 2014-09-02 2021-01-12 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by MyD88 and CD40 polypeptides
ES2777305T5 (en) * 2014-09-04 2025-09-30 Cellectis Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
US20180133252A9 (en) * 2014-09-09 2018-05-17 Unum Therapeutics Inc. Chimeric receptors and uses thereof in immune therapy
ES2771926T3 (es) 2014-09-13 2020-07-07 Novartis Ag Terapias de combinación
KR20250067191A (ko) 2014-09-17 2025-05-14 노파르티스 아게 입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
JP6613304B2 (ja) 2014-09-17 2019-12-04 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 抗ｃｄ２７６抗体（ｂ７ｈ３）
CN107002084B (zh) * 2014-09-19 2021-09-10 希望之城公司 靶向IL13Rα2的共刺激嵌合抗原受体T细胞
US10259855B2 (en) * 2014-10-02 2019-04-16 The Wistar Institute Of Anatomy And Biology Methods and compositions for treating cancer
AU2015327868A1 (en) 2014-10-03 2017-04-20 Novartis Ag Combination therapies
JP2017531430A (ja) * 2014-10-07 2017-10-26 セレクティスＣｅｌｌｅｃｔｉｓ Ｃａｒによって誘導される免疫細胞の活性を調節するための方法
KR20170068504A (ko) 2014-10-08 2017-06-19 노파르티스 아게 키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도
MY167722A (en) * 2014-10-09 2018-09-21 Univ Yamaguchi Car expression vector and car-expressing t cells
ES2753391T3 (es) 2014-10-14 2020-04-08 Halozyme Inc Composiciones de adenosina desaminasa 2 (ADA2), variantes de la misma y métodos de uso de las mismas
BR112017008042A2 (pt) * 2014-10-20 2017-12-26 Juno Therapeutics Inc métodos e composições para dosagem em terapia de célula adotiva
JP6882978B2 (ja) 2014-10-29 2021-06-02 バイスクルアールディー・リミテッド Ｍｔ１−ｍｍｐに特異的な二環性ペプチドリガンド
CN107106609A (zh) 2014-10-31 2017-08-29 宾夕法尼亚大学董事会 刺激和扩展t细胞的组合物和方法
WO2016069282A1 (en) 2014-10-31 2016-05-06 The Trustees Of The University Of Pennsylvania Altering gene expression in modified t cells and uses thereof
CA2964783C (en) 2014-11-05 2024-01-23 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) to selectively target protein complexes
CN107109438B (zh) 2014-11-05 2021-09-03 朱诺治疗学股份有限公司 用于转导及细胞处理的方法
AU2015343013B2 (en) 2014-11-05 2020-07-16 Board Of Regents, The University Of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
WO2016073748A1 (en) * 2014-11-05 2016-05-12 Board Of Regents, The University Of Texas System Biomarkers and targets for cancer immunotherapy
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
IL313511A (en) * 2014-11-12 2024-08-01 Seagen Inc Compounds acting on glycans and methods of using them
CN105601746B (zh) * 2014-11-21 2021-02-19 三生国健药业（上海）股份有限公司 一种嵌合Fc受体的融合蛋白及其制备方法和应用
CA2969456A1 (en) 2014-12-03 2016-06-09 Juno Therapeutics, Inc. Methods and compositions for adoptive cell therapy
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
AU2015357526B2 (en) 2014-12-05 2022-03-17 Eureka Therapeutics, Inc. Chimeric antigen receptors targeting B-cell maturation antigen and uses thereof
EP3227324A4 (en) 2014-12-05 2018-08-29 Memorial Sloan Kettering Cancer Center Antibodies targeting g-protein coupled receptor and methods of use
BR112017011893A2 (pt) 2014-12-05 2018-07-24 City Of Hope células t modificadas no receptor de antígeno quimérico direcionado para cs1
KR20240135036A (ko) 2014-12-05 2024-09-10 메모리얼 슬로안 케터링 캔서 센터 B-세포 성숙화 항원을 표적화하는 항체 및 사용 방법
SI3227339T1 (sl) 2014-12-05 2022-02-28 Memorial Sloan-Kettering Cancer Center Himerni antigenski receptorji, ki ciljajo na receptor, povezan z G-proteinom, in njihova uporaba
CN113968913A (zh) * 2014-12-08 2022-01-25 美国卫生和人力服务部 抗cd70嵌合抗原受体
HK1245326A1 (zh) 2014-12-12 2018-08-24 Voyager Therapeutics, Inc. 用於生产scaav的组合物和方法
EA036379B1 (ru) 2014-12-12 2020-11-02 Блубёрд Био, Инк. Химерные антигенные рецепторы к bcma
EP4400516A1 (en) 2014-12-15 2024-07-17 The Regents of the University of California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
EP3234120B1 (en) 2014-12-15 2025-09-03 The Regents of the University of California Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing
US10993997B2 (en) 2014-12-19 2021-05-04 The Broad Institute, Inc. Methods for profiling the t cell repertoire
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
KR102376244B1 (ko) * 2014-12-24 2022-03-21 오토러스 리미티드 세포
CA3197849A1 (en) * 2014-12-29 2016-07-07 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
MA41346A (fr) 2015-01-12 2017-11-21 Juno Therapeutics Inc Eléments régulateurs post-transcriptionnels d'hépatite modifiée
WO2016115482A1 (en) 2015-01-16 2016-07-21 Novartis Pharma Ag Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor
JP6865688B2 (ja) 2015-01-16 2021-04-28 ジュノー セラピューティクス インコーポレイテッド Ｒｏｒ１に特異的な抗体およびキメラ抗原受容体
ES2869972T3 (es) 2015-01-26 2021-10-26 Cellectis Sistemas de receptores de antígenos quiméricos dirigidos por mAb para clasificar/agotar células inmunitarias genomanipuladas
CN113862292B (zh) * 2015-01-29 2024-12-27 明尼苏达大学董事会 嵌合抗原受体、组合物以及方法
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
CN113713091A (zh) * 2015-02-06 2021-11-30 新加坡国立大学 工程免疫细胞及其用途和生产方法
JP6724023B2 (ja) 2015-02-09 2020-07-15 リサーチ ディベロップメント ファウンデーション 改善された補体活性化を示す操作された免疫グロブリンｆｃポリペプチド
US20160228544A1 (en) * 2015-02-11 2016-08-11 Ensysce Biosciences, Inc. Single Walled Carbon Nanotube Polynucleotide Complexes and Methods Related Thereto
WO2016134284A1 (en) * 2015-02-19 2016-08-25 University Of Florida Research Foundation, Inc. Chimeric antigen receptors and uses thereof
CN107530424A (zh) 2015-02-20 2018-01-02 俄亥俄州国家创新基金会 针对nkg2d和肿瘤相关抗原的二价抗体
MA41613A (fr) * 2015-02-23 2018-01-02 Abbvie Stemcentrx Llc Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs
WO2016138034A1 (en) 2015-02-24 2016-09-01 The Regents Of The University Of California Binding-triggered transcriptional switches and methods of use thereof
EP3804741A3 (en) 2015-02-24 2021-07-14 Board of Regents, The University of Texas System Selection methods for genetically-modified t cells
JP7237449B2 (ja) * 2015-02-27 2023-03-13 アイセル・ジーン・セラピューティクス・エルエルシー 血液系腫瘍を標的としたキメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
KR102133857B1 (ko) * 2015-03-02 2020-07-20 이노베이티브 셀룰러 테라퓨틱스 코퍼레이션 리미티드 Ｐｄ－ｌ１에 의해 유도된 면역관용의 감소
US10195272B2 (en) 2015-03-02 2019-02-05 The Nemours Foundation Adoptive t-cell therapy using FcεRI-based chimeric antigen receptors for treating IgE-mediated allergic diseases
CA2978186A1 (en) * 2015-03-05 2016-09-09 Fred Hutchinson Cancer Research Center Immunomodulatory fusion proteins and uses thereof
WO2016145298A1 (en) 2015-03-12 2016-09-15 The Regents Of The University Of California METHODS FOR TREATING CANCER WITH RORgamma INHIBITORS
WO2016149254A1 (en) * 2015-03-17 2016-09-22 Chimera Bioengineering, Inc. Smart car devices, de car polypeptides, side cars and uses thereof
US10738116B2 (en) 2015-03-19 2020-08-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dual specific anti-CD22-anti-CD19 chimeric antigen receptors
ES2789348T3 (es) 2015-03-20 2020-10-26 Us Health Anticuerpos neutralizantes para GP120 y sus usos
WO2016154621A1 (en) 2015-03-26 2016-09-29 The California Institute For Biomedical Research SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
AU2016243124A1 (en) 2015-03-27 2017-11-02 University Of Southern California CAR T-cell therapy directed to LHR for the treatment of solid tumors
US20190119385A1 (en) * 2015-03-27 2019-04-25 University Of Southern California Hla-g as a novel target for car t-cell immunotherapy
US11261232B2 (en) * 2015-04-02 2022-03-01 Memorial Sloan Kettering Cancer Center TNFRSF14 / HVEM proteins and methods of use thereof
AU2016243026B2 (en) 2015-04-03 2022-03-31 Eureka Therapeutics, Inc. Constructs targeting AFP peptide/MHC complexes and uses thereof
RS61907B1 (sr) 2015-04-06 2021-06-30 Subdomain Llc Polipeptidi koji sadrže de novo vezujući domen i njihova primena
AU2016246457B2 (en) 2015-04-06 2020-10-15 Cytoimmune Therapeutics, Inc. EGFR-directed car therapy for glioblastoma
MX2017012939A (es) 2015-04-08 2018-05-22 Novartis Ag Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
WO2016168773A2 (en) 2015-04-15 2016-10-20 The California Institute For Biomedical Research Optimized pne-based chimeric receptor t cell switches and uses thereof
WO2016166568A1 (en) 2015-04-16 2016-10-20 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells
SG11201708516YA (en) 2015-04-17 2017-11-29 David Maxwell Barrett Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
EP3283508B1 (en) 2015-04-17 2021-03-17 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
EP3288638A1 (en) 2015-04-25 2018-03-07 The General Hospital Corporation Anti-fugetactic agent and anti-cancer agent combination therapy and compositions for the treatment of cancer
EP3288570A4 (en) 2015-04-29 2018-11-21 Fred Hutchinson Cancer Research Center Modified stem cells and uses thereof
WO2016176651A2 (en) * 2015-04-29 2016-11-03 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
GB201507368D0 (en) 2015-04-30 2015-06-17 Ucl Business Plc Cell
WO2016176639A1 (en) * 2015-04-30 2016-11-03 University Of Southern California Secretory tnt car cell immunotherapy
WO2016174652A1 (en) 2015-04-30 2016-11-03 Technion Research & Development Foundation Limited Chimeric antigen receptors and methods of their use
US10925972B2 (en) 2015-05-01 2021-02-23 The Regents Of The University Of California Glycan-dependent immunotherapeutic molecules
JP2018515491A (ja) 2015-05-05 2018-06-14 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγの作動薬及び疾患の療法として使用するジヒドロ−２Ｈ−ベンゾ［ｂ］［１，４］オキサジンスルホンアミド及び関連化合物
CN107667173A (zh) 2015-05-06 2018-02-06 斯尼普技术有限公司 改变微生物种群和改善微生物群
EP3294342A4 (en) 2015-05-08 2018-11-07 President and Fellows of Harvard College Universal donor stem cells and related methods
US20200316231A1 (en) * 2015-05-10 2020-10-08 The Trustees Of The University Of Pennsylvania Compositions And Methods For Imaging Immune Cells
US11253616B2 (en) 2017-09-06 2022-02-22 The Trustees Of The University Of Pennsylvania Small molecules for dual function positron emission tomography (PET) and cell suicide switches
WO2016180467A1 (en) * 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination
EP3294773A1 (en) 2015-05-15 2018-03-21 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
CN107995913B (zh) 2015-05-18 2022-02-11 T细胞受体治疗公司 使用融合蛋白对tcr重编程的组合物和方法
CN108137669B (zh) * 2015-05-18 2023-02-17 优瑞科生物技术公司 抗ror1嵌合抗原受体
US10434153B1 (en) 2015-05-20 2019-10-08 Kim Leslie O'Neill Use of car and bite technology coupled with an scFv from an antibody against human thymidine kinase 1 to specifically target tumors
US10752670B2 (en) 2015-05-20 2020-08-25 Cellectis Anti-GD3 specific chimeric antigen receptors for cancer immunotherapy
TW202523682A (zh) 2015-05-20 2025-06-16 美商博德研究所有限公司 共有之gata3相關之腫瘤特異性新抗原
HK1245095A1 (zh) 2015-05-20 2018-08-24 Novartis Ag 依维莫司(everolimus)与达托里昔布(dactolisib)的医药组合
CA2986755A1 (en) * 2015-05-28 2016-12-01 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
IL295224B2 (en) 2015-05-28 2025-07-01 Kite Pharma Inc Methods of conditioning patients for t cell therapy
MX388325B (es) 2015-05-28 2025-03-19 Kite Pharma Inc Metodos de diagnostico para tratamiento con linfocitos t.
JP6949728B2 (ja) 2015-05-29 2021-10-13 ジュノー セラピューティクス インコーポレイテッド 遺伝子操作された細胞における阻害相互作用を調節するための組成物および方法
EP3303381A1 (en) 2015-05-29 2018-04-11 Fred Hutchinson Cancer Research Center Compositions for cellular immunotherapy
AU2016271124C1 (en) 2015-05-30 2020-05-14 Molecular Templates, Inc. De-immunized, Shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
JP7010473B2 (ja) 2015-06-04 2022-02-10 ユニバーシティ オブ サザン カリフォルニア Ｌｙｍ－１およびｌｙｍ－２標的化ｃａｒ細胞免疫療法
US20160355777A1 (en) * 2015-06-05 2016-12-08 Novartis Ag Flow-through paramagnetic particle-based cell separation and paramagnetic particle removal
KR20180023949A (ko) 2015-06-09 2018-03-07 메모리얼 슬로안-케터링 캔서 센터 인간 hla에 의해 제시된 ebv 잠복성 막 단백질 2a 펩티드에 특이적인 t 세포 수용체-유사 항체 작용제
EP4424326A3 (en) 2015-06-10 2024-11-13 ImmunityBio, Inc. Modified nk-92 cells for treating cancer
KR20180025894A (ko) 2015-06-11 2018-03-09 라이세라 코퍼레이션 Rory의 작용제로서 사용하기 위한 아릴 디히드로-2h-벤조[b][1,4]옥사진 술폰아미드 및 관련 화합물 및 질환의 치료
CN105177031B (zh) * 2015-06-12 2018-04-24 北京艺妙神州医疗科技有限公司 嵌合抗原受体修饰的t细胞及其用途
CN107708741A (zh) * 2015-06-12 2018-02-16 免疫医疗公司 用嵌合抗原受体(car)构建体和表达car构建体的t细胞(car‑t)或nk细胞(car‑nk)进行的疾病疗法
US10639329B2 (en) 2015-06-12 2020-05-05 Lentigen Technology, Inc. Method to treat cancer with engineered T-cells
CA3012607A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Crispr enzymes and systems
FI3909972T3 (fi) 2015-06-19 2024-05-03 Sebastian Kobold Pd1-cd28-fuusioproteiineja ja niiden käyttö lääkkeessä
TWI833684B (zh) 2015-06-25 2024-03-01 美商生物細胞基因治療有限公司 嵌合抗原受體（ｃａｒ）、組合物及其使用方法
US11173179B2 (en) 2015-06-25 2021-11-16 Icell Gene Therapeutics Llc Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
US12577289B2 (en) 2015-06-30 2026-03-17 Arizona Board Of Regents On Behalf Of The University Of Arizona Surrogate co-receptors for t cells and methods of use
WO2017004252A1 (en) 2015-06-30 2017-01-05 The Arizona Board Of Regents On Behalf Of The University Of Arizona Redirected cells with mhc chimeric receptors and methods of use in immunotherapy
EP3320087A4 (en) * 2015-07-08 2019-01-23 The Johns Hopkins University BONE MARROW FILTRATION LYMPHOCYTES (MILS) AS A T-CELL SOURCE FOR CHIMERIC ANTIGEN RECEPTOR (CAR) THERAPY
US11116795B2 (en) * 2015-07-10 2021-09-14 The Trustees Of The University Of Pennsylvania Treatment of a canine CD20 positive disease or condition using a canine CD20-specific chimeric antigen receptor
EP3322801A1 (en) 2015-07-15 2018-05-23 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
AU2016297014B2 (en) 2015-07-21 2021-06-17 Novartis Ag Methods for improving the efficacy and expansion of immune cells
WO2018126369A1 (en) 2017-01-05 2018-07-12 Shanghai Sidansai Biotechnology Co., Ltd Humanized anti-cd19 antibody and use thereof with chimeric antigen receptor
US10493139B2 (en) 2015-07-24 2019-12-03 Innovative Cellular Therapeutics CO., LTD. Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor
RU2766690C2 (ru) 2015-07-28 2022-03-15 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Модифицированные моноциты/макрофаги, экспрессирующие химерные антигенные рецепторы, и их применения
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
GB2592821B (en) 2015-07-31 2022-01-12 Univ Minnesota Modified cells and methods of therapy
KR102011789B1 (ko) * 2015-08-05 2019-08-19 주식회사 셀랩메드 키메라 항원 수용체 및 키메라 항원 수용체가 발현된 t 세포
WO2017027291A1 (en) 2015-08-07 2017-02-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Bispecific car t-cells for solid tumor targeting
EP3331913A1 (en) 2015-08-07 2018-06-13 Novartis AG Treatment of cancer using chimeric cd3 receptor proteins
US11286531B2 (en) 2015-08-11 2022-03-29 The Johns Hopkins University Assaying ovarian cyst fluid
US11352439B2 (en) 2015-08-13 2022-06-07 Kim Leslie O'Neill Macrophage CAR (MOTO-CAR) in immunotherapy
CN106467906B (zh) * 2015-08-20 2019-09-27 北京马力喏生物科技有限公司 构建体、转基因淋巴细胞及其制备方法和用途
US10976232B2 (en) 2015-08-24 2021-04-13 Gpb Scientific, Inc. Methods and devices for multi-step cell purification and concentration
WO2017040324A1 (en) * 2015-08-28 2017-03-09 The Trustees Of The University Of Pennsylvania Methods and compositions for cells expressing a chimeric intracellular signaling molecule
US11649435B2 (en) * 2015-08-28 2023-05-16 The Trustees Of The University Of Pennsylvania Methods and compositions for cells expressing a chimeric intracellular signaling molecule
US10526408B2 (en) 2015-08-28 2020-01-07 Research Development Foundation Engineered antibody FC variants
US11279769B2 (en) 2015-08-31 2022-03-22 Helixmith Co., Ltd Anti-Sialyl Tn chimeric antigen receptors
JP6905163B2 (ja) 2015-09-03 2021-07-21 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア サイトカイン放出症候群を予測するバイオマーカー
EP3347474B1 (en) * 2015-09-11 2020-11-04 Biosceptre (UK) Limited Chimeric antigen receptors and uses thereof
ES2980794T3 (es) 2015-09-15 2024-10-03 Acerta Pharma Bv Combinaciones terapéuticas de un inhibidor de CD19 y un inhibidor de BTK
CN108348545A (zh) * 2015-09-18 2018-07-31 综合医院公司以麻省总医院名义经营 具有抗趋除特性的修饰的t细胞及其用途
US11890348B2 (en) 2015-09-18 2024-02-06 The General Hospital Corporation Localized delivery of anti-fugetactic agent for treatment of cancer
WO2017053556A1 (en) 2015-09-22 2017-03-30 The Trustees Of The University Of Pennsylvania Method of redirecting t cells to treat hiv infection
AU2016326738B2 (en) 2015-09-24 2023-08-31 Abvitro Llc HIV antibody compositions and methods of use
JP7341661B2 (ja) 2015-09-25 2023-09-11 アブビトロ， エルエルシー ネイティブに対合するｔ細胞受容体配列のｔ細胞受容体標的識別のための高スループットプロセス
EP3355937A4 (en) 2015-09-28 2019-04-17 Regents of the University of Minnesota CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS AS THERAPEUTIC INTERVENTIONS AT AUTO AND ALLO IMMUNITY
WO2017058752A1 (en) * 2015-09-28 2017-04-06 Trustees Of Dartmouth College Chimeric antigen receptor anti-inflammatory cells and methods of use
BR112018006991A2 (en) * 2015-10-06 2018-10-16 City Of Hope psca-targeted chimeric antigen receptors
AU2016335750B2 (en) 2015-10-07 2023-05-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia
WO2017059796A1 (en) 2015-10-08 2017-04-13 Shanghai Sidansai Biotechnology Co., Ltd Activation and expansion of t cells
EP4289944A3 (en) * 2015-10-08 2024-03-13 National University Corporation Tokai National Higher Education and Research System Method for preparing genetically-modified t cells which express chimeric antigen receptor
US12241053B2 (en) 2015-10-09 2025-03-04 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
JP6991134B2 (ja) * 2015-10-09 2022-01-12 ガーダント ヘルス， インコーポレイテッド 無細胞ｄｎａを使用する集団ベースの処置レコメンダ
CN114181960B (zh) 2015-10-09 2024-08-23 美天施生物科技有限公司 嵌合抗原受体和使用方法
CN105153315B (zh) * 2015-10-09 2019-04-02 重庆精准生物技术有限公司 免疫抑制受体联合肿瘤抗原嵌合受体及其应用
CN105924530B (zh) * 2015-10-13 2019-08-06 中国人民解放军总医院 嵌合抗原受体及其基因和重组表达载体、car20-nkt细胞及其制备方法和应用
CN106755023A (zh) * 2015-10-15 2017-05-31 中国人民解放军军事医学科学院附属医院 带安全开关的嵌合抗原受体免疫细胞及其制备方法与应用
CN108290939B (zh) 2015-10-16 2023-01-13 纽约市哥伦比亚大学理事会 用于抑制谱系特异性抗原的组合物和方法
AU2016336868B2 (en) 2015-10-16 2022-04-14 Ludwig-Maximilians-Universität München CXCR6-transduced T cells for targeted tumor therapy
EP3365026B1 (en) 2015-10-19 2021-09-22 University of Massachusetts Anti-cancer and anti-inflammatory therapeutics and methods thereof
EP3364969A4 (en) 2015-10-20 2019-07-10 Kite Pharma, Inc. METHOD FOR THE PRODUCTION OF T CELLS FOR T CELL THERAPY
US11248238B2 (en) 2015-10-22 2022-02-15 Juno Therapeutics Gmbh Methods, kits, agents and apparatuses for transduction
SG11201803330WA (en) 2015-10-22 2018-05-30 Juno Therapeutics Gmbh Methods for culturing cells and kits and apparatus for same
JP7194020B2 (ja) 2015-10-22 2022-12-21 ジュノ セラピューティクス ゲーエムベーハー 細胞の培養方法ならびにそのためのキットおよび装置
WO2017070654A1 (en) * 2015-10-23 2017-04-27 Sorrento Therapeutics, Inc. Programmable universal cell receptors and methods of using the same
CN105132445B (zh) * 2015-10-23 2018-10-02 马健颖 一种特异识别肿瘤细胞的受体蛋白、t淋巴细胞及nk细胞
US11059879B2 (en) 2015-10-27 2021-07-13 Board Of Regents, The University Of Texas System Chimeric antigen receptor molecules and uses thereof
WO2017075478A2 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
DK3368571T5 (da) 2015-10-30 2024-09-30 Univ California Transformerende, vækstfaktor-beta-responsive polypeptider og fremgangsmåder til anvendelse deraf
EP4074731A1 (en) * 2015-11-04 2022-10-19 City of Hope Chimeric antigen receptors targeting her2
MX2018005618A (es) * 2015-11-05 2018-08-01 Juno Therapeutics Inc Receptores quimericos que contienen dominios inductores de traf y composiciones y metodos relacionados.
US11020429B2 (en) 2015-11-05 2021-06-01 Juno Therapeutics, Inc. Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
EP3373969A4 (en) 2015-11-12 2019-08-14 Siamab Therapeutics, Inc. GLYCANINTERAGING COMPOUNDS AND METHOD OF USE
CN105331585A (zh) * 2015-11-13 2016-02-17 科济生物医药（上海）有限公司 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞
AU2016355178B9 (en) 2015-11-19 2019-05-30 Massachusetts Institute Of Technology Lymphocyte antigen CD5-like (CD5L)-interleukin 12B (p40) heterodimers in immunity
CN105384826A (zh) * 2015-11-19 2016-03-09 广州熙帝生物科技有限公司 表达嵌合抗原受体的脐血有核细胞及其应用
EP3708587B1 (en) * 2015-11-27 2024-05-22 Cartherics Pty. Ltd. Genetically modified cells and uses thereof
CN108884140B (zh) 2015-12-03 2022-10-25 朱诺治疗学股份有限公司 修饰的嵌合受体及相关组合物和方法
CA3007258A1 (en) 2015-12-03 2017-06-08 Mark L. Bonyhadi Compositions and methods for reducing immune responses against cell therapies
EA201891338A1 (ru) 2015-12-04 2018-12-28 Новартис Аг Композиции и способы для иммуноонкологии
US11090373B2 (en) * 2015-12-04 2021-08-17 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Antigen-specific T cells for inducing immune tolerance
EP4012415A3 (en) 2015-12-04 2022-12-07 Juno Therapeutics, Inc. Methods and compositions related to toxicity associated with cell therapy
US11479755B2 (en) 2015-12-07 2022-10-25 2Seventy Bio, Inc. T cell compositions
CN109069426B (zh) 2015-12-14 2021-10-29 X4 制药有限公司 治疗癌症的方法
WO2017106332A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
EP3393504B1 (en) 2015-12-22 2025-09-24 Novartis AG Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
PL3393468T3 (pl) 2015-12-22 2023-01-23 X4 Pharmaceuticals, Inc. Metody leczenia niedoboru odporności
SG11201805449PA (en) 2015-12-28 2018-07-30 Novartis Ag Methods of making chimeric antigen receptor -expressing cells
AU2016382512A1 (en) 2015-12-30 2018-07-12 Novartis Ag Immune effector cell therapies with enhanced efficacy
JP7068169B2 (ja) 2016-01-08 2022-05-16 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 条件付活性ヘテロ二量体ポリペプチド及びその使用方法
GB201600328D0 (en) 2016-01-08 2016-02-24 Univ Oslo Hf Anti-CD37 chimeric antigen receptors and immune cells expressing them
CN105950645A (zh) * 2016-01-11 2016-09-21 灏灵赛奥（天津）生物科技有限公司 Car-cd19抗原受体的人源化融合基因片段、其构建方法及应用
WO2017123548A1 (en) * 2016-01-14 2017-07-20 Seattle Children's Hospital (dba Seattle Children's Research Institute) Tumor-specific ifna secretion by car t-cells to reprogram the solid tumor microenvironment
US11505599B2 (en) 2016-01-14 2022-11-22 Memorial Sloan-Kettering Cancer Center T cell receptor-like antibodies specific for Foxp3-derived peptides
WO2017123911A1 (en) * 2016-01-15 2017-07-20 The Wistar Institute Of Anatomy And Biology Methods and compositions for treating cancer
EA201891641A1 (ru) 2016-01-21 2019-01-31 Пфайзер Инк. Химерные антигенные рецепторы, нацеленные на вариант iii рецептора эпидермального фактора роста
US10221242B2 (en) 2016-01-21 2019-03-05 Pfizer Inc. Antibodies specific for epidermal growth factor receptor variant III and their uses
CN105567640A (zh) * 2016-01-27 2016-05-11 苏州佰通生物科技有限公司 一种嵌合抗原受体脂肪干细胞及其制备方法
HK1258353A1 (zh) 2016-02-23 2019-11-08 Immune Design Corp. 多基因组逆转录病毒载体制剂及用於制备及使用该制剂的方法和系统
US11542486B2 (en) 2016-03-02 2023-01-03 Board Of Regents, The University Of Texas System Human kynureninase enzyme variants having improved pharmacological properties
AU2017225733A1 (en) 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore
US10563172B2 (en) 2016-03-14 2020-02-18 Wisconsin Alumni Research Foundation Methods of T cell expansion and activation
US20190355459A1 (en) 2016-03-16 2019-11-21 Juno Therapeutics, Inc. Methods for adaptive design of a treatment regimen and related treatments
EP3430548A1 (en) 2016-03-16 2019-01-23 Juno Therapeutics, Inc. Methods for determining dosing of a therapeutic agent and related treatments
KR20240116832A (ko) * 2016-03-17 2024-07-30 고쿠리츠다이가쿠호우진 야마구치 다이가쿠 면역 기능 제어 인자를 발현하는 면역 담당 세포 및 발현 벡터
KR102499191B1 (ko) 2016-03-18 2023-02-13 프레드 허친슨 캔서 센터 Cd20 면역요법을 위한 조성물 및 방법
US12590321B2 (en) 2016-03-19 2026-03-31 Exuma Biotech Corp. Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof
US11325948B2 (en) 2016-03-19 2022-05-10 Exuma Biotech Corp. Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
US11111505B2 (en) 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
KR20190021200A (ko) 2016-03-22 2019-03-05 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 독성을 예방 또는 경감시키기 위한 조기 개재 방법
US11549099B2 (en) 2016-03-23 2023-01-10 Novartis Ag Cell secreted minibodies and uses thereof
CN109219445B (zh) * 2016-04-01 2022-08-26 上海煦顼技术有限公司 嵌合抗原受体修饰细胞治疗癌症的应用
KR20200068750A (ko) 2016-04-01 2020-06-15 카이트 파마 인코포레이티드 키메라 수용체 및 그의 사용 방법
US10654934B2 (en) 2016-04-01 2020-05-19 Innovative Cellular Therapeutics CO., LTD. Use of chimeric antigen receptor modified cells to treat cancer
MY210545A (en) 2016-04-01 2025-09-30 Kite Pharma Inc Chimeric receptors to flt3 and methods of use thereof
CN109414455B (zh) 2016-04-01 2023-01-20 凯德药业股份有限公司 Bcma结合分子及其使用方法
PT3436079T (pt) * 2016-04-01 2021-10-06 Kite Pharma Inc Recetores de antigénios quiméricos e de células t e métodos de uso
CN108778312B (zh) 2016-04-08 2022-07-15 爱默蕾大学 使用基于细胞的疗法治疗癌症和传染病的方法
JP7282521B2 (ja) 2016-04-08 2023-05-29 パーデュー・リサーチ・ファウンデイション Ｃａｒ ｔ細胞療法のための方法および組成物
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
EP3443001B1 (en) 2016-04-11 2025-04-30 Obsidian Therapeutics, Inc. REGULATED BIOCIRCUIT SYSTEMS
CN106399255B (zh) * 2016-04-13 2019-10-18 阿思科力(苏州)生物科技有限公司 Pd-1 car-t细胞及其制备方法和应用
US10188749B2 (en) 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
IL262365B2 (en) 2016-04-15 2024-11-01 Alpine Immune Sciences Inc Immunomodulatory proteins ICOS ligand variants and uses thereof
EP4706777A2 (en) 2016-04-15 2026-03-11 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
MY209117A (en) 2016-04-15 2025-06-23 Novartis Ag Compositions and methods for selective protein expression
EP3446119A1 (en) 2016-04-18 2019-02-27 The Broad Institute Inc. Improved hla epitope prediction
CN105907719B (zh) * 2016-04-18 2019-10-18 阿思科力(苏州)生物科技有限公司 Anti ROBO1 CAR-T细胞及其制备和应用
CN109414512A (zh) 2016-04-22 2019-03-01 科济生物医药（上海）有限公司 用于细胞免疫疗法的组合物和方法
WO2017192536A1 (en) 2016-05-02 2017-11-09 University Of Kansas Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy
CN116850305A (zh) 2016-05-06 2023-10-10 朱诺治疗学股份有限公司 基因工程化细胞及其制备方法
US11261223B2 (en) * 2016-05-11 2022-03-01 The University Of Chicago Methods of treating cancers with CT45 targeted therapies
AU2017268842B2 (en) 2016-05-27 2022-08-11 Aadigen, Llc Peptides and nanoparticles for intracellular delivery of genome-editing molecules
AU2017271606B2 (en) * 2016-05-27 2024-08-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services FLT3-specific chimeric antigen receptors and methods using same
CN105837693A (zh) * 2016-05-30 2016-08-10 李斯文 一种基于bcma的抗原嵌合受体及其制备方法和应用
US20210177896A1 (en) 2016-06-02 2021-06-17 Novartis Ag Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
MX2018014991A (es) 2016-06-03 2019-08-29 Memorial Sloan Kettering Cancer Center Terapias adoptivas de celulas como opciones de tratamiento temprano.
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
MA45341A (fr) 2016-06-06 2019-04-10 Hutchinson Fred Cancer Res Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive
US11390658B2 (en) 2016-06-06 2022-07-19 St. Jude Children's Research Hospital Anti-CD7 chimeric antigen receptor and method of use thereof
EP3458479B1 (en) 2016-06-08 2020-11-04 AbbVie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
SG11201810640RA (en) 2016-06-08 2018-12-28 Intrexon Corp Cd33 specific chimeric antigen receptors
JP2019526529A (ja) 2016-06-08 2019-09-19 アッヴィ・インコーポレイテッド 抗ｂ７−ｈ３抗体及び抗体薬物コンジュゲート
EP3469000A1 (en) 2016-06-08 2019-04-17 AbbVie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
BR112018075630A2 (pt) 2016-06-08 2019-03-19 Abbvie Inc. anticorpos anti-cd98 e conjugados de fármaco de anticorpo
CN116173232A (zh) 2016-06-08 2023-05-30 艾伯维公司 抗cd98抗体及抗体药物偶联物
BR112018075644A2 (pt) 2016-06-08 2019-04-09 Abbvie Inc. anticorpos anti-cd98 e conjugados de anticorpo e fármaco
CN107523545A (zh) * 2016-06-20 2017-12-29 上海细胞治疗研究院 一种高效稳定表达抗体的杀伤性细胞及其用途
ES2870920T3 (es) 2016-06-21 2021-10-28 X4 Pharmaceuticals Inc Inhibidores de CXCR4 y usos de los mismos
CN109640988A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
WO2017223243A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
CN106117367B (zh) * 2016-06-24 2020-02-11 安徽未名细胞治疗有限公司 一种her-3特异性嵌合抗原受体及其应用
JP7114490B2 (ja) 2016-06-24 2022-08-08 アイセル・ジーン・セラピューティクス・エルエルシー キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
MA45491A (fr) 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
WO2018005559A1 (en) 2016-06-27 2018-01-04 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
CN109476749A (zh) 2016-06-30 2019-03-15 豪夫迈·罗氏有限公司 改良的过继性t细胞疗法
TWI691510B (zh) 2016-07-12 2020-04-21 美商凱特製藥公司 抗原結合分子和使用彼之方法
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
GB2567093A (en) 2016-07-15 2019-04-03 Viracta Therapeutics Inc Histone deacetylase inhibitors for use in immunotherapy
US20190336504A1 (en) 2016-07-15 2019-11-07 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
AU2017299854A1 (en) * 2016-07-18 2019-01-31 Helix Biopharma Corp. CAR immune cells directed to carcinoembryonic antigen related cell adhesion molecule 6 to treat cancer
EP3487878A4 (en) 2016-07-20 2020-03-25 University of Utah Research Foundation CD229-CAR-T CELLS AND METHOD FOR USE THEREOF
US11384156B2 (en) 2016-07-25 2022-07-12 The Nemours Foundation Adoptive T-cell therapy using EMPD-specific chimeric antigen receptors for treating IgE-mediated allergic diseases
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
CN110088127A (zh) 2016-07-28 2019-08-02 高山免疫科学股份有限公司 Cd155变体免疫调节蛋白及其用途
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
BR112019001570A2 (pt) 2016-07-28 2019-07-09 Novartis Ag terapias de combinação de receptores de antígeno quiméricos e inibidores de pd-1
US20240018268A1 (en) 2016-07-29 2024-01-18 Juno Therapeutics, Inc. Anti-idiotypic antibodies against anti-cd19 antibodies
JP7483373B2 (ja) 2016-07-29 2024-05-15 ジュノー セラピューティクス インコーポレイテッド 複製可能ウイルスの存在または非存在を評価するための方法
MA45779A (fr) 2016-07-29 2019-06-05 Juno Therapeutics Inc Polypeptides immunomdulateurs et compositions et procédés associés
US20190161542A1 (en) 2016-08-01 2019-05-30 Novartis Ag Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
EP3494138A1 (en) 2016-08-02 2019-06-12 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
US11078481B1 (en) 2016-08-03 2021-08-03 KSQ Therapeutics, Inc. Methods for screening for cancer targets
US11630103B2 (en) 2016-08-17 2023-04-18 The Broad Institute, Inc. Product and methods useful for modulating and evaluating immune responses
EP4342978A3 (en) 2016-09-01 2024-07-03 Chimera Bioengineering Inc. Gold optimized car t-cells
EP4282969A3 (en) 2016-09-02 2024-01-31 Lentigen Technology, Inc. Compositions and methods for treating cancer with duocars
US11078483B1 (en) 2016-09-02 2021-08-03 KSQ Therapeutics, Inc. Methods for measuring and improving CRISPR reagent function
JP2019530440A (ja) 2016-09-02 2019-10-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア インターロイキン６受容体α結合単鎖可変断片を含む方法および組成物
US20190262399A1 (en) 2016-09-07 2019-08-29 The Broad Institute, Inc. Compositions and methods for evaluating and modulating immune responses
BR112019004662A2 (pt) 2016-09-12 2019-05-28 Juno Therapeutics Inc conjuntos de sacos de biorreator de perfusão
CA3037518A1 (en) 2016-09-21 2018-03-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptor (car) that targets chemokine receptor ccr4 and its use
JP2020501512A (ja) * 2016-09-23 2020-01-23 ユニバーシティ オブ サザン カリフォルニア キメラ抗原受容体およびその組成物ならびにそれらの使用の方法
WO2018064208A1 (en) 2016-09-28 2018-04-05 The Broad Institute, Inc. Systematic screening and mapping of regulatory elements in non-coding genomic regions, methods, compositions, and applications thereof
ES3013602T3 (en) 2016-09-28 2025-04-14 Kite Pharma Inc Antigen binding molecules and methods of use thereof
EP4353319A3 (en) 2016-09-28 2024-06-05 Atossa Therapeutics, Inc. Methods of adoptive cell therapy
CN110139873A (zh) 2016-10-03 2019-08-16 朱诺治疗学股份有限公司 Hpv特异性结合分子
CA3036745A1 (en) 2016-10-07 2018-04-12 TCR2 Therapeutics Inc. Compositions and methods for t-cell receptors reprogramming using fusion proteins
EP3523331A1 (en) 2016-10-07 2019-08-14 Novartis AG Chimeric antigen receptors for the treatment of cancer
US12447213B2 (en) 2016-10-07 2025-10-21 The Broad Institute, Inc. Modulation of novel immune checkpoint targets
CN107151654B (zh) * 2016-10-11 2020-05-05 深圳宾德生物技术有限公司 一种人源t淋巴细胞的培养基及其制备方法和应用
CN107936120B (zh) * 2016-10-13 2021-03-09 上海赛比曼生物科技有限公司 Cd19靶向性的嵌合抗原受体及其制法和应用
BR112019006652A2 (pt) 2016-10-13 2019-07-02 Juno Therapeutics Inc métodos e composições para imunoterapia envolvendo moduladores da via metabólica do triptofano
JP7181862B2 (ja) 2016-10-18 2022-12-01 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 腫瘍浸潤リンパ球および治療の方法
CN110267982B (zh) 2016-10-19 2024-02-23 斯克利普斯研究所 具有人源化靶向部分和/或经过优化的嵌合抗原受体相互作用结构域的嵌合抗原受体效应细胞开关以及其用途
CA3040296A1 (en) 2016-10-20 2018-04-26 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
WO2018075820A2 (en) 2016-10-20 2018-04-26 Celgene Corporation Cereblon-based heterodimerizable chimeric antigen receptors
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
AU2017355544A1 (en) 2016-11-03 2019-05-16 Juno Therapeutics, Inc. Combination therapy of a T cell therapy and a BTK inhibitor
US20190292246A1 (en) 2016-11-03 2019-09-26 Juno Therapeutics, Inc. Combination therapy of a cell based therapy and a microglia imhibitor
KR20240005168A (ko) 2016-11-04 2024-01-11 2세븐티 바이오, 인코포레이티드 항-bcma car t 세포 조성물
WO2018089386A1 (en) 2016-11-11 2018-05-17 The Broad Institute, Inc. Modulation of intestinal epithelial cell differentiation, maintenance and/or function through t cell action
US11261428B2 (en) 2018-03-15 2022-03-01 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
US11332713B2 (en) 2016-11-16 2022-05-17 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
EP3541847A4 (en) 2016-11-17 2020-07-08 Seattle Genetics, Inc. COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
SG11201903830TA (en) * 2016-11-22 2019-05-30 Nat Univ Singapore Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
US11851491B2 (en) 2016-11-22 2023-12-26 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
CN110114070A (zh) 2016-11-23 2019-08-09 诺华公司 使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法
AU2017368320A1 (en) * 2016-12-02 2019-05-02 Cartesian Therapeutics, Inc. Cancer immuno therapy with highly enriched CD8+ chimeric antigen receptor T cells
BR112019011065A2 (pt) 2016-12-03 2019-10-01 Juno Therapeutics Inc métodos para determinação da dosagem de células t car
AU2017368332A1 (en) 2016-12-03 2019-06-13 Juno Therapeutics, Inc. Methods for modulation of CAR-T cells
MA46995A (fr) 2016-12-03 2019-10-09 Acerta Pharma Bv Méthodes et compositions pour l'utilisation de lymphocytes t thérapeutiques en association avec des inhibiteurs de kinase
AU2017370644A1 (en) 2016-12-05 2019-06-13 Juno Therapeutics, Inc. Production of engineered cells for adoptive cell therapy
CN108165568B (zh) * 2016-12-07 2020-12-08 上海恒润达生生物科技有限公司 一种培养CD19CAR-iNKT细胞方法及用途
CN107058315B (zh) * 2016-12-08 2019-11-08 上海优卡迪生物医药科技有限公司 敲减人PD-1的siRNA、重组表达CAR-T载体及其构建方法和应用
CN110291200B (zh) 2016-12-12 2024-05-14 西雅图儿童医院（Dba西雅图儿童研究所） 对哺乳动物细胞中转基因表达的药剂配体诱导具有增大的灵敏度的嵌合转录因子变异体
CN108218994A (zh) * 2016-12-14 2018-06-29 上海恒润达生生物科技有限公司 一种方法培养t记忆干细胞
AU2017378482B2 (en) 2016-12-16 2024-06-13 R&D Systems, Inc. Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
US11278570B2 (en) 2016-12-16 2022-03-22 B-Mogen Biotechnologies, Inc. Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
CN108276493B (zh) * 2016-12-30 2023-11-14 南京传奇生物科技有限公司 一种嵌合抗原受体及其应用
WO2018119518A1 (en) 2017-01-01 2018-07-05 Lee Chi Yu Gregory Rp215 chimeric antigen receptor construct and methods of making and using same
JP7348063B2 (ja) 2017-01-05 2023-09-20 フレッド ハッチンソン キャンサー センター ワクチン効力を改善するためのシステム及び方法
EP3565638B8 (en) 2017-01-06 2024-04-10 BicycleRD Limited Bicycle conjugate for treating cancer
CA3049165A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
BR112019013940A2 (pt) 2017-01-06 2020-02-11 Iovance Biotherapeutics, Inc. Método de tratar um câncer com uma população de linfócitos infiltrantes de tumor, processo para preparação de uma população de linfócitos infiltrantes de tumor, população de linfócitos infiltrantes de tumor, e, composição farmacêutica.
EP3346001A1 (en) * 2017-01-06 2018-07-11 TXCell Monospecific regulatory t cell population with cytotoxicity for b cells
CN108285920A (zh) * 2017-01-09 2018-07-17 上海恒润达生生物科技有限公司 一种体内检测cart细胞表达的技术及其用途
MX2019008227A (es) 2017-01-10 2020-08-17 Juno Therapeutics Inc Analisis epigenetico de terapia celular y metodos relacionados.
GB201700553D0 (en) 2017-01-12 2017-03-01 Genagon Therapeutics Ab Therapeutic agents
WO2018132695A1 (en) * 2017-01-13 2018-07-19 Celdara Medical, Llc Chimeric antigen receptors targeting tim-1
MX2019008538A (es) 2017-01-20 2019-11-05 Juno Therapeutics Gmbh Conjugados de superficie celular y composiciones y métodos celulares relacionados.
WO2018140391A1 (en) 2017-01-24 2018-08-02 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
CN108342363B (zh) * 2017-01-25 2021-02-12 北京马力喏生物科技有限公司 共表达抗msln嵌合抗原受体和免疫检查点抑制分子的转基因淋巴细胞及其用途
EP4043485A1 (en) 2017-01-26 2022-08-17 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
RU2674894C2 (ru) * 2017-01-30 2018-12-13 Общество с ограниченной ответственностью "ПЛАНТА" Новые люциферазы и способы их использования
WO2018144597A1 (en) * 2017-01-31 2018-08-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods of sensitizing cancer cells to immune cell killing
CN110582509A (zh) 2017-01-31 2019-12-17 诺华股份有限公司 使用具有多特异性的嵌合t细胞受体蛋白治疗癌症
CN110612119B (zh) 2017-02-07 2024-10-29 西雅图儿童医院（Dba西雅图儿童研究所） 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂
CN108395482B (zh) 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
WO2018148671A1 (en) 2017-02-12 2018-08-16 Neon Therapeutics, Inc. Hla-based methods and compositions and uses thereof
PT3583129T (pt) * 2017-02-14 2021-12-14 Kite Pharma Inc Moléculas de ligação a cd70 e seus métodos de uso
IL268349B2 (en) 2017-02-17 2024-08-01 Hutchinson Fred Cancer Res Combination therapies for treatment of bcma-related cancers and autoimmune disorders
US12163952B2 (en) 2017-02-27 2024-12-10 Juno Therapeutics, Inc. Determining toxicity risk in CAR T-cell therapy
WO2018157072A1 (en) 2017-02-27 2018-08-30 Life Technologies Corporation Expansion of populations of t cells by the use of modified serum free media
JP7178355B2 (ja) 2017-02-28 2022-11-25 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞療法のための組成物および方法
EP3589647A1 (en) 2017-02-28 2020-01-08 Novartis AG Shp inhibitor compositions and uses for chimeric antigen receptor therapy
KR102746901B1 (ko) 2017-03-03 2024-12-26 옵시디안 테라퓨틱스, 인크. Cd19 조성물 및 면역요법을 위한 방법
CA3055200A1 (en) 2017-03-03 2018-09-07 Obsidian Therapeutics, Inc. Compositions and methods for immunotherapy
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
KR102653141B1 (ko) 2017-03-03 2024-04-01 씨젠 인크. 글리칸-상호작용 화합물 및 사용 방법
WO2018169922A2 (en) 2017-03-13 2018-09-20 Kite Pharma, Inc. Chimeric antigen receptors for melanoma and uses thereof
SG11201908271WA (en) 2017-03-14 2019-10-30 Juno Therapeutics Inc Methods for cryogenic storage
PT3596116T (pt) 2017-03-16 2023-12-04 Alpine Immune Sciences Inc Proteínas imunomoduladoras de pd-l1 variante e suas utilizações
EP3596114A2 (en) 2017-03-16 2020-01-22 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
JP2020511144A (ja) 2017-03-16 2020-04-16 アルパイン イミューン サイエンシズ インコーポレイテッド Ｐｄ−ｌ２バリアント免疫調節タンパク質及びその使用
AU2018236461B2 (en) 2017-03-17 2025-03-27 Fred Hutchinson Cancer Center Immunomodulatory fusion proteins and uses thereof
WO2018175636A2 (en) 2017-03-22 2018-09-27 Novartis Ag Compositions and methods for immunooncology
JP2020515542A (ja) 2017-03-23 2020-05-28 ザ ジェネラル ホスピタル コーポレイション Ｃｘｃｒ４／ｃｘｃｒ７の遮断およびヒトパピローマウイルス関連疾患の治療
JP7137896B2 (ja) * 2017-03-24 2022-09-15 レンティジェン・テクノロジー・インコーポレイテッド 抗ｃｄ３３免疫療法によりがんを処置するための組成物および方法
MX2019011570A (es) 2017-03-27 2019-11-18 Nat Univ Singapore Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales.
KR102660336B1 (ko) 2017-03-27 2024-04-26 내셔널 유니버시티 오브 싱가포르 절단된 nkg2d 키메라 수용체 및 자연 살해 세포 면역요법에서의 그의 용도
WO2018183888A2 (en) 2017-03-31 2018-10-04 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling
WO2018183908A1 (en) 2017-03-31 2018-10-04 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating ovarian tumors
EP3490605B1 (en) 2017-04-01 2023-06-07 AVM Biotechnology, LLC Replacement of cytotoxic preconditioning before cellular immunotherapy
EP3606518A4 (en) 2017-04-01 2021-04-07 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR DETECTION AND MODULATION OF IMMUNOTHERAPY RESISTANCE GENE SIGNATURE IN CANCER
US12303561B2 (en) 2017-04-03 2025-05-20 Biontech Us Inc. Protein antigens and uses thereof
AU2018250148B2 (en) 2017-04-03 2021-09-23 Kite Pharma, Inc. Treatment using chimeric receptor T cells incorporating optimized polyfunctional T cells
EP3607319A1 (en) 2017-04-07 2020-02-12 Juno Therapeutics, Inc. Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
WO2018191558A1 (en) 2017-04-12 2018-10-18 The Broad Institute, Inc. Modulation of epithelial cell differentiation, maintenance and/or function through t cell action, and markers and methods of use thereof
US20200071773A1 (en) 2017-04-12 2020-03-05 Massachusetts Eye And Ear Infirmary Tumor signature for metastasis, compositions of matter methods of use thereof
CN110709700A (zh) 2017-04-14 2020-01-17 朱诺治疗学股份有限公司 评估细胞表面糖基化的方法
US11753434B2 (en) 2017-04-14 2023-09-12 Dana-Farber Cancer Institute, Inc. Compositions and methods for transient gene therapy with enhanced stability
CN108727497A (zh) * 2017-04-17 2018-11-02 沈阳美达博生物科技有限公司 一种cd19抗体及其应用
WO2018195175A1 (en) 2017-04-18 2018-10-25 FUJIFILM Cellular Dynamics, Inc. Antigen-specific immune effector cells
US20210293783A1 (en) 2017-04-18 2021-09-23 The General Hospital Corporation Compositions for detecting secretion and methods of use
WO2018195339A1 (en) 2017-04-19 2018-10-25 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
WO2018195397A2 (en) 2017-04-21 2018-10-25 Kyn Therapeutics Indole ahr inhibitors and uses thereof
SG10201912400VA (en) 2017-04-24 2020-02-27 Kite Pharma Inc Humanized antigen-binding domains against cd19 and methods of use
JP7339160B2 (ja) 2017-04-27 2023-09-05 ジュノ セラピューティクス ゲーエムベーハー オリゴマー粒子試薬およびその使用方法
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
US20200078404A1 (en) 2017-05-01 2020-03-12 Juno Therapeutics, Inc. Combination of a cell therapy and an immunomodulatory compound
CN107226867B (zh) * 2017-07-25 2018-02-06 重庆精准生物技术有限公司 抗人cd19抗原的嵌合抗原受体及其应用
WO2018201794A1 (zh) * 2017-05-02 2018-11-08 重庆精准生物技术有限公司 抗人cd19抗原的嵌合抗原受体及其应用
US20200224161A1 (en) * 2017-05-10 2020-07-16 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
EP3622092A4 (en) 2017-05-11 2021-06-23 The Broad Institute, Inc. METHODS AND COMPOSITIONS OF USE OF CD8 + TUMOR-INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
MX2019013514A (es) 2017-05-12 2020-01-20 Crispr Therapeutics Ag Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia.
AU2018269194B2 (en) 2017-05-15 2025-05-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bicistronic chimeric antigen receptors and their uses
US10415017B2 (en) 2017-05-17 2019-09-17 Thunder Biotech, Inc. Transgenic macrophages, chimeric antigen receptors, and associated methods
EP3625342B1 (en) 2017-05-18 2022-08-24 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
EP3406733A1 (en) 2017-05-24 2018-11-28 SIB Swiss Institute of Bioinformatics Kinase mutants and uses thereof
BR112019024719A2 (pt) 2017-05-24 2020-06-16 Effector Therapeutics, Inc. Composições e métodos para resposta imunológica antitumor aprimorada
JP7187486B2 (ja) 2017-05-25 2022-12-12 レイドス， インコーポレイテッド Ｐｄ－１およびｃｔｌａ－４二重インヒビターペプチド
TWI862477B (zh) 2017-05-26 2024-11-21 美商凱特製藥公司 製備和使用胚胎間充質先驅細胞的方法
CA3065126A1 (en) 2017-06-01 2018-12-06 Innovative Cellular Therapeutics CO., LTD. Chimeric antigen receptor cell preparation and uses thereof
CN111201438A (zh) 2017-06-02 2020-05-26 朱诺治疗学股份有限公司 与和细胞疗法相关的毒性有关的制品和方法
AU2018275894B2 (en) 2017-06-02 2025-04-24 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
WO2018222898A1 (en) * 2017-06-02 2018-12-06 Mayo Foundation For Medical Education And Research System and method for providing clinical outcomes driven expertise for disease treatment
US12384830B2 (en) 2017-06-02 2025-08-12 Regents Of The University Of Minnesota Compositions and methods for improving immunotherapy
KR20200015717A (ko) 2017-06-09 2020-02-12 프로비던스 헬스 앤드 서비시즈 - 오레곤 암 치료를 위한 인간 종양 반응성 t 세포의 확인을 위한 cd39 및 cd103의 활용
WO2018232195A1 (en) 2017-06-14 2018-12-20 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
HRP20210567T1 (hr) 2017-06-20 2021-09-03 Institut Curie Imune stanice kojima nedostaje suv39hl
AU2018289428B2 (en) 2017-06-21 2024-06-27 The General Hospital Corporation Methods and compositions for chimeric antigen receptor targeting cancer cells
CA3287539A1 (en) 2017-06-21 2026-03-02 Icell Gene Therapeutics Llc CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF
CN118307674A (zh) 2017-06-22 2024-07-09 诺华股份有限公司 针对cd73的抗体分子及其用途
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
CA3068286A1 (en) 2017-06-22 2018-12-27 Board Of Regents, The University Of Texas System Methods for producing regulatory immune cells and uses thereof
JP7301757B2 (ja) 2017-06-26 2023-07-03 バイスクルアールディー・リミテッド 検出可能部分を持つ二環式ペプチドリガンドおよびその使用
SG11201912240QA (en) 2017-06-28 2020-01-30 Regeneron Pharma Anti-human papillomavirus (hpv) antigen-binding proteins and methods of use thereof
EP3644721A1 (en) 2017-06-29 2020-05-06 Juno Therapeutics, Inc. Mouse model for assessing toxicities associated with immunotherapies
WO2019006418A2 (en) 2017-06-30 2019-01-03 Intima Bioscience, Inc. ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
US12144825B2 (en) 2017-06-30 2024-11-19 Cellectis Cellular immunotherapy for repetitive administration
US11235004B2 (en) 2017-06-30 2022-02-01 Innovative Cellular Therapeutics Holdings, Ltd. Lymphocyte cell lines and uses thereof
CN107287164A (zh) * 2017-07-07 2017-10-24 青岛协和华美医学诊断技术有限公司 靶向cd19的嵌合抗原受体t细胞、制备方法及应用
JP7141725B2 (ja) 2017-07-07 2022-09-26 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド 変異ｃｄ２８共刺激ドメインを有するキメラ抗原受容体
CN107365798B (zh) * 2017-07-13 2020-07-14 山东省齐鲁细胞治疗工程技术有限公司 一种携带iCasp9自杀基因的CD19-CAR-T细胞及其应用
US12049643B2 (en) 2017-07-14 2024-07-30 The Broad Institute, Inc. Methods and compositions for modulating cytotoxic lymphocyte activity
WO2019018402A2 (en) * 2017-07-17 2019-01-24 Janssen Biotech, Inc. ANTIGEN-BINDING REGIONS DIRECTED AGAINST FIBRONECTIN TYPE III DOMAINS AND METHODS OF USING THE SAME
BR112020001719A2 (pt) 2017-07-29 2020-07-21 Juno Therapeutics Inc reagentes para expansão de células que expressam receptores recombinantes
US10442867B2 (en) 2017-07-31 2019-10-15 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-CD19/CD20 immunotherapy
US12485102B2 (en) 2017-08-02 2025-12-02 The Wistar Institute Of Anatomy And Biology Methods and compositions for treating cancer
WO2019028417A1 (en) 2017-08-03 2019-02-07 The Scripps Research Institute MODIFICATION OF B-LYMPHOCYTE RECEPTORS IN B-LYMPHOCYTES
CN111183147B (zh) 2017-08-04 2024-07-05 拜斯科技术开发有限公司 Cd137特异性的双环肽配体
IL319255A (en) 2017-08-07 2025-04-01 Univ Johns Hopkins Methods and materials for cancer assessment and treatment
AU2018313950A1 (en) 2017-08-09 2020-02-13 Juno Therapeutics, Inc. Methods for producing genetically engineered cell compositions and related compositions
CN111263641B (zh) 2017-08-09 2025-10-31 朱诺治疗学股份有限公司 用于制备基因工程化细胞的方法和组合物
US20190038733A1 (en) 2017-08-10 2019-02-07 National University Of Singapore T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof
WO2019036657A1 (en) 2017-08-17 2019-02-21 Kyn Therapeutics AHR INHIBITORS AND USES THEREOF
WO2019046832A1 (en) 2017-09-01 2019-03-07 Juno Therapeutics, Inc. GENE EXPRESSION AND EVALUATION OF RISK OF DEVELOPMENT OF TOXICITY FOLLOWING CELL THERAPY
EP3675876A4 (en) 2017-09-01 2021-06-02 GPB Scientific, Inc. METHOD FOR PRODUCING THERAPEUTICALLY ACTIVE CELLS USING MICROFLUIDICS
EP3679370A1 (en) 2017-09-07 2020-07-15 Juno Therapeutics, Inc. Methods of identifying cellular attributes related to outcomes associated with cell therapy
CN107557337B (zh) * 2017-09-15 2020-06-26 山东兴瑞生物科技有限公司 一种抗ror1安全型嵌合抗原受体修饰的免疫细胞及其应用
KR20230052312A (ko) 2017-09-15 2023-04-19 카이트 파마 인코포레이티드 관리 연속성 및 신원 연속성 생물학적 샘플 추적으로 환자-특이적 면역요법 절차를 수행하기 위한 방법 및 시스템
JP2020533986A (ja) 2017-09-15 2020-11-26 ライフ テクノロジーズ コーポレーション 細胞を培養および増殖させるための組成物および方法
WO2019060425A1 (en) 2017-09-19 2019-03-28 Massachusetts Institute Of Technology COMPOSITIONS FOR CHIMERIC ANTIGENIC RECEPTOR T CELL THERAPY AND USES THEREOF
CA3076261A1 (en) 2017-09-19 2019-03-28 Admare Vintageco1 Investments Ltd. Anti-hla-a2 antibodies and methods of using the same
CN109517820B (zh) 2017-09-20 2021-09-24 北京宇繁生物科技有限公司 一种靶向HPK1的gRNA以及HPK1基因编辑方法
EP3684822A4 (en) 2017-09-20 2021-06-16 The University of British Columbia NEW ANTI-HLA-A2 ANTIBODIES AND USES THEREOF
JP2020535802A (ja) 2017-09-21 2020-12-10 ザ・ブロード・インスティテュート・インコーポレイテッド 標的化核酸編集のための系、方法、及び組成物
WO2019060693A1 (en) 2017-09-22 2019-03-28 Kymera Therapeutics, Inc. CRBN LIGANDS AND USES THEREOF
CA3076099A1 (en) 2017-09-22 2019-03-28 Kite Pharma, Inc. Linkers for chimeric antigen receptors
MX2020003190A (es) 2017-09-22 2020-11-11 Kymera Therapeutics Inc Degradadores de proteinas y usos de los mismos.
US10844371B2 (en) 2017-09-22 2020-11-24 Kite Pharma, Inc. Antigen binding molecules and methods of use thereof
WO2019067504A1 (en) * 2017-09-26 2019-04-04 Longwood University SPECIFIC CHIMERIC ANTIGEN RECEPTOR AT PD-1 AS IMMUNOTHERAPY
CN109554349B (zh) * 2017-09-27 2022-06-24 亘喜生物科技（上海）有限公司 Pd-1基因表达沉默的工程化免疫细胞
TWI731268B (zh) * 2017-09-29 2021-06-21 財團法人國家衛生研究院 可增強抗腫瘤與抗病毒ｔ細胞存活與其功能性之方法與組合物
EP3695408B1 (en) 2017-10-02 2026-01-21 The Broad Institute, Inc. Medical use of cdk4/6- and checkpoint-inhibitors in phased combination, in treatment of cancer
BR112020006643A2 (pt) 2017-10-03 2020-09-24 Juno Therapeutics Inc moléculas de ligação específica ao hpv
WO2019074892A1 (en) 2017-10-09 2019-04-18 Wisconsin Alumni Research Foundation ANTIBODIES TARGETING GLIOBLASTOME STRAIN TYPE CELLS AND METHODS OF USE
KR102813968B1 (ko) 2017-10-10 2025-05-29 알파인 이뮨 사이언시즈, 인코포레이티드 Ctla-4 변이체 면역조절 단백질 및 이의 용도
CN119930795A (zh) 2017-10-12 2025-05-06 得克萨斯大学体系董事会 用于免疫疗法的t细胞受体
CA3084470A1 (en) 2017-10-18 2019-04-25 Kite Pharma, Inc. Methods of administering chimeric antigen receptor immunotherapy
JP7585034B2 (ja) 2017-10-18 2024-11-18 ノバルティス アーゲー 選択的タンパク質分解のための組成物及び方法
SMT202600062T1 (it) 2017-10-18 2026-03-09 Alpine Immune Sciences Inc Proteine immunomodulatrici del ligando di icos variante e composizioni e metodi correlati
CN109694854B (zh) * 2017-10-20 2023-11-21 亘喜生物科技（上海）有限公司 通用型嵌合抗原受体t细胞制备技术
WO2019084055A1 (en) 2017-10-23 2019-05-02 Massachusetts Institute Of Technology CLASSIFICATION OF GENETIC VARIATION FROM UNICELLULAR TRANSCRIPTOMS
US12053490B2 (en) 2017-10-26 2024-08-06 St. Jude Children's Research Hospital, Inc. Methods and compositions for treating CD33+ cancers and improving in vivo persistence of chimeric antigen receptor T cells
EP3700932A1 (en) 2017-10-27 2020-09-02 Kite Pharma, Inc. T cell receptor antigen binding molecules and methods of use thereof
US20210179709A1 (en) 2017-10-31 2021-06-17 Novartis Ag Anti-car compositions and methods
SG11202003657VA (en) 2017-11-01 2020-05-28 Juno Therapeutics Inc Process for producing a t cell composition
AU2018358067A1 (en) 2017-11-01 2020-05-07 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for B-cell maturation antigen
US11851679B2 (en) 2017-11-01 2023-12-26 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
JP7447006B2 (ja) 2017-11-01 2024-03-11 ジュノー セラピューティクス インコーポレイテッド Ｂ細胞成熟抗原（ｂｃｍａ）に特異的なキメラ抗原受容体
BR112020008478A2 (pt) 2017-11-01 2020-10-20 Editas Medicine, Inc. métodos, composições e componentes para edição de crispr-cas9 de tgfbr2 em células t para imunota-rapia
EP3704230B1 (en) 2017-11-01 2024-10-23 Juno Therapeutics, Inc. Process for generating therapeutic compositions of engineered cells
US11564946B2 (en) 2017-11-01 2023-01-31 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
AU2018360031B2 (en) 2017-11-03 2025-08-21 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-ROR1 immunotherapy
US20200289613A1 (en) 2017-11-04 2020-09-17 Aravive Biologics, Inc. Methods of treating metastatic cancers using axl decoy receptors
SG11202003427XA (en) 2017-11-06 2020-05-28 Juno Therapeutics Inc Combination of a cell therapy and a gamma secretase inhibitor
JP2021502077A (ja) 2017-11-06 2021-01-28 エディタス・メディシン，インコーポレイテッド 免疫療法のためのｔ細胞におけるｃｂｌｂのｃｒｉｓｐｒ−ｃａｓ９編集のための方法、組成物および構成要素
KR20200085780A (ko) 2017-11-07 2020-07-15 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 암의 치료에서 car-t 또는 car-nk 세포를 사용한 lilrb4 표적화
CN111683962B (zh) 2017-11-10 2025-05-16 美国政府(由卫生和人类服务部的部长所代表) 靶向肿瘤抗原的嵌合抗原受体
JP2021502094A (ja) 2017-11-10 2021-01-28 ジュノー セラピューティクス インコーポレイテッド 閉鎖系極低温容器
EP3710039A4 (en) 2017-11-13 2021-08-04 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER BY TARGETING THE CLEC2D-KLRB1 PATH
WO2019094955A1 (en) 2017-11-13 2019-05-16 The Broad Institute, Inc. Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas
AU2018369639C1 (en) 2017-11-14 2025-04-03 Arcellx, Inc. D-domain containing polypeptides and uses thereof
IL274677B2 (en) 2017-11-14 2025-01-01 Arcellx Inc Therapies with multifunctional immune system cells
SG11202004512XA (en) 2017-11-15 2020-06-29 Novartis Ag Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
WO2019099707A1 (en) 2017-11-16 2019-05-23 Kite Pharma, Inc Modified chimeric antigen receptors and methods of use
EP3714041A1 (en) * 2017-11-22 2020-09-30 Iovance Biotherapeutics, Inc. Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
CN109837244A (zh) * 2017-11-25 2019-06-04 深圳宾德生物技术有限公司 一种敲除pd1的靶向cd19的嵌合抗原受体t细胞及其制备方法和应用
BR112020010579A2 (pt) 2017-11-30 2020-11-10 Novartis Ag receptor de antígeno quimérico de alvejamento de bcma e usos do mesmo
US20210198372A1 (en) 2017-12-01 2021-07-01 Juno Therapeutics, Inc. Methods for dosing and for modulation of genetically engineered cells
US12084514B2 (en) 2017-12-04 2024-09-10 The Board Of Regents Of The University Of Oklahoma Anti-DCLK1 antibodies and chimeric antigen receptors, and compositions and methods of use thereof
WO2019113557A1 (en) 2017-12-08 2019-06-13 Juno Therapeutics, Inc. Process for producing a composition of engineered t cells
CA3084446A1 (en) 2017-12-08 2019-06-13 Juno Therapeutics, Inc. Phenotypic markers for cell therapy and related methods
JP7433230B2 (ja) 2017-12-08 2024-02-19 ジュノー セラピューティクス インコーポレイテッド 細胞を培養するための無血清培地配合物およびその使用の方法
US11766455B2 (en) 2017-12-14 2023-09-26 Ezy Biotech Llc Subject-specific tumor inhibiting cells and the use thereof
WO2019118937A1 (en) 2017-12-15 2019-06-20 Juno Therapeutics, Inc. Anti-cct5 binding molecules and methods of use thereof
EP3724885A2 (en) 2017-12-15 2020-10-21 Iovance Biotherapeutics, Inc. Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
WO2019117976A1 (en) 2017-12-17 2019-06-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptide hydrogels and use thereof
US11793867B2 (en) 2017-12-18 2023-10-24 Biontech Us Inc. Neoantigens and uses thereof
CN108018312B (zh) * 2017-12-20 2019-09-10 上海优卡迪生物医药科技有限公司 一种t淋巴细胞白血病的car-t治疗载体及其构建方法和应用
US10966999B2 (en) 2017-12-20 2021-04-06 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
CN111511754B (zh) 2017-12-20 2023-09-12 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸
GB201721833D0 (en) * 2017-12-22 2018-02-07 Cancer Research Tech Ltd Fusion proteins
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
CN109970864A (zh) * 2017-12-28 2019-07-05 上海细胞治疗研究院 一种双向激活共刺激分子受体及其用途
CN109970866B (zh) * 2017-12-28 2022-10-04 上海细胞治疗研究院 一种cd28双向激活共刺激分子受体及其用途
CN109971712B (zh) * 2017-12-28 2023-06-20 上海细胞治疗研究院 特异性靶向cd19抗原且高水平稳定表达pd-1抗体的car-t细胞及用途
SG11202006148UA (en) 2018-01-03 2020-07-29 Alpine Immune Sciences Inc Multi-domain immunomodulatory proteins and methods of use thereof
US12491153B2 (en) 2018-01-03 2025-12-09 Qu Biologics Inc. Innate targeting of adoptive cellular therapies
US11994512B2 (en) 2018-01-04 2024-05-28 Massachusetts Institute Of Technology Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
JP2021509903A (ja) * 2018-01-05 2021-04-08 マックスサイト インコーポレーティッド 癌の長期ｃａｒ処置
TW201930591A (zh) 2018-01-08 2019-08-01 瑞士商諾華公司 用於與嵌合抗原受體療法併用之免疫增強rna
US11919937B2 (en) 2018-01-09 2024-03-05 Board Of Regents, The University Of Texas System T cell receptors for immunotherapy
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
US10561686B2 (en) 2018-01-12 2020-02-18 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
CN112088008B (zh) * 2018-01-11 2024-01-02 浙江煦顼技术有限公司 修饰细胞的扩增及其用途
WO2019140387A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
BR112020014446A2 (pt) 2018-01-15 2020-12-29 Pfizer Inc. Métodos para administrar imunoterapia de receptor de antígeno quimérico em combinação com agonista de 4-1bb
CN111629715A (zh) 2018-01-18 2020-09-04 弗莱德哈钦森癌症研究中心 通过调节细胞活化状态改变体内免疫细胞的炎症状态
JP7549303B2 (ja) 2018-01-22 2024-09-11 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞の使用方法
KR102115236B1 (ko) * 2018-01-29 2020-05-27 (주)에스엠티바이오 췌장 또는 담관계암 치료를 위한 키메라 항원 수용체
KR20200116481A (ko) 2018-01-29 2020-10-12 메르크 파텐트 게엠베하 Gcn2 억제제 및 이의 용도
EP3746071A4 (en) 2018-01-29 2021-09-01 Merck Patent GmbH GCN2 INHIBITORS AND THEIR USES
US11535903B2 (en) 2018-01-31 2022-12-27 Juno Therapeutics, Inc. Methods and reagents for assessing the presence or absence of replication competent virus
JP7383620B2 (ja) 2018-01-31 2023-11-20 セルジーン コーポレイション 養子細胞療法およびチェックポイント阻害剤を使用する併用療法
EP3746116A1 (en) 2018-01-31 2020-12-09 Novartis AG Combination therapy using a chimeric antigen receptor
WO2019152957A1 (en) 2018-02-02 2019-08-08 Arizona Board Of Regents On Behalf Of Arizona State University Dna-chimeric antigen receptor t cells for immunotherapy
SG11202007426XA (en) 2018-02-06 2020-09-29 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
AU2019219454A1 (en) 2018-02-09 2020-08-27 National University Of Singapore Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
US20210087511A1 (en) * 2018-02-09 2021-03-25 Global Life Sciences Solutions Usa Llc Bioprocessing methods for cell therapy
US10889792B2 (en) 2018-02-09 2021-01-12 Global Life Sciences Solutions Usa Llc Cell expansion vessel systems and methods
CN112055744A (zh) 2018-02-09 2020-12-08 环球生命科技咨询美国有限责任公司 用于在生物处理系统中的流体管线管理的装置
WO2019154313A1 (zh) 2018-02-11 2019-08-15 江苏恒瑞医药股份有限公司 一种分离的嵌合抗原受体以及包含其的修饰t细胞及用途
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
CN110157677A (zh) * 2018-02-12 2019-08-23 深圳宾德生物技术有限公司 一种靶向性t淋巴细胞及其制备方法和应用
TWI707849B (zh) 2018-02-13 2020-10-21 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
WO2019160956A1 (en) 2018-02-13 2019-08-22 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
EP3752531A1 (en) 2018-02-14 2020-12-23 Kite Pharma, Inc. Anti-idiotypic antibodies directed to the antigen-binding portion of an bcma-binding molecule
CN112534044A (zh) 2018-02-16 2021-03-19 凯德药业股份有限公司 经修饰的多能干细胞及制备和使用方法
CA3091478A1 (en) 2018-02-17 2019-08-22 Flagship Pioneering Innovations V, Inc. Compositions and methods for membrane protein delivery
JP7273421B2 (ja) 2018-02-21 2023-05-15 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用
CN112105382A (zh) 2018-02-23 2020-12-18 恩多塞特公司 用于car t细胞疗法的顺序方法
JP2021514953A (ja) 2018-02-23 2021-06-17 バイスクルテクス・リミテッド 多量体二環式ペプチドリガンド
GB201803178D0 (en) 2018-02-27 2018-04-11 Univ Oslo Hf Specific binding molecules for htert
MX2020009272A (es) 2018-03-06 2021-01-08 Univ Pennsylvania Receptores de antígeno quimérico del antígeno de membrana específico de próstata y métodos de uso de los mismos.
WO2019170845A1 (en) 2018-03-09 2019-09-12 Ospedale San Raffaele S.R.L. Il-1 antagonist and toxicity induced by cell therapy
WO2019175328A1 (en) 2018-03-14 2019-09-19 Imba - Institut Für Molekulare Biotechnologie Gmbh Bh4pathwayactivationandusethereoffortreatingcancer
US20190284553A1 (en) 2018-03-15 2019-09-19 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
DE102018108612A1 (de) 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
CN112055717B (zh) 2018-04-02 2024-04-26 新加坡国立大学 用在免疫细胞中表达的膜结合抗细胞因子非信号传导粘合剂中和人细胞因子
AU2019249209A1 (en) 2018-04-05 2020-10-15 Juno Therapeutics, Inc. T cell receptors and engineered cells expressing same
CA3094468A1 (en) 2018-04-05 2019-10-10 Juno Therapeutics, Inc. Methods of producing cells expressing a recombinant receptor and related compositions
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
CA3096202A1 (en) 2018-04-06 2019-10-10 The Regents Of The University Of California Methods of treating egfrviii expressing glioblastomas
CA3095757A1 (en) 2018-04-06 2019-10-10 The Regents Of The University Of California Methods of treating glioblastomas
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
CA3095920A1 (en) 2018-04-10 2019-10-17 Amgen Inc. Chimeric receptors to dll3 and methods of use thereof
TWI784324B (zh) 2018-04-12 2022-11-21 美商凱特製藥公司 利用腫瘤微環境之特性之嵌合受體t細胞治療
WO2019200252A1 (en) 2018-04-13 2019-10-17 The Johns Hopkins University Non-invasive detection of response to immunotherapy
SG11202010116PA (en) 2018-04-13 2020-11-27 Sangamo Therapeutics France Chimeric antigen receptor specific for interleukin-23 receptor
WO2019200250A1 (en) 2018-04-13 2019-10-17 Velculescu Victor E Non-invasive detection of response to a targeted therapy
US10973834B2 (en) 2018-04-16 2021-04-13 Arrys Therapeutics, Inc. EP4 inhibitors and use thereof
CA3096549A1 (en) 2018-04-16 2019-10-24 Board Of Regents, The University Of Texas System Human kynureninase enzymes and uses thereof
US10869888B2 (en) 2018-04-17 2020-12-22 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
JP7527641B2 (ja) 2018-04-18 2024-08-05 アブクロン・インコーポレイテッド スイッチ分子及びスイッチャブルキメラ抗原受容体
KR102591947B1 (ko) 2018-04-19 2023-10-25 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
US20210161958A1 (en) * 2018-04-19 2021-06-03 The Trustees Of The University Of Pennsylvania Compositions and methods for treating melanoma with a chimeric antigen receptor
ES2969982T3 (es) 2018-04-24 2024-05-23 Vertex Pharma Compuestos de pteridinona y usos de los mismos
ES2919572T3 (es) 2018-04-24 2022-07-27 Merck Patent Gmbh Compuestos antiproliferación y usos de los mismos
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
EP3784351A1 (en) 2018-04-27 2021-03-03 Novartis AG Car t cell therapies with enhanced efficacy
JP2021523110A (ja) * 2018-05-01 2021-09-02 フレッド ハッチンソン キャンサー リサーチ センター 遺伝子発現のためのナノ粒子及びその使用
US20210396739A1 (en) 2018-05-01 2021-12-23 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
CA3098865A1 (en) 2018-05-02 2019-11-07 The Trustees Of The University Of Pennsylvania Compositions and methods of phospholipase a2 receptor chimeric autoantibody receptor t cells
US20210121466A1 (en) 2018-05-03 2021-04-29 Juno Therapeutics, Inc. Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
CN108753774B (zh) * 2018-05-03 2021-03-30 山东省齐鲁细胞治疗工程技术有限公司 干扰il-6表达的cd19-car-t细胞及其应用
EP3790958A1 (en) 2018-05-08 2021-03-17 Life Technologies Corporation Compositions and methods for culturing and expanding cells
US12227763B2 (en) 2018-05-11 2025-02-18 Crispr Therapeutics Ag Methods and compositions for treating cancer
EP3793565B1 (en) 2018-05-14 2022-01-05 Gilead Sciences, Inc. Mcl-1 inhibitors
WO2019222657A1 (en) 2018-05-18 2019-11-21 The Johns Hopkins University Cell-free dna for assessing and/or treating cancer
KR20210008408A (ko) 2018-05-23 2021-01-21 싱가포르국립대학교 T-세포 악성 종양의 면역요법을 위한 cd2 표면 발현 및 키메라 항원 수용체의 발현에 대한 차단
EP3801769A1 (en) 2018-05-25 2021-04-14 Novartis AG Combination therapy with chimeric antigen receptor (car) therapies
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
CN108715859B (zh) * 2018-05-31 2021-08-03 中国医学科学院血液病医院(中国医学科学院血液学研究所) 靶向cd22的嵌合抗原受体及其应用
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
KR102544086B1 (ko) 2018-06-01 2023-06-16 카이트 파마 인코포레이티드 키메라 항원 수용체 t 세포 요법
UY38251A (es) 2018-06-01 2019-12-31 Novartis Ag Moléculas de unión contra bcma y usos de las mismas
JP7411578B2 (ja) * 2018-06-01 2024-01-11 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ 癌を治療するための物質及び方法
US20210371932A1 (en) 2018-06-01 2021-12-02 Massachusetts Institute Of Technology Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
WO2019237035A1 (en) 2018-06-08 2019-12-12 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
WO2019241315A1 (en) 2018-06-12 2019-12-19 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
CA3100724A1 (en) 2018-06-13 2019-12-19 Novartis Ag B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
KR20190141511A (ko) * 2018-06-14 2019-12-24 주식회사 녹십자랩셀 신규 펩티드, 이를 포함하는 키메라 항원 수용체 및 이를 발현하는 면역 세포
US12036240B2 (en) 2018-06-14 2024-07-16 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
US12065476B2 (en) 2018-06-15 2024-08-20 Alpine Immune Sciences, Inc. PD-1 variant immunomodulatory proteins and uses thereof
BR112020025764A2 (pt) 2018-06-19 2021-05-11 Biontech Us Inc. neoantígenos e usos dos mesmos
AU2019288669B2 (en) 2018-06-21 2025-06-26 R&D Systems, Inc. Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
IL279489B2 (en) 2018-06-22 2025-10-01 Bicycletx Ltd Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate
US20210155941A1 (en) 2018-06-22 2021-05-27 Kite Pharma Eu B.V. Compositions and methods for making engineered t cells
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
CA3104862A1 (en) 2018-07-03 2020-01-09 Sotio, LLC Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereof
WO2020010227A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US11292792B2 (en) 2018-07-06 2022-04-05 Kymera Therapeutics, Inc. Tricyclic CRBN ligands and uses thereof
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
EP3820572B1 (en) 2018-07-13 2023-08-16 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
JPWO2020017479A1 (ja) 2018-07-17 2021-08-02 ノイルイミューン・バイオテック株式会社 抗ｇｐｃ３一本鎖抗体を含むｃａｒ
EA202190304A1 (ru) 2018-07-18 2022-01-21 Эмджен Инк. Химерные рецепторы к steap1 и способы их применения
MD4324851T2 (ro) 2018-07-19 2025-12-31 Regeneron Pharma Receptori antigenici chimerici cu specificitate BCMA și utilizările acestora
CA3107383A1 (en) 2018-07-23 2020-01-30 Magenta Therapeutics, Inc. Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy
CN108949759B (zh) * 2018-07-23 2021-06-01 合肥一兮生物科技有限公司 敲减人IL-15的siRNA、CD19 CAR表达载体、CAR-T细胞及构建方法和应用
SG11202101014XA (en) 2018-08-02 2021-02-25 Kite Pharma Inc Chimeric antigen receptor therapy t cell expansion kinetics and uses thereof
CN113474450A (zh) 2018-08-09 2021-10-01 朱诺治疗学股份有限公司 产生工程化细胞的方法以及所述工程化细胞的组合物
EA202190469A1 (ru) 2018-08-09 2021-06-28 Джуно Терапьютикс, Инк. Способы оценки интегрированных нуклеиновых кислот
EP3835320A4 (en) * 2018-08-10 2022-06-01 Eutilex Co., Ltd. Chimeric antigen receptor binding to hla-dr, and car-t cell
KR20210045418A (ko) 2018-08-14 2021-04-26 소티오, 엘엘씨 크렙스 사이클을 조정하는 트랜스 대사 분자와 조합된 키메라 항원 수용체 폴리펩타이드 및 이의 치료적 용도
US20210324357A1 (en) 2018-08-20 2021-10-21 The Brigham And Women's Hospital, Inc. Degradation domain modifications for spatio-temporal control of rna-guided nucleases
US12391685B2 (en) 2018-08-20 2025-08-19 The Broad Institute, Inc. Inhibitors of RNA-guided nuclease target binding and uses thereof
US12460244B2 (en) 2018-08-20 2025-11-04 The Broad Institute, Inc. Inhibitors of RNA-guided nuclease activity and uses thereof
CN110856724B (zh) * 2018-08-24 2022-05-27 杭州康万达医药科技有限公司 包含核酸及car修饰的免疫细胞的治疗剂及其应用
BR112021003830A2 (pt) 2018-08-28 2021-07-20 Fred Hutchinson Cancer Research Center métodos e composições para terapia celular t adotiva incorporando sinalização notch induzida
CA3110837A1 (en) 2018-08-28 2020-03-05 Vor Biopharma Inc. Genetically engineered hematopoietic stem cells and uses thereof
EP3844186A4 (en) 2018-08-29 2022-08-17 National University of Singapore METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
JP7156653B2 (ja) 2018-08-30 2022-10-19 イノベイティブ セルラー セラピューティクス ホールディングス，エルティディ 固形腫瘍を治療するためのキメラ抗原受容体細胞
US12240915B2 (en) 2018-08-30 2025-03-04 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cells for treating solid tumor
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
CA3109959A1 (en) 2018-08-31 2020-03-05 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
WO2020047449A2 (en) 2018-08-31 2020-03-05 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
US11866494B2 (en) * 2018-08-31 2024-01-09 Innovative Cellular Therapeutics Holdings, Ltd. CAR T therapy through uses of co-stimulation
US12030875B2 (en) 2018-09-07 2024-07-09 PIC Therapeutics, Inc. EIF4E inhibitors and uses thereof
MX2021002574A (es) 2018-09-11 2021-06-08 Juno Therapeutics Inc Metodos para el analisis por espectrometria de masas de composiciones de celulas modificadas.
AU2019345151B2 (en) 2018-09-19 2025-04-17 Alpine Immune Sciences, Inc. Methods and uses of variant CD80 fusion proteins and related constructs
EP3856777A1 (en) 2018-09-24 2021-08-04 The Medical College of Wisconsin, Inc. Anti-cd30 antibodies and methods of use
WO2020069409A1 (en) 2018-09-28 2020-04-02 Novartis Ag Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
EP3856779A1 (en) 2018-09-28 2021-08-04 Novartis AG Cd22 chimeric antigen receptor (car) therapies
EP3856763A1 (en) 2018-09-28 2021-08-04 Massachusetts Institute of Technology Collagen-localized immunomodulatory molecules and methods thereof
AU2019354391A1 (en) 2018-10-01 2021-05-06 Adicet Therapeutics, Inc. Compositions and methods regarding engineered and non- engineered γδ-Τ cells for treatment of hematological tumors
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
WO2020072656A1 (en) 2018-10-03 2020-04-09 Gilead Sciences, Inc. Imidozopyrimidine derivatives
EP3488851A1 (en) 2018-10-03 2019-05-29 AVM Biotechnology, LLC Immunoablative therapies
US11851663B2 (en) 2018-10-14 2023-12-26 Snipr Biome Aps Single-vector type I vectors
US20210379057A1 (en) 2018-10-16 2021-12-09 Massachusetts Institute Of Technology Nutlin-3a for use in treating a mycobacterium tuberculosis infection
BR112021007690A2 (pt) 2018-10-22 2021-08-10 Shanghai GenBase Biotechnology Co., Ltd. anticorpo anti-cldn18.2 e uso do mesmo
KR102933479B1 (ko) 2018-10-23 2026-03-04 리제너론 파아마슈티컬스, 인크. Ny-eso-1 t 세포 수용체 및 이의 사용 방법
WO2020086742A1 (en) 2018-10-24 2020-04-30 Obsidian Therapeutics, Inc. Er tunable protein regulation
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
EP3870146A4 (en) * 2018-10-25 2022-08-10 Innovative Cellular Therapeutics Holdings, Ltd. Increase or maintaining t-cell subpopulations in adoptive t-cell therapy
US20220170097A1 (en) 2018-10-29 2022-06-02 The Broad Institute, Inc. Car t cell transcriptional atlas
WO2020092057A1 (en) 2018-10-30 2020-05-07 Yale University Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells
TW202136261A (zh) 2018-10-31 2021-10-01 美商基利科學股份有限公司 經取代之6-氮雜苯并咪唑化合物
TWI721623B (zh) 2018-10-31 2021-03-11 美商基利科學股份有限公司 經取代之6-氮雜苯并咪唑化合物
EP3874024A1 (en) 2018-10-31 2021-09-08 Juno Therapeutics GmbH Methods for selection and stimulation of cells and apparatus for same
KR20210113169A (ko) 2018-11-01 2021-09-15 주노 쎄러퓨티크스 인코퍼레이티드 Β세포 성숙 항원에 특이적인 키메라 항원 수용체를 이용한 치료 방법
SG11202104524YA (en) 2018-11-01 2021-05-28 Gracell Biotechnologies Shanghai Co Ltd Compositions and methods for t cell engineering
EP3877054B1 (en) 2018-11-06 2023-11-01 Juno Therapeutics, Inc. Process for producing genetically engineered t cells
CN109467604A (zh) * 2018-11-07 2019-03-15 南京卡提医学科技有限公司 嵌合抗原受体DAP12-T2A-CD8α-CD19scFv-TREM1及其用途
CA3118889A1 (en) * 2018-11-07 2020-05-14 Sotio, LLC Anti-gpc3 chimeric antigen receptors (cars) in combination with trans co-stimulatory molecules and therapeutic uses thereof
CN109503717A (zh) * 2018-11-07 2019-03-22 南京卡提医学科技有限公司 嵌合抗原受体DAP12-T2A-CD8α-CD19scfv-NKp44及其用途
WO2020097403A1 (en) 2018-11-08 2020-05-14 Juno Therapeutics, Inc. Methods and combinations for treatment and t cell modulation
US12496274B2 (en) 2018-11-14 2025-12-16 Flagship Pioneering Innovations V, Inc. Compositions and methods for compartment-specific cargo delivery
WO2020102503A2 (en) 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Fusosome compositions for t cell delivery
KR20210104713A (ko) 2018-11-16 2021-08-25 주노 쎄러퓨티크스 인코퍼레이티드 Ｂ 세포 악성 종양 치료를 위한 조작된 ｔ 세포 투약 방법
EP3883955A1 (en) 2018-11-19 2021-09-29 Board of Regents, The University of Texas System A modular, polycistronic vector for car and tcr transduction
US10918667B2 (en) 2018-11-20 2021-02-16 Innovative Cellular Therapeutics CO., LTD. Modified cell expressing therapeutic agent and uses thereof
EP3883585A4 (en) * 2018-11-20 2022-12-14 Innovative Cellular Therapeutics Holdings, Ltd. MODIFIED CELL EXPRESSING THERAPEUTIC AND USES THEREOF
US12590148B2 (en) 2018-11-26 2026-03-31 Nkarta, Inc. Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
WO2020113029A2 (en) 2018-11-28 2020-06-04 Board Of Regents, The University Of Texas System Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
MX2021006393A (es) 2018-11-29 2021-10-13 Univ Texas Metodos para expansion ex vivo de celulas exterminadoras naturales y uso de las mismas.
PL3886875T3 (pl) 2018-11-30 2024-09-09 Juno Therapeutics, Inc. Metody leczenia z wykorzystaniem adoptywnej terapii komórkowej
WO2020113141A2 (en) 2018-11-30 2020-06-04 Alpine Immune Sciences, Inc. Cd86 variant immunomodulatory proteins and uses thereof
JP7623943B2 (ja) 2018-11-30 2025-01-29 カイメラ セラピューティクス， インコーポレイテッド Ｉｒａｋ分解剤およびそれらの使用
PL3886894T3 (pl) 2018-11-30 2024-07-01 Juno Therapeutics, Inc. Metody dawkowania i leczenia nowotworów b-komórkowych w adoptywnej terapii komórkowej
WO2020117952A2 (en) 2018-12-05 2020-06-11 Genentech, Inc. Diagnostic methods and compositions for cancer immunotherapy
CN118931967A (zh) * 2018-12-07 2024-11-12 亘喜生物科技（上海）有限公司 用于免疫疗法的组合物和方法
PT3894549T (pt) 2018-12-10 2024-10-16 Amgen Inc Transposase piggybac mutada
US12227551B2 (en) 2018-12-11 2025-02-18 Obsidian Therapeutics, Inc. Membrane bound IL12 compositions and methods for tunable regulation
KR102840400B1 (ko) 2018-12-12 2025-08-04 카이트 파마 인코포레이티드 키메라 항원 수용체 및 car-t 세포 및 사용 방법
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
EP3670530A1 (en) 2018-12-18 2020-06-24 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies
EP3670659A1 (en) 2018-12-20 2020-06-24 Abivax Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
KR20210106437A (ko) 2018-12-20 2021-08-30 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
JP2022514618A (ja) 2018-12-21 2022-02-14 バイスクルテクス・リミテッド Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド
US12551567B2 (en) 2018-12-21 2026-02-17 Bicyclerd Limited Bicyclic peptide ligands specific for PD-L1
AU2019404547B2 (en) 2018-12-21 2025-01-30 Biontech Us Inc. Method and systems for prediction of HLA class II-specific epitopes and characterization of CD4+ T cells
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
WO2020142780A1 (en) * 2019-01-06 2020-07-09 Tocagen Inc. Car t cell methods and constructs
EP3914719A4 (en) 2019-01-24 2023-04-05 Valorisation-HSJ, Limited Partnership Cell-specific transcriptional regulatory sequences and uses thereof
CA3123303A1 (en) 2019-01-29 2020-08-06 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
EP3920693A4 (en) 2019-02-04 2022-10-05 Minerva Biotechnologies Corporation ANTI-NME ANTIBODIES AND METHODS OF TREATMENT OF CANCER OR CANCER METASTASIS
US12419913B2 (en) 2019-02-08 2025-09-23 Dna Twopointo, Inc. Modification of CAR-T cells
EP3924055B1 (en) 2019-02-15 2024-04-03 Novartis AG Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
AU2020221324A1 (en) 2019-02-15 2021-09-02 University Of Southern California Lym-1 and Lym-2 antibody compositions and improved CAR constructs
CN113490528B (zh) 2019-02-15 2024-12-03 诺华股份有限公司 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
JP7710373B2 (ja) 2019-02-21 2025-07-18 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
US20220152150A1 (en) 2019-02-25 2022-05-19 Novartis Ag Mesoporous silica particles compositions for viral delivery
WO2020180591A1 (en) 2019-03-01 2020-09-10 Allogene Therapeutics, Inc. Dll3 targeting chimeric antigen receptors and binding agents
US20220133795A1 (en) 2019-03-01 2022-05-05 Iovance Biotherapeutics, Inc. Expansion of Tumor Infiltrating Lymphocytes From Liquid Tumors and Therapeutic Uses Thereof
MX2021010541A (es) 2019-03-04 2021-12-15 Univ Health Network Receptores de linfocitos t y metodos de uso de estos.
JP7748284B2 (ja) 2019-03-04 2025-10-02 ユニバーシティー ヘルス ネットワーク Ｔ細胞受容体及びその使用方法
AU2020232691B2 (en) 2019-03-05 2023-06-29 Nkarta, Inc. CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
EP3935066A1 (en) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
US11766447B2 (en) 2019-03-07 2023-09-26 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
KR102707808B1 (ko) 2019-03-07 2024-09-19 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. 2'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭
KR20210149251A (ko) 2019-03-08 2021-12-08 옵시디안 테라퓨틱스, 인크. 조율가능한 조절을 위한 인간 탄산 무수화효소 2 조성물 및 방법
WO2020182681A1 (en) 2019-03-08 2020-09-17 Klinikum Der Universität München Ccr8 expressing lymphocytes for targeted tumor therapy
WO2020186101A1 (en) 2019-03-12 2020-09-17 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
US20220142948A1 (en) 2019-03-18 2022-05-12 The Broad Institute, Inc. Compositions and methods for modulating metabolic regulators of t cell pathogenicity
CN120131907A (zh) 2019-03-19 2025-06-13 瓦尔希伯伦私人肿瘤研究基金会 采用Omomyc和结合PD-1或CTLA-4的抗体治疗癌症的联合疗法
EP3938405A4 (en) * 2019-03-20 2022-12-28 Javelin Oncology, Inc. ANTI-ADAM12 ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS, AND COMPOSITIONS AND METHODS THEREOF
EP3942025A1 (en) 2019-03-21 2022-01-26 Novartis AG Car-t cell therapies with enhanced efficacy
CN113795586B (zh) 2019-03-25 2026-03-27 大学健康网络 T细胞受体及其使用方法
US20220184222A1 (en) 2019-04-02 2022-06-16 Bicycletx Limited Bicycle toxin conjugates and uses thereof
TWI875749B (zh) 2019-04-05 2025-03-11 美商凱麥拉醫療公司 Stat降解劑及其用途
CN120172958A (zh) 2019-04-12 2025-06-20 C4医药公司 Ikaros和aiolos的三环降解物
AU2020272074A1 (en) * 2019-04-12 2021-11-25 The Trustees Of The University Of Pennsylvania Compositions and Methods Comprising a High Affinity Chimeric Antigen Receptor (CAR) with Cross-Reactivity to Clinically-Relevant EGFR Mutated Proteins
WO2020210678A1 (en) 2019-04-12 2020-10-15 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
US12404331B2 (en) 2019-04-19 2025-09-02 Tcrcure Biopharma Corp. Anti-PD-1 antibodies and uses thereof
US20220251152A1 (en) 2019-04-24 2022-08-11 Novartis Ag Compositions and methods for selective protein degradation
JP7664180B2 (ja) 2019-04-26 2025-04-17 アロジーン セラピューティクス，インコーポレイテッド リツキシマブ耐性キメラ抗原受容体およびその用途
KR20220004028A (ko) 2019-04-26 2022-01-11 알로젠 테라퓨틱스 인코포레이티드 동종 car t 세포를 제조하는 방법
US20220249558A1 (en) 2019-04-30 2022-08-11 Crispr Therapeutics Ag Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
EP3962527A4 (en) 2019-04-30 2023-11-01 Senti Biosciences, Inc. CHIMERIC RECEPTORS AND METHODS OF USE THEREOF
AU2020265741A1 (en) 2019-05-01 2021-11-25 Editas Medicine, Inc. Cells expressing a recombinant receptor from a modified TGFBR2 Locus, related polynucleotides and methods
EP3962519A1 (en) 2019-05-01 2022-03-09 Juno Therapeutics, Inc. Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
US20200384027A1 (en) 2019-05-03 2020-12-10 Kite Pharma, Inc. Methods of administering chimeric antigen receptor immunotherapy
CA3139346A1 (en) 2019-05-07 2020-11-12 Gracell Biotechnologies (Shanghai) Co., Ltd. Engineered immune cell targeting bcma and use thereof
US11162079B2 (en) 2019-05-10 2021-11-02 The Regents Of The University Of California Blood type O Rh-hypo-immunogenic pluripotent cells
US20220235340A1 (en) 2019-05-20 2022-07-28 The Broad Institute, Inc. Novel crispr-cas systems and uses thereof
PE20220568A1 (es) 2019-05-21 2022-04-20 Novartis Ag Moleculas de union a cd19 y usos de las mismas
CA3141162A1 (en) 2019-05-22 2020-11-26 Leidos, Inc. Lag3 binding peptides
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
EP3973072A1 (en) 2019-05-23 2022-03-30 Vogelsang, Matjaz Method for removal of nucleic acids impurities from liquid composition comprising genetically engineered particles or proteins
CN114051532A (zh) * 2019-05-24 2022-02-15 希望之城公司 用于治疗ccr4阳性恶性肿瘤的经ccr4靶向性嵌合抗原受体修饰的t细胞
US20220226464A1 (en) 2019-05-28 2022-07-21 Massachusetts Institute Of Technology Methods and compositions for modulating immune responses
WO2020243423A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
JPWO2020246563A1 (https=) * 2019-06-05 2020-12-10
AU2020286471B2 (en) * 2019-06-07 2025-07-31 The Trustees Of The University Of Pennsylvania Dual CAR expressing T cells individually linked to CD28 and 4-1BB
MX2021015125A (es) 2019-06-07 2022-04-06 Juno Therapeutics Inc Cultivo automatizado de celulas t.
WO2020251972A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
EP3983538A1 (en) 2019-06-12 2022-04-20 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
EP3983537A1 (en) 2019-06-12 2022-04-20 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
EP3983006A1 (en) 2019-06-12 2022-04-20 Juno Therapeutics, Inc. Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein
WO2020257823A2 (en) 2019-06-21 2020-12-24 Kite Pharma, Inc. TGF-β RECEPTORS AND METHODS OF USE
AU2020301413A1 (en) 2019-06-24 2022-02-10 Children's Hospital Los Angeles BCL11B overexpression to enhance human thymopoiesis T cell function
CR20210687A (es) 2019-06-25 2022-03-03 Gilead Sciences Inc PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO
JP2022538974A (ja) 2019-06-26 2022-09-07 マサチューセッツ インスチテュート オブ テクノロジー 免疫調節融合タンパク質－金属水酸化物錯体およびその方法
BR112021026517A2 (pt) 2019-06-28 2022-05-10 Kymera Therapeutics Inc Degradadores de irak e usos dos mesmos
WO2021003297A1 (en) 2019-07-02 2021-01-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind egfrviii and their use
JP2022539248A (ja) 2019-07-02 2022-09-07 フレッド ハッチンソン キャンサー リサーチ センター 組換えａｄ３５ベクター及び関連遺伝子治療改善
GB201909573D0 (en) 2019-07-03 2019-08-14 Cancer Research Tech Ltd Modulation of T cell cytotoxicity and related therapy
JPWO2021010326A1 (https=) 2019-07-12 2021-01-21
WO2021011868A1 (en) 2019-07-17 2021-01-21 Kymera Therapeutics, Inc. Irak degraders and uses thereof
US20220267726A1 (en) 2019-07-18 2022-08-25 Gpb Scientific, Inc. Ordered processing of blood products to produce therapeutically active cells
US20220251572A1 (en) 2019-07-23 2022-08-11 Mnemo Therapeutics Immune cells defective for suv39h1
MX2022000896A (es) 2019-07-24 2022-02-14 Regeneron Pharma Receptores de antigenos quimericos con especificidad por mage-a4 y usos de los mismos.
JP7669346B2 (ja) 2019-07-30 2025-04-28 ユニバーシティー ヘルス ネットワーク Ｔ細胞受容体及びその使用方法
MX2022001210A (es) 2019-07-30 2022-05-03 Univ Health Network Moléculas de complejo mayor de histocompatibilidad (mhc) de clase ii y métodos para su uso.
US20220281948A1 (en) 2019-07-30 2022-09-08 University Health Network Mhc class ii molecules and methods of use thereof
TWI860386B (zh) 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物
CN110305849B (zh) * 2019-08-01 2021-03-30 广东万海细胞生物科技有限公司 稳定表达car的t细胞及其制备方法与应用
GB201911066D0 (en) 2019-08-02 2019-09-18 Achilles Therapeutics Ltd T cell therapy
JP7739261B2 (ja) * 2019-08-09 2025-09-16 エイ２・バイオセラピューティクス・インコーポレイテッド ヘテロ接合性の喪失に応答する細胞表面受容体
WO2021030627A1 (en) 2019-08-13 2021-02-18 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
US12421557B2 (en) 2019-08-16 2025-09-23 The Broad Institute, Inc. Methods for predicting outcomes and treating colorectal cancer using a cell atlas
JP2022545467A (ja) 2019-08-22 2022-10-27 ジュノー セラピューティクス インコーポレイテッド Ｔ細胞療法とｚｅｓｔｅホモログ２エンハンサー（ＥＺＨ２）阻害剤との併用療法および関連方法
EP4021485A1 (en) * 2019-08-28 2022-07-06 King's College London B cell targeted parallel car (pcar) therapeutic agents
US20230092895A1 (en) 2019-08-30 2023-03-23 Obsidian Therapeutics, Inc. Tandem cd19 car-based compositions and methods for immunotherapy
WO2021041922A1 (en) 2019-08-30 2021-03-04 The Broad Institute, Inc. Crispr-associated mu transposase systems
EP4022637A2 (en) 2019-08-30 2022-07-06 Juno Therapeutics, Inc. Machine learning methods for classifying cells
EP4025244A1 (en) 2019-09-02 2022-07-13 Institut Curie Immunotherapy targeting tumor neoantigenic peptides
KR20220054383A (ko) 2019-09-03 2022-05-02 알로젠 테라퓨틱스 인코포레이티드 T 세포 요법을 위한 t 세포를 제조하는 방법
AU2020341454A1 (en) 2019-09-03 2022-03-10 Sana Biotechnology, Inc. CD24-associated particles and related methods and uses thereof
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
CA3153700A1 (en) 2019-09-09 2021-03-18 Scribe Therapeutics Inc. Compositions and methods for use in immunotherapy
CA3150224A1 (en) 2019-09-10 2021-03-18 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
CN112480263A (zh) * 2019-09-12 2021-03-12 普米斯生物技术(苏州)有限公司 一种双特异t细胞激活器活化t细胞的设计及其应用
CN114945366B (zh) 2019-09-13 2025-01-07 林伯士萨顿公司 Hpk1拮抗剂和其用途
WO2021051088A1 (en) * 2019-09-13 2021-03-18 Ohio State Innovation Foundation Nk cell immunotherapy compositions, methods of making and methods of using same
US20220348651A1 (en) 2019-09-18 2022-11-03 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
US20230127263A1 (en) * 2019-09-20 2023-04-27 The University Of North Carolina At Chapel Hill Modified t cells and methods of preparing the same
JP2023501871A (ja) 2019-09-20 2023-01-20 上海吉倍生物技術有限公司 Ｂｃｍａ標的化抗体及びキメラ抗原受容体
WO2021061648A1 (en) 2019-09-23 2021-04-01 Massachusetts Institute Of Technology Methods and compositions for stimulation of endogenous t cell responses
KR102685211B1 (ko) * 2019-09-26 2024-07-16 주식회사 헬릭스미스 항-c-Met 항체 또는 그의 항원 결합 단편을 포함하는 키메라 항원 수용체, 및 이의 용도
US12297426B2 (en) 2019-10-01 2025-05-13 The Broad Institute, Inc. DNA damage response signature guided rational design of CRISPR-based systems and therapies
KR102287180B1 (ko) * 2019-10-01 2021-08-09 충북대학교 산학협력단 Cd138에 특이적으로 결합하는 키메릭 항원 수용체, 이를 발현하는 면역세포 및 이의 항암 용도
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
AU2020358863A1 (en) 2019-10-03 2022-05-12 Celyntra Therapeutics Sa CRISPR systems with engineered dual guide nucleic acids
US12195725B2 (en) 2019-10-03 2025-01-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
US11981922B2 (en) 2019-10-03 2024-05-14 Dana-Farber Cancer Institute, Inc. Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
US11793787B2 (en) 2019-10-07 2023-10-24 The Broad Institute, Inc. Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
CN114555123B (zh) 2019-10-18 2024-04-02 四十七公司 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法
WO2021078910A1 (en) 2019-10-22 2021-04-29 Institut Curie Immunotherapy targeting tumor neoantigenic peptides
EP4048696A1 (en) 2019-10-23 2022-08-31 Kite Pharma, Inc. Anti-idiotypic antigen binding molecules and methods of use thereof
CN110679588A (zh) * 2019-10-23 2020-01-14 厦门生命互联科技有限公司 一种嵌合抗原受体t细胞冻存介质及用途
TWI717880B (zh) 2019-10-24 2021-02-01 中國醫藥大學附設醫院 Hla-g特異性嵌合抗原受體、核酸、hla-g特異性嵌合抗原受體表達質體、表達hla-g特異性嵌合抗原受體細胞、其用途以及用於治療癌症之醫藥組合物
WO2021084050A1 (en) 2019-10-30 2021-05-06 Juno Therapeutics Gmbh Cell selection and/or stimulation devices and methods of use
US11844800B2 (en) 2019-10-30 2023-12-19 Massachusetts Institute Of Technology Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
KR20220091576A (ko) 2019-10-31 2022-06-30 포티 세븐, 인코포레이티드 혈액암의 항-cd47 및 항-cd20 기반 치료
EP4070855B1 (en) 2019-11-01 2025-12-24 Kyoto Prefectural Public University Corporation B-cell antibody receptor and use thereof
IL292665B2 (en) 2019-11-06 2026-02-01 Kite Pharma Inc Chimeric antigen receptor T cell therapy
IL292667B1 (en) 2019-11-07 2026-02-01 Juno Therapeutics Inc Combination of T-cell therapy and (s)-3-[4-(4-morpholin-4-ylmethyl-benzyloxy)-l-oxo-3,l-dihydro-isoindol-2-yl]-piperidine-6,2-dione
US12195723B2 (en) 2019-11-08 2025-01-14 The Broad Institute, Inc. Engineered antigen presenting cells and uses thereof
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
JP7543404B2 (ja) 2019-11-20 2024-09-02 ジーアイ・セル・インコーポレイテッド Ｔ細胞培養用培地組成物及びこれを用いたｔ細胞の培養方法
IL292924A (en) 2019-11-26 2022-07-01 Novartis Ag Chimeric antigen receptors cd19 and cd22 and their uses
EP4065605A4 (en) 2019-11-26 2023-07-12 Ramot at Tel-Aviv University Ltd. Antibodies to carbohydrate antigens
PH12022551291A1 (en) 2019-11-26 2023-11-20 Novartis Ag Chimeric antigen receptors binding bcma and cd19 and uses thereof
PT4065582T (pt) 2019-11-26 2025-05-22 Ikena Oncology Inc Derivados polimórficos do carbazol e utilizações dos mesmos
KR20220122656A (ko) 2019-12-06 2022-09-02 주노 쎄러퓨티크스 인코퍼레이티드 Ｇｐｒｃ5ｄ-표적화 결합 도메인에 대한 항-이디오타입 항체 및 관련 조성물 및 방법
IL293393A (en) 2019-12-06 2022-07-01 Juno Therapeutics Inc Cell therapy-related toxicity and response-related methods for the treatment of b-cell malignancies
CN115916817A (zh) 2019-12-06 2023-04-04 朱诺治疗学股份有限公司 针对bcma靶向结合结构域的抗独特型抗体及相关组合物和方法
US12522651B2 (en) 2019-12-09 2026-01-13 Versiti Blood Research Institute Foundation, Inc. BCG car constructs and methods of their manufacture and use
US12551564B2 (en) 2019-12-10 2026-02-17 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2021127190A1 (en) 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2021127283A2 (en) 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof
MX2022007759A (es) 2019-12-20 2022-07-19 Novartis Ag Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico.
BR112022012410A2 (pt) 2019-12-23 2022-08-30 Kymera Therapeutics Inc Degradadores smarca e usos dos mesmos
WO2021133917A1 (en) 2019-12-23 2021-07-01 Kymera Therapeutics, Inc. Smarca inhibitors and uses thereof
LT4081305T (lt) 2019-12-24 2024-11-25 Carna Biosciences, Inc. Diacilglicerolio kinazę moduliuojantys junginiai
JP7088902B2 (ja) * 2019-12-27 2022-06-21 クレージュ メディカル カンパニー，リミテッド キメラ抗原受容体タンパク質をコードする核酸およびキメラ抗原受容体タンパク質を発現するｔリンパ球
US20230028754A1 (en) 2019-12-28 2023-01-26 Gpb Scientific, Inc. Microfluidic cartridges for processing particles and cells
CN116234829A (zh) 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
CN113150167A (zh) * 2020-01-22 2021-07-23 中国人民解放军总医院第五医学中心 一种能够反转pd-1免疫抑制信号的car t细胞结构em1设计
US12165747B2 (en) 2020-01-23 2024-12-10 The Broad Institute, Inc. Molecular spatial mapping of metastatic tumor microenvironment
AU2021211713A1 (en) 2020-01-23 2022-08-25 The Children's Medical Center Corporation Stroma-free T cell differentiation from human pluripotent stem cells
IL294988A (en) 2020-01-24 2022-09-01 Regeneron Pharma Antigen preferentially expressed in melanoma t-cell receptors (prame) and methods of using them
JP2023513434A (ja) 2020-01-24 2023-03-31 ジュノー セラピューティクス インコーポレイテッド 養子細胞療法における投与ならびに濾胞性リンパ腫および辺縁帯リンパ腫の処置のための方法
US20230090117A1 (en) 2020-01-28 2023-03-23 Juno Therapeutics, Inc. Methods for t cell transduction
EP4100422A1 (en) 2020-02-03 2022-12-14 MVZ Prof. Niendorf Pathologie Hamburg-West GmbH Marker set for the diagnosis and treatment of cancer
AU2021217003A1 (en) 2020-02-04 2022-09-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Anti-dinitrophenol chimeric antigen receptors
IL295381B1 (en) 2020-02-12 2026-04-01 Juno Therapeutics Inc BCMA-directed chimeric T-cell antigen receptor compounds and methods and uses thereof
IL295384B1 (en) 2020-02-12 2026-04-01 Juno Therapeutics Inc T-cell preparations with chimeric antigen receptor directed against CD19 and methods and uses thereof
JP2023513606A (ja) 2020-02-14 2023-03-31 ザ・ジョンズ・ホプキンス・ユニバーシティー 核酸を評価するための方法および材料
KR20260017503A (ko) 2020-02-14 2026-02-05 길리애드 사이언시즈, 인코포레이티드 Ccr8에 결합하는 항체 및 융합 단백질, 및 이의 용도
WO2021167908A1 (en) 2020-02-17 2021-08-26 Board Of Regents, The University Of Texas System Methods for expansion of tumor infiltrating lymphocytes and use thereof
US12076343B2 (en) 2020-02-19 2024-09-03 Innovative Cellular Therapeutics Holdings, Ltd. Engineered safety in cell therapy
KR20220147109A (ko) 2020-02-27 2022-11-02 노파르티스 아게 키메라 항원 수용체 발현 세포의 제조 방법
KR20220146530A (ko) 2020-02-27 2022-11-01 노파르티스 아게 키메라 항원 수용체-발현 세포의 제조 방법
CN111269326A (zh) * 2020-02-28 2020-06-12 南京北恒生物科技有限公司 新型嵌合抗原受体及其用途
AU2021230289A1 (en) 2020-03-03 2022-09-29 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof
IL296103A (en) 2020-03-05 2022-11-01 Neotx Therapeutics Ltd Methods and compositions for treating cancer with immune cells
US11896619B2 (en) 2020-03-10 2024-02-13 Massachusetts Institute Of Technology Compositions and methods for immunotherapy of NPM1c-positive cancer
KR20240096884A (ko) 2020-03-10 2024-06-26 매사추세츠 인스티튜트 오브 테크놀로지 조작된 기억-유사 nk 세포 및 이의 조성물을 생성하기 위한 방법
CA3171250A1 (en) 2020-03-10 2021-09-16 E. Lynne KELLEY Methods for treating neutropenia
CN113402612A (zh) 2020-03-17 2021-09-17 西比曼生物科技（香港）有限公司 靶向cd19和cd20的联合嵌合抗原受体及其应用
US12528785B2 (en) 2020-03-19 2026-01-20 Kymera Therapeutics, Inc. MDM2 degraders and uses thereof
JP2023521663A (ja) 2020-03-31 2023-05-25 サナ バイオテクノロジー，インコーポレイテッド 標的化脂質粒子及び組成物ならびにその使用
EP3892720A1 (en) 2020-04-06 2021-10-13 Innovative Cellular Therapeutics Holdings, Ltd. Presenting cell and use thereof in cell therapy
KR20230009386A (ko) 2020-04-10 2023-01-17 주노 쎄러퓨티크스 인코퍼레이티드 Ｂ-세포 성숙 항원을 표적화하는 키메라 항원 수용체로 조작된 세포 요법 관련 방법 및 용도
US20230340040A1 (en) * 2020-04-14 2023-10-26 St. Jude Children's Research Hospital, Inc. Chimeric myd88 receptors
US12241086B2 (en) * 2020-04-15 2025-03-04 Amgen Inc. Process for generating genetically engineered autologous T cells
US12378521B2 (en) 2020-04-15 2025-08-05 Amgen Inc. Method for enhancing production of genetically engineered autologous T cells
EP4136228A4 (en) 2020-04-15 2024-09-11 California Institute of Technology THERMAL REGULATION OF T-CELL IMMUNOTHERAPY BY MOLECULAR AND PHYSICAL ACTUATION
GB202005599D0 (en) 2020-04-17 2020-06-03 Univ London Modulation of t cell cytotoxicity and related therapy
CN116157125A (zh) 2020-04-28 2023-05-23 朱诺治疗学股份有限公司 针对bcma的t细胞疗法与免疫调节化合物的组合
WO2021219990A1 (en) 2020-04-28 2021-11-04 Achilles Therapeutics Uk Limited T cell therapy
GB202006254D0 (en) 2020-04-28 2020-06-10 Institute Of Cancer Res Anti-cancer vaccines and related therapy
US12433954B2 (en) 2020-05-01 2025-10-07 Massachusetts Institute Of Technology Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
JP7564888B2 (ja) 2020-05-01 2024-10-09 ギリアード サイエンシーズ， インコーポレイテッド Ｃｄ７３阻害性２，４－ジオキソピリミジン化合物
US20210340524A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
US12497623B2 (en) 2020-05-04 2025-12-16 The Trustees Of The University Of Pennsylvania Non-signaling HIV fusion inhibitors and methods of use thereof
AU2021266706A1 (en) 2020-05-05 2022-12-15 Regeneron Pharmaceuticals, Inc. Car comprising CD28 zeta and CD3 zeta
WO2021228999A1 (en) 2020-05-12 2021-11-18 Institut Curie Neoantigenic epitopes associated with sf3b1 mutations
WO2021231661A2 (en) 2020-05-13 2021-11-18 Juno Therapeutics, Inc. Process for producing donor-batched cells expressing a recombinant receptor
JP7727662B2 (ja) 2020-05-13 2025-08-21 ジュノー セラピューティクス インコーポレイテッド 臨床応答に関連する特徴量の特定方法およびその使用
US20230190780A1 (en) * 2020-05-15 2023-06-22 Precision Biosciences, Inc. Methods for immunotherapy
AU2021275239A1 (en) 2020-05-21 2022-12-15 Board Of Regents, The University Of Texas System T cell receptors with VGLL1 specificity and uses thereof
IL298558A (en) 2020-05-27 2023-01-01 Antion Biosciences Sa Adapter molecules redirect CAR T cells to the antigen of interest
US12043654B2 (en) 2020-06-02 2024-07-23 Innovative Cellular Therapeutics Holdings, Ltd. Anti-GCC antibody and CAR thereof for treating digestive system cancer
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
WO2021247897A1 (en) 2020-06-03 2021-12-09 Kymera Therapeutics, Inc. Deuterated irak degraders and uses thereof
CN115867294A (zh) 2020-06-04 2023-03-28 凯瑞斯马治疗公司 嵌合抗原受体的新型构建体
WO2021244654A1 (en) * 2020-06-05 2021-12-09 Nanjing Legend Biotech Co., Ltd. Activation induced cytokine production in immune cells
US20220057381A1 (en) 2020-06-08 2022-02-24 Janssen Biotech, Inc. Cell-based assay for determining the in vitro tumor killing activity of chimeric antigen expressing immune cells
CN116367857A (zh) 2020-06-08 2023-06-30 米纳瓦生物技术公司 抗nme抗体及治疗癌症或癌症转移的方法
CA3185455A1 (en) 2020-06-11 2021-12-16 Novartis Ag Zbtb32 inhibitors and uses thereof
WO2021262723A1 (en) * 2020-06-22 2021-12-30 Lentigen Technology, Inc. Compositions and methods for treating cancer with tslpr-cd19 or tslpr-cd22 immunotherapy
CN115916199A (zh) 2020-06-23 2023-04-04 诺华股份有限公司 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
US20230293530A1 (en) 2020-06-24 2023-09-21 Yeda Research And Development Co. Ltd. Agents for sensitizing solid tumors to treatment
EP4171616A1 (en) 2020-06-26 2023-05-03 Juno Therapeutics GmbH Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
KR20230028796A (ko) 2020-06-26 2023-03-02 미네르바 바이오테크놀로지 코포레이션 항-nme 항체 및 암 또는 암 전이의 치료 방법
AU2021308078A1 (en) 2020-07-17 2023-02-09 Children's Hospital Los Angeles Chimeric MyD88 receptors for redirecting immunosuppressive signaling and related compositions and methods
KR102297396B1 (ko) 2020-07-29 2021-09-06 (주)티카로스 면역시냅스를 안정화시키는 키메라 항원 수용체(car) t 세포
CA3190266A1 (en) 2020-07-30 2022-02-03 Institut Curie Immune cells defective for socs1
WO2022026496A2 (en) 2020-07-31 2022-02-03 Leidos, Inc. Lag3 binding peptides
IL300248A (en) 2020-08-03 2023-03-01 Bicycletx Ltd peptide-based linkers
US20230271940A1 (en) 2020-08-03 2023-08-31 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2022029660A1 (en) 2020-08-05 2022-02-10 Juno Therapeutics, Inc. Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods
IL300516A (en) 2020-08-13 2023-04-01 Sana Biotechnology Inc Methods for treating susceptible patients with hypoimmunogenic cells, and related methods and compounds
JP2023538303A (ja) 2020-08-13 2023-09-07 イェール ユニバーシティー 所望の表現型を有するｃａｒ ｔ細胞の操作および選択のための組成物および方法
KR20230084470A (ko) 2020-08-14 2023-06-13 카이트 파마 인코포레이티드 면역 세포 기능의 향상
WO2022038158A1 (en) 2020-08-17 2022-02-24 Bicycletx Limited Bicycle conjugates specific for nectin-4 and uses thereof
WO2022040454A1 (en) 2020-08-20 2022-02-24 A2 Biotherapeutics, Inc. Compositions and methods for treating mesothelin positive cancers
KR102859550B1 (ko) 2020-08-20 2025-09-16 에이투 바이오쎄라퓨틱스, 인크. Ceacam 양성 암을 치료하기 위한 조성물 및 방법
KR20230054391A (ko) 2020-08-21 2023-04-24 12343096 캐나다 인코포레이티드 모듈러 조립 수용체 및 그의 용도
US20230302155A1 (en) 2020-08-21 2023-09-28 Novartis Ag Compositions and methods for in vivo generation of car expressing cells
US12152251B2 (en) 2020-08-25 2024-11-26 Kite Pharma, Inc. T cells with improved functionality
US20230302135A1 (en) * 2020-08-26 2023-09-28 Arizona Board Of Regents On Behalf Of The University Of Arizona Hybrid allosteric receptor-engineered stem cells
WO2022081426A1 (en) 2020-10-12 2022-04-21 Leidos, Inc. Immunomodulatory peptides
JP2023545472A (ja) * 2020-10-16 2023-10-30 ネオンク テクノロジーズ インク． Ｃｎｓ感染症の治療のためのｐｏｈとレムデシビルとの組み合わせ
WO2022086620A1 (en) 2020-10-20 2022-04-28 The Methodist Hospital System Psma-targeted immunotherapies for cancers
EP4232071A4 (en) 2020-10-23 2024-08-28 Asher Biotherapeutics, Inc. FUSIONS WITH CD8 ANTIGEN-BINDING MOLECULES TO MODULATE IMMUNE CELL FUNCTION
US20220155299A1 (en) 2020-10-28 2022-05-19 Kite Pharma, Inc. Flow cytometric method for characterization of t-cell impurities
US20250215081A1 (en) 2020-11-06 2025-07-03 Novartis Ag Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
CA3201499A1 (en) 2020-11-13 2022-05-19 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
KR20230107617A (ko) 2020-11-13 2023-07-17 노파르티스 아게 키메라 항원 수용체(car)-발현 세포를 사용한 병용 요법
CN112195250A (zh) * 2020-11-20 2021-01-08 山东省医学科学院附属医院 一种qPCR试剂盒及应用
WO2022115492A1 (en) 2020-11-24 2022-06-02 Lyell Immunopharma, Inc. Methods for making, compositions comprising, and methods of using rejuvenated t cells
WO2022120353A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
AU2021392032A1 (en) 2020-12-03 2023-06-22 Century Therapeutics, Inc. Genetically engineered cells and uses thereof
EP4259144A4 (en) 2020-12-09 2025-08-20 Kymera Therapeutics Inc SMARCA DEGRADING AGENTS AND THEIR USES
WO2022133030A1 (en) 2020-12-16 2022-06-23 Juno Therapeutics, Inc. Combination therapy of a cell therapy and a bcl2 inhibitor
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
AU2021410635A1 (en) 2020-12-24 2023-06-29 Kite Pharma, Inc. Prostate cancer chimeric antigen receptors
PH12023500015A1 (en) 2020-12-30 2024-03-11 Kymera Therapeutics Inc Irak degraders and uses thereof
EP4271817A2 (en) 2020-12-30 2023-11-08 Alaunos Therapeutics, Inc. Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
CA3200509A1 (en) 2020-12-31 2022-07-07 Sonja SCHREPFER Methods and compositions for modulating car-t activity
US12576400B2 (en) 2021-01-08 2026-03-17 Cellanome, Inc. Methods for incubating and analyzing a cell in a compartment of a fluidic device
JP2024502618A (ja) 2021-01-08 2024-01-22 セラノーム， インコーポレイテッド 生体試料を分析するためのデバイスおよび方法
WO2022150582A1 (en) 2021-01-10 2022-07-14 Kite Pharma, Inc. T cell therapy
US20250186539A2 (en) 2021-01-11 2025-06-12 Bicycletx Limited Methods for treating cancer
EP4274901A1 (en) 2021-01-11 2023-11-15 Sana Biotechnology, Inc. Use of cd8-targeted viral vectors
JP2024505428A (ja) 2021-01-14 2024-02-06 アンスティテュ キュリー Ｈｅｒ２単一ドメイン抗体バリアントおよびそのｃａｒ
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
CN117062611A (zh) * 2021-01-26 2023-11-14 惠和生物技术(上海)有限公司 嵌合抗原受体（car）构建体和表达car构建体的nk细胞
CA3209218A1 (en) * 2021-01-27 2022-08-04 H. Lee Moffitt Cancer Center And Research Institute Inc. Bi-specific car t cells for b cell malignancies
AU2022212090A1 (en) 2021-01-28 2023-07-06 Allogene Therapeutics, Inc. Methods for transducing immune cells
FI4284512T3 (fi) 2021-01-28 2025-05-22 Regeneron Pharma Koostumuksia ja menetelmiä sytokiinien vapautumisoireyhtymän hoitamiseksi
JP2024506858A (ja) 2021-02-02 2024-02-15 リミナル・バイオサイエンシーズ・リミテッド Ｇｐｒ８４アンタゴニストおよびその使用
CN117120090A (zh) 2021-02-12 2023-11-24 林伯士萨顿公司 Hpk1拮抗剂和其用途
WO2022174268A1 (en) 2021-02-15 2022-08-18 Kymera Therapeutics, Inc. Irak4 degraders and uses thereof
CN116867494A (zh) 2021-02-15 2023-10-10 凯麦拉医疗公司 Irak4降解剂和其用途
TW202241469A (zh) 2021-02-20 2022-11-01 美商凱特製藥公司 免疫療法
EP4298212A4 (en) 2021-02-25 2026-04-15 Celyntra Therapeutics Sa Compositions and methods for targeting, editing, or modifying genes
JP2024509853A (ja) 2021-03-03 2024-03-05 ジュノー セラピューティクス インコーポレイテッド Ｔ細胞療法およびｄｇｋ阻害剤の組合せ
CA3212530A1 (en) 2021-03-05 2022-09-09 Shanghai GenBase Biotechnology Co., Ltd. Anti-cldn6 antibody and use thereof
EP4301756A4 (en) 2021-03-05 2025-02-26 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
IL305571A (en) 2021-03-11 2023-10-01 Kite Pharma Inc Improving the function of immune system cells
WO2022189639A1 (en) 2021-03-11 2022-09-15 Mnemo Therapeutics Tumor neoantigenic peptides and uses thereof
EP4304632A2 (en) 2021-03-11 2024-01-17 Mnemo Therapeutics Tumor neoantigenic peptides
US20250041412A1 (en) 2021-03-11 2025-02-06 Institut Curie Transmembrane neoantigenic peptides
WO2022196719A1 (ja) 2021-03-17 2022-09-22 第一三共株式会社 抗アセチルコリン受容体自己抗体に対するキメラ受容体をコードする遺伝子
KR20230159851A (ko) 2021-03-22 2023-11-22 주노 쎄러퓨티크스 인코퍼레이티드 치료 세포 조성물의 효력을 결정하는 방법
CN117321200A (zh) 2021-03-22 2023-12-29 朱诺治疗学股份有限公司 评估病毒载体颗粒效力的方法
CA3212948A1 (en) 2021-03-26 2022-09-29 David M. Hilbert Multifunctional immune cell therapies
US20240181052A1 (en) 2021-03-29 2024-06-06 Juno Therapeutics, Inc. Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
AU2022252220A1 (en) 2021-03-29 2023-10-12 Juno Therapeutics, Inc. Combination of a car t cell therapy and an immunomodulatory compound for treatment of lymphoma
WO2022213062A1 (en) 2021-03-29 2022-10-06 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
EP4320435A1 (en) 2021-04-09 2024-02-14 Achilles Therapeutics UK Limited Batch release assay for pharmaceutical products relating to t cell therapies
GB202109886D0 (en) 2021-07-08 2021-08-25 Achilles Therapeutics Uk Ltd Assay
AU2022256074A1 (en) 2021-04-09 2023-11-02 Nimbus Clio, Inc. Cbl-b modulators and uses thereof
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
IL307612A (en) 2021-04-16 2023-12-01 Celgene Corp Combined therapies with BCMA-directed T-cell therapy
KR20230171994A (ko) 2021-04-16 2023-12-21 셀진 코포레이션 선행 줄기 세포 이식을 받은 환자에서의 t 세포 요법
JP2024514879A (ja) 2021-04-16 2024-04-03 イケナ オンコロジー， インコーポレイテッド Ｍｅｋ阻害剤及びその使用
WO2022221126A1 (en) 2021-04-16 2022-10-20 Kite Pharma, Inc. Methods and systems for scheduling a patient-specific immunotherapy procedure
AU2022259428A1 (en) 2021-04-16 2023-10-26 Kite Pharma, Inc. Taci/bcma dual binding molecules
EP4326293A4 (en) 2021-04-22 2025-03-12 Baylor College of Medicine METHODS FOR MODIFYING IMMUNE CELLS HAVING REDUCED FRATRICIDAL ACTIVITY
AU2022261141A1 (en) * 2021-04-23 2023-11-30 Myeloid Therapeutics, Inc. Compositions and methods for conditioning patients for cell therapy
EP4330381A1 (en) 2021-04-27 2024-03-06 Novartis AG Viral vector production system
CN117203328A (zh) 2021-04-27 2023-12-08 武田药品工业株式会社 重组抗原呈递细胞
CA3217914A1 (en) 2021-05-04 2022-11-10 Kevin BRAY Chimeric antigen receptors with mage-a4 specificity and uses thereof
US20250283037A1 (en) 2021-05-06 2025-09-11 Juno Therapeutics Gmbh Methods for stimulating and transducing t cells
AU2022271290A1 (en) 2021-05-07 2023-11-23 Kymera Therapeutics, Inc. Cdk2 degraders and uses thereof
EP4337227A2 (en) 2021-05-14 2024-03-20 Kite Pharma, Inc. Chimeric antigen receptor t cell therapy
TW202313094A (zh) 2021-05-18 2023-04-01 美商基利科學股份有限公司 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
BR112023024231A2 (pt) 2021-05-19 2024-01-30 Sana Biotechnology Inc Células t primárias rhd negativas hipoimunogênicas
IL308696A (en) 2021-05-24 2024-01-01 Kite Pharma Inc Nkg2d-based chimeric antgen receptor
WO2022251434A1 (en) * 2021-05-26 2022-12-01 Emory University Jak inhibitors for managing conditions in patients with down's syndrome or other trisomy
AU2022283291A1 (en) 2021-05-27 2023-11-02 Sana Biotechnology, Inc. Hypoimmunogenic cells comprising engineered hla-e or hla-g
AU2022280957A1 (en) 2021-05-28 2023-11-30 Sana Biotechnology, Inc. Lipid particles containing a truncated baboon endogenous retrovirus (baev) envelope glycoprotein and related methods and uses
EP4419672A2 (en) 2021-06-01 2024-08-28 Artisan Development Labs, Inc. Compositions and methods for targeting, editing, or modifying genes
CA3218590A1 (en) 2021-06-07 2022-12-15 Providence Health & Services - Oregon Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
WO2022261061A1 (en) 2021-06-08 2022-12-15 Kite Pharma, Inc. Gpc3 binding molecules
EP4370676A2 (en) 2021-06-18 2024-05-22 Artisan Development Labs, Inc. Compositions and methods for targeting, editing or modifying human genes
WO2022269250A1 (en) 2021-06-22 2022-12-29 Achilles Therapeutics Uk Limited A method for producing antigen-specific t cells
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271677A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CA3222277A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
KR20240005901A (ko) 2021-06-23 2024-01-12 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
US20240316104A1 (en) 2021-06-29 2024-09-26 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
AU2022301302A1 (en) 2021-07-01 2024-01-25 Indapta Therapeutics, Inc. Engineered natural killer (nk) cells and related methods
WO2023278553A1 (en) 2021-07-01 2023-01-05 Kite Pharma, Inc. Closed-system and method for autologous and allogeneic cell therapy manufacturing
JP2024525485A (ja) 2021-07-02 2024-07-12 カイト ファーマ インコーポレイテッド 細胞療法適用において使用される遺伝子構築物由来の遺伝子産物におけるバリアントを特定するための方法
US20240368145A1 (en) 2021-07-09 2024-11-07 Immunic Ag Methods for treating cancer
KR20240046319A (ko) 2021-07-14 2024-04-08 사나 바이오테크놀로지, 인크. 저면역원성 세포에서의 y 염색체-연결 항원의 변경된 발현
MX2024000713A (es) * 2021-07-16 2024-03-25 Sana Biotechnology Inc Vectores policistrónicos para terapias a base de células.
WO2023004300A2 (en) * 2021-07-19 2023-01-26 The Trustees Of The University Of Pennsylvania Chimeric antigen receptor (car)-t signaling optimization for tuning antigen activation threshold
US20230190799A1 (en) * 2021-07-21 2023-06-22 City Of Hope Chimeric antigen receptor t cells targeting cea and anti-cea-il2 immunocytokines for cancer therapy
US20230268031A1 (en) 2021-07-30 2023-08-24 Kite Pharma, Inc. Monitoring and management of cell therapy-induced toxicities
US20250114452A1 (en) 2021-08-04 2025-04-10 The Regents Of The University Of Colorado, A Body Corporate Lat activating chimeric antigen receptor t cells and methods of use thereof
WO2023015217A1 (en) 2021-08-04 2023-02-09 Sana Biotechnology, Inc. Use of cd4-targeted viral vectors
US20240342280A1 (en) * 2021-08-09 2024-10-17 The Trustees Of The University Of Pennsylvania Optimizing t cell differentiation state with micrornas
WO2023019226A1 (en) 2021-08-11 2023-02-16 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy
TW202321435A (zh) 2021-08-11 2023-06-01 美商薩那生物科技公司 用於改變低免疫原性細胞中之基因表現之可誘導系統
JP2024535677A (ja) 2021-08-11 2024-10-02 サナ バイオテクノロジー，インコーポレイテッド 即時血液媒介性炎症反応を減少させるための同種細胞療法を目的とした遺伝子改変細胞
AU2022325231A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
KR20240073006A (ko) 2021-08-11 2024-05-24 사나 바이오테크놀로지, 인크. 동종이계 세포 요법을 위한 유전자 변형된 1차 세포
WO2023021113A1 (en) 2021-08-18 2023-02-23 Julius-Maximilians-Universität Würzburg Hybrid tumor/cancer therapy based on targeting the resolution of or inducing transcription-replication conflicts (trcs)
JP2024531364A (ja) 2021-08-20 2024-08-29 ノバルティス アーゲー キメラ抗原受容体発現細胞を作製する方法
WO2023021494A1 (en) 2021-08-20 2023-02-23 Rudd Christopher E Compositions and methods for anti-virus chimeric antigen receptor
US20240424096A1 (en) 2021-08-24 2024-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) IL-10 Expressing Cells For Enhanced Cancer Immunotherapies
US12157732B2 (en) 2021-08-25 2024-12-03 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof
JP2024534127A (ja) 2021-08-25 2024-09-18 ピク セラピューティクス， インコーポレイテッド ｅＩＦ４Ｅ阻害剤及びその使用
WO2023049933A1 (en) 2021-09-27 2023-03-30 Sotio Biotech Inc. Chimeric receptor polypeptides in combination with trans metabolism molecules that re-direct glucose metabolites out of the glycolysis pathway and therapeutic uses thereof
AU2022366987A1 (en) 2021-10-14 2024-05-16 Arsenal Biosciences, Inc. Immune cells having co-expressed shrnas and logic gate systems
TWI863006B (zh) 2021-10-18 2024-11-21 美商凱特製藥公司 用於嵌合抗原受體之信號傳導域
US20230183216A1 (en) 2021-10-28 2023-06-15 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
EP4422756A1 (en) 2021-10-29 2024-09-04 Gilead Sciences, Inc. Cd73 compounds
US12187744B2 (en) 2021-10-29 2025-01-07 Kymera Therapeutics, Inc. IRAK4 degraders and synthesis thereof
WO2023081735A1 (en) 2021-11-03 2023-05-11 Celgene Corporation Chimeric antigen receptors specific for b-cell maturation antigen for use in treating myeloma
US20260083848A1 (en) 2021-11-03 2026-03-26 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
US20250000906A1 (en) 2021-11-16 2025-01-02 Sotio Biotech Inc. Treatment of myxoid/round cell liposarcoma patients
WO2023092119A2 (en) 2021-11-22 2023-05-25 Ludwig Institute For Cancer Research Ltd Methods for predicting responsiveness to a cancer therapy
US20250354167A1 (en) 2021-12-09 2025-11-20 Zygosity Limited Vector
US20250059239A1 (en) 2021-12-17 2025-02-20 Sana Biotechnology, Inc. Modified paramyxoviridae fusion glycoproteins
EP4448775A1 (en) 2021-12-17 2024-10-23 Sana Biotechnology, Inc. Modified paramyxoviridae attachment glycoproteins
WO2023114984A1 (en) 2021-12-17 2023-06-22 Ikena Oncology, Inc. Tead inhibitors and uses thereof
KR102809807B1 (ko) * 2021-12-21 2025-05-16 한림대학교 산학협력단 항-cldn18.2를 포함하는 키메릭 항원 수용체를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 및 이의 제조 방법
CN118488946A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
EP4452415B1 (en) 2021-12-22 2026-02-25 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
MX2024007528A (es) 2021-12-23 2024-08-30 Sana Biotechnology Inc Linfocitos t del receptor de antígeno quimérico (car) para el tratamiento de enfermedades autoinmunitarias y métodos asociados.
EP4456910A1 (en) 2021-12-28 2024-11-06 Mnemo Therapeutics Immune cells with inactivated suv39h1 and modified tcr
TW202334400A (zh) 2021-12-30 2023-09-01 美商Ｔｒ１Ｘ股份有限公司 表現il-10及嵌合抗原受體之cd4+ t細胞及其用途
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
TW202340474A (zh) 2022-01-11 2023-10-16 大陸商深圳市珈鈺生物科技有限公司 樹突細胞腫瘤疫苗和其用途
WO2023137472A2 (en) 2022-01-14 2023-07-20 Tune Therapeutics, Inc. Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression
US20250134999A1 (en) 2022-01-14 2025-05-01 Tune Therapeutics, Inc. Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
EP4215245A1 (en) 2022-01-19 2023-07-26 Innovative Cellular Therapeutics Holdings, Ltd. Enhanced chimeric antigen receptor cells in hypoxic tumor microenvironment
US20250115916A1 (en) 2022-01-21 2025-04-10 Mnemo Therapeutics Modulation of suv39h1 expression by rnas
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
JP2025504002A (ja) 2022-01-28 2025-02-06 ジュノー セラピューティクス インコーポレイテッド 細胞組成物を製造する方法
EP4472967A4 (en) 2022-01-31 2026-04-15 Kymera Therapeutics Inc Iraqi Degradation Agents and Their Uses
EP4472646A1 (en) 2022-02-01 2024-12-11 Sana Biotechnology, Inc. Cd3-targeted lentiviral vectors and uses thereof
WO2023150181A1 (en) 2022-02-01 2023-08-10 President And Fellows Of Harvard College Methods and compositions for treating cancer
US20250144235A1 (en) 2022-02-02 2025-05-08 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
JP2025508371A (ja) * 2022-02-11 2025-03-26 フレッド ハッチンソン キャンサー センター Ｓｔｅａｐ１に結合するキメラ抗原受容体
WO2023154578A1 (en) 2022-02-14 2023-08-17 Sana Biotechnology, Inc. Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
US20230296610A1 (en) 2022-02-15 2023-09-21 Kite Pharma, Inc. Predicting adverse events from immunotherapy
KR20240155390A (ko) 2022-02-17 2024-10-28 사나 바이오테크놀로지, 인크. 조작된 cd47 단백질 및 이의 용도
IL314801A (en) 2022-02-22 2024-10-01 Juno Therapeutics Inc Proteinase 3 (PR3) Chimeric Autoantigen Receptor T Cells and Related Methods and Uses
TW202340457A (zh) 2022-02-28 2023-10-16 美商凱特製藥公司 同種異體治療細胞
EP4486881A1 (en) 2022-03-01 2025-01-08 Celyntra Therapeutics SA Composition and methods for transgene insertion
WO2023172883A1 (en) 2022-03-07 2023-09-14 Alpine Immune Sciences, Inc. Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses
CN119156403A (zh) 2022-03-08 2024-12-17 阿伦蒂斯治疗股份公司 抗紧密连接蛋白-1抗体增加t细胞可用性的用途
WO2023173057A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023173053A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
US20250101382A1 (en) 2022-03-11 2025-03-27 Sana Biotechnology, Inc. Genetically modified cells and compositions and uses thereof
WO2023173137A1 (en) 2022-03-11 2023-09-14 Yale University Compositions and methods for efficient and stable genetic modification of eukaryotic cells
CA3253296A1 (en) 2022-03-17 2023-09-21 Gilead Sciences, Inc. Zinc Finger Degradation Agents of the Ikaros Family and Their Uses
US20250195573A1 (en) 2022-03-18 2025-06-19 The Regents Of The University Of Colorado, A Body Corporate Genetically engineered t-cell co-receptors and methods of use thereof
AU2023240346A1 (en) 2022-03-24 2024-09-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
JP2025510795A (ja) 2022-03-24 2025-04-15 アンスティテュ・クリー 神経膠芽腫における腫瘍転位因子由来のネオ抗原ペプチドを標的化する免疫療法
GB202204386D0 (en) 2022-03-28 2022-05-11 Cambridge Entpr Ltd Engineered immune cell platform
US20250222027A1 (en) 2022-04-01 2025-07-10 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
WO2023196921A1 (en) 2022-04-06 2023-10-12 The Regents Of The University Of Colorado, A Body Corporate Granzyme expressing t cells and methods of use
WO2023196933A1 (en) 2022-04-06 2023-10-12 The Regents Of The University Of Colorado, A Body Corporate Chimeric antigen receptor t cells and methods of use thereof
WO2023205719A1 (en) 2022-04-21 2023-10-26 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2023211889A1 (en) 2022-04-25 2023-11-02 Ikena Oncology, Inc. Polymorphic compounds and uses thereof
EP4514382A1 (en) 2022-04-28 2025-03-05 Musc Foundation for Research Development Chimeric antigen receptor modified regulatory t cells for treating cancer
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
WO2023213969A1 (en) 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
US20250161360A1 (en) 2022-05-10 2025-05-22 Yale University Compositions and methods of synthetic ctla-4 tails for reprogramming of car-t cells and enhancement of anti-tumor efficacy
US20250295771A1 (en) 2022-05-11 2025-09-25 Celgene Corporation Methods and uses related to t cell therapy and production of same
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
EP4279085A1 (en) 2022-05-20 2023-11-22 Mnemo Therapeutics Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease
IL316768A (en) 2022-05-25 2025-01-01 Ikena Oncology Inc MEK inhibitors and their uses
EP4532695A1 (en) 2022-05-25 2025-04-09 Celgene Corporation Methods of manufacturing t cell therapies
WO2023230548A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Method for predicting response to a t cell therapy
WO2023230276A1 (en) 2022-05-27 2023-11-30 Kite Pharma, Inc. Compositions and methods for preparing engineered lymphocytes for cell therapy
CA3253031A1 (en) 2022-05-27 2023-11-30 Kite Pharma, Inc. NON-VIRAL ADMINISTRATION OF CELL THERAPY CONSTRUCTIONS
AU2023282907A1 (en) 2022-06-09 2024-11-14 Kite Pharma, Inc. Methods of preparing lymphocytes for cell therapy
WO2023239940A1 (en) 2022-06-10 2023-12-14 Research Development Foundation Engineered fcriib selective igg1 fc variants and uses thereof
WO2023242343A1 (en) 2022-06-15 2023-12-21 Immunoscape Pte. Ltd. Human t cell receptors specific for antigenic peptides derived from mitogen-activated protein kinase 8 interacting protein 2 (mapk8ip2), epstein-barr virus or human endogenous retrovirus, and uses thereof
EP4543923A1 (en) 2022-06-22 2025-04-30 Juno Therapeutics, Inc. Treatment methods for second line therapy of cd19-targeted car t cells
US20250382640A1 (en) 2022-06-29 2025-12-18 Juno Therapeutics, Inc. Lipid nanoparticles for delivery of nucleic acids
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
CN120051297A (zh) 2022-06-30 2025-05-27 因达普塔治疗公司 工程化自然杀伤(nk)细胞与抗体疗法的组合及相关方法
US20240116928A1 (en) 2022-07-01 2024-04-11 Gilead Sciences, Inc. Cd73 compounds
WO2024026377A1 (en) 2022-07-27 2024-02-01 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
AU2023314413A1 (en) 2022-07-28 2025-02-13 Lentigen Technology, Inc. Chimeric antigen receptor therapies for treating solid tumors
IL318575A (en) 2022-08-02 2025-03-01 Liminal Biosciences Ltd HETEROARYL CARBOXAMIDE AND GPR84-RELATED ANTAGONISTS AND USES THEREOF
US20260041767A1 (en) 2022-08-02 2026-02-12 National University Corporation Hokkaido University Methods of improving cellular therapy with organelle complexes
JP2025527247A (ja) 2022-08-02 2025-08-20 リミナル・バイオサイエンシーズ・リミテッド アリール－トリアゾリル及び関連するｇｐｒ８４アンタゴニストならびにそれらの使用
CN120051456A (zh) 2022-08-02 2025-05-27 里米诺生物科学有限公司 取代的吡啶酮gpr84拮抗剂及其用途
JP2025526690A (ja) 2022-08-10 2025-08-15 武田薬品工業株式会社 免疫原性が低い改変細胞
US20260053924A1 (en) 2022-08-19 2026-02-26 Sotio Biotech Inc. Genetically engineered immune cells with chimeric receptor polypeptides in combination with multiple trans metabolism molecules and therapeutic uses thereof
WO2024040207A1 (en) 2022-08-19 2024-02-22 Sotio Biotech Inc. Genetically engineered natural killer (nk) cells with chimeric receptor polypeptides in combination with trans metabolism molecules and therapeutic uses thereof
CA3264572A1 (en) 2022-08-26 2024-02-29 Juno Therapeutics, Inc. DELTA-TYPE CHIMERICAL ANTIBODIES AND ANTIGENIC RECEPTORS (DLL3)
US20240091261A1 (en) 2022-08-26 2024-03-21 Kite Pharma, Inc. Immune cell function
CN120152717A (zh) 2022-09-08 2025-06-13 朱诺治疗学股份有限公司 T细胞疗法和连续或间歇dgk抑制剂给药的组合
EP4587047A1 (en) 2022-09-15 2025-07-23 Novartis AG Treatment of autoimmune disorders using chimeric antigen receptor therapy
CN120239746A (zh) 2022-09-19 2025-07-01 图恩疗法股份有限公司 用于调节t细胞功能的组合物、系统和方法
CN116063560A (zh) * 2022-09-21 2023-05-05 东莞市东南部中心医院 一种sh Blimp-1 CAR-T细胞的构建及应用
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
WO2024064824A2 (en) 2022-09-21 2024-03-28 Yale University Compositions and methods for identification of membrane targets for enhancement of nk cell therapy
WO2024062138A1 (en) 2022-09-23 2024-03-28 Mnemo Therapeutics Immune cells comprising a modified suv39h1 gene
EP4593871A1 (en) 2022-09-30 2025-08-06 Caribou Biosciences, Inc. Anti-ror1 chimeric antigen receptors (cars), car-nk cells and related methods
WO2024077256A1 (en) 2022-10-07 2024-04-11 The General Hospital Corporation Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
WO2024081820A1 (en) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
US20240226210A9 (en) * 2022-10-24 2024-07-11 Broaden Bioscience And Technology Corp Oncolytic virus combined with car t cells for anti-tumor therapy
CN120112650A (zh) 2022-10-26 2025-06-06 诺华股份有限公司 慢病毒配制品
WO2024092227A1 (en) 2022-10-28 2024-05-02 Kite Pharma, Inc. Factors for optimizing immunotherapy
WO2024091669A1 (en) 2022-10-28 2024-05-02 Ginkgo Bioworks, Inc. Chimeric antigen receptors comprising an intracellular domain pair
KR20250097844A (ko) 2022-10-28 2025-06-30 카이트 파마 인코포레이티드 면역요법의 효능 향상 및 지속적인 반응
CN120051287A (zh) 2022-10-28 2025-05-27 凯德药业股份有限公司 工程化淋巴细胞的加速施用
WO2024097315A2 (en) 2022-11-02 2024-05-10 Sana Biotechnology, Inc. Cell therapy products and methods for producing same
WO2024097905A1 (en) 2022-11-02 2024-05-10 Celgene Corporation Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
WO2024098024A1 (en) 2022-11-04 2024-05-10 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
EP4615960A1 (en) 2022-11-09 2025-09-17 C3S2 GmbH Methods for manufacturing engineered immune cells
WO2024102948A1 (en) 2022-11-11 2024-05-16 Celgene Corporation Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
EP4584283A1 (en) 2022-11-14 2025-07-16 Caribou Biosciences, Inc. Anti-cll-1 chimeric antigen receptors, engineered cells and related methods
CN120548323A (zh) 2022-11-18 2025-08-26 首尔国立大学校产学协力团 利用ctla-4变体及嵌合抗原受体的双基因转导免疫细胞及其用途
US20240208961A1 (en) 2022-11-22 2024-06-27 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
TW202440623A (zh) 2022-11-28 2024-10-16 美商艾洛基因醫療公司 靶向密連蛋白１８﹒２之嵌合抗原受體及結合劑以及其用途
KR20250114116A (ko) 2022-12-01 2025-07-28 제너레이션 바이오 컴퍼니 세포 표적화를 위한 스텔스 지질 나노입자 조성물
WO2024124044A1 (en) 2022-12-07 2024-06-13 The Brigham And Women’S Hospital, Inc. Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
CN121100267A (zh) 2022-12-09 2025-12-09 朱诺治疗学股份有限公司 使用全息成像预测细胞表型的机器学习方法
CN120712102A (zh) 2022-12-13 2025-09-26 朱诺治疗学股份有限公司 对baff-r和cd19具特异性的嵌合抗原受体及其方法和用途
EP4638436A1 (en) 2022-12-22 2025-10-29 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2024151541A1 (en) 2023-01-09 2024-07-18 Sana Biotechnology, Inc. Type-1 diabetes autoimmune mouse
WO2024155821A1 (en) 2023-01-18 2024-07-25 Yale University Chimeric antigen receptors (car) with intrinsically disordered regions and methods of use thereof
CN121002052A (zh) 2023-02-03 2025-11-21 C3S2 有限公司 用于非病毒生产工程化免疫细胞的方法
WO2024178128A1 (en) * 2023-02-22 2024-08-29 Elysion Therapeutics, Inc. Lysis sensing receptors and uses thereof
WO2024178397A2 (en) 2023-02-24 2024-08-29 Elevatebio Technologies, Inc. Modified immune effector cells and methods of use
KR20260005874A (ko) 2023-02-28 2026-01-12 주노 쎄러퓨티크스 인코퍼레이티드 전신 자가면역 질환을 치료하기 위한 세포 요법
WO2024182539A1 (en) 2023-02-28 2024-09-06 Lyell Immunopharma, Inc. Methods of culturing reprogrammed cells
KR20250158048A (ko) 2023-03-03 2025-11-05 아스널 바이오사이언시스, 인크. Psma 및 ca9을 표적으로 하는 시스템
AU2024233069A1 (en) 2023-03-09 2025-09-11 Kite Pharma, Inc. Antigen binding molecules and methods of use
PE20252678A1 (es) 2023-03-13 2025-11-24 Arsenal Biosciences Inc Activadores de vias sinteticas
KR20250162836A (ko) 2023-03-17 2025-11-19 카이트 파마 인코포레이티드 종양 미세환경이 면역요법의 효능에 미치는 영향
CN121605309A (zh) 2023-03-23 2026-03-03 阿伦蒂斯治疗股份公司 使用抗紧密连接蛋白-1抗体的癌症治疗的生物标志物
WO2024206155A1 (en) 2023-03-24 2024-10-03 Cornell University Utilizing t cells derived from tumor draining lymph nodes for chimeric antigen receptor (car) t cell therapy for the treatment of cancer
CA3278900A1 (en) 2023-03-31 2024-10-03 AbelZeta Inc. BISPECIFIC CHIMERIC ANTIGENIC RECEPTORS TARGETING CD20 AND BCMA
WO2024211852A1 (en) * 2023-04-07 2024-10-10 Fate Therapeutics, Inc. Ipsc-derived nk cell for lymphoma treatment
KR20250169609A (ko) 2023-04-07 2025-12-03 리제너론 파마슈티칼스 인코포레이티드 림포톡신 β 수용체 작용제를 이용한 암 치료 방법
CN120882725A (zh) 2023-04-11 2025-10-31 吉利德科学公司 Kras调节化合物
EP4694916A1 (en) 2023-04-14 2026-02-18 SOTIO Biotech Inc. Engineered immune cells for treating cancer in combination with il-2/il-15 receptor ?? agonists
WO2024215987A1 (en) 2023-04-14 2024-10-17 Sotio Biotech Inc. IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES
WO2024220597A2 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Digital droplet based assay for detecting replication competent lentiviral vector
EP4698665A1 (en) 2023-04-18 2026-02-25 Sana Biotechnology, Inc. Engineered protein g fusogens and related lipid particles and methods thereof
KR20250169631A (ko) 2023-04-18 2025-12-03 주노 쎄러퓨티크스 인코퍼레이티드 치료 세포 조성물의 효력을 평가하기 위한 세포독성 검정
EP4698666A1 (en) 2023-04-18 2026-02-25 Sana Biotechnology, Inc. Universal protein g fusogens and adapter systems thereof and related lipid particles and uses
WO2024220598A2 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Lentiviral vectors with two or more genomes
WO2024220619A1 (en) 2023-04-21 2024-10-24 Kite Pharma, Inc. Allogenic therapeutic cells with reduced risk of immune rejection
WO2024220917A1 (en) 2023-04-21 2024-10-24 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
CN121038806A (zh) 2023-04-25 2025-11-28 阿森纳生物科学公司 用于转录调控的新颖受体
WO2024226829A2 (en) 2023-04-26 2024-10-31 Yale University Enpp3-binding molecules, compositions formed therefrom, and methods of use thereof for the treatment of cancer
WO2024226858A1 (en) 2023-04-26 2024-10-31 Juno Therapeutics, Inc. Methods for viral vector manufacturing
TW202506996A (zh) 2023-04-27 2025-02-16 日商武田藥品工業股份有限公司 擴增ｃｄ５６＋／ｃｄ３－細胞之方法
EP4703374A1 (en) 2023-04-28 2026-03-04 Shenzhen Shenxin Biotechnology Co., Ltd. Modified delivery vector and use thereof
WO2024229302A1 (en) 2023-05-03 2024-11-07 Sana Biotechnology, Inc. Methods of dosing and administration of engineered islet cells
AU2024267555A1 (en) 2023-05-11 2025-11-20 Alaya.Bio Inc. Extracellular vesicles for the delivery of payloads to eukaryotic cells
EP4713352A1 (en) 2023-05-15 2026-03-25 Yale University Chimeric antigen receptor compositions, car-mast cells formed therefrom, and methods of use thereof
EP4713464A1 (en) * 2023-05-17 2026-03-25 Mayo Foundation for Medical Education and Research Materials and methods for increasing immune responses within a mammal
WO2024236547A1 (en) 2023-05-18 2024-11-21 Inceptor Bio, Llc Modified phagocytic cells expressing chimeric antigen receptors comprising a herpes virus entry mediator (hvem) co-stimulatory domain and uses thereof
EP4714977A1 (en) 2023-05-19 2026-03-25 Seoul National University R&DB Foundation Use of anti-cd3 antibody for selectively depleting activated t cells
CN121604968A (zh) 2023-05-22 2026-03-03 萨那生物科技公司 递送胰岛细胞的方法及相关方法
CN121464348A (zh) 2023-05-23 2026-02-03 朱诺治疗学股份有限公司 T细胞的激活标记物和评估t细胞激活的方法
CN120981456A (zh) 2023-05-24 2025-11-18 金橘生物科技公司 杂环化合物及其用途
WO2024243514A1 (en) * 2023-05-25 2024-11-28 Trustees Of Dartmouth College Leveraging photothermal heating for surface processing of active agents
CN121335919A (zh) 2023-05-25 2026-01-13 瑞泽恩制药公司 结合呈递的hpv16、mart1、cmv、ebv或流感肽的t细胞受体
US12531162B1 (en) * 2023-05-31 2026-01-20 Northeastern University Multi-dimensional phenotypic space for genotype to phenotype mapping and intelligent design of cancer drug therapies using a deep learning net
EP4720316A2 (en) 2023-06-14 2026-04-08 Arsenal Biosciences, Inc. Non-viral cell engineering
IL321486A (en) 2023-06-23 2025-08-01 Kymera Therapeutics Inc Iraqi joints and their uses
CN121712794A (zh) 2023-06-29 2026-03-20 迪斯派奇生物治疗公司 合成细胞因子受体
US20250042922A1 (en) 2023-06-30 2025-02-06 Gilead Sciences, Inc. Kras modulating compounds
US12319747B2 (en) 2023-07-03 2025-06-03 Medicovestor, Inc. Methods of using anti-SP17 immunotherapeutics
WO2025014896A1 (en) 2023-07-07 2025-01-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Humanized 40h3 antibody
US20250066328A1 (en) 2023-07-26 2025-02-27 Gilead Sciences, Inc. Parp7 inhibitors
AU2024297978A1 (en) 2023-07-26 2026-02-05 Gilead Sciences, Inc. Parp7 inhibitors
WO2025029840A1 (en) 2023-07-31 2025-02-06 Tune Therapeutics, Inc. Compositions and methods for multiplexed activation and repression of t cell gene expression
CN121909284A (zh) 2023-07-31 2026-04-21 图恩疗法股份有限公司 用于调节il-2基因表达的组合物和方法
WO2025030010A1 (en) 2023-08-01 2025-02-06 Vor Biopharma Inc. Compositions comprising genetically engineered hematopoietic stem cells and methods of use thereof
WO2025038750A2 (en) 2023-08-14 2025-02-20 President And Fellows Of Harvard College Methods and compositions for treating cancer
AU2024328949A1 (en) 2023-08-23 2026-03-12 Sana Biotechnology, Inc. Modified cd47 proteins and their uses
WO2025051339A1 (en) 2023-09-05 2025-03-13 Tiber Biotech Srl SINGLE-CHAIN VARIABLE FRAGMENT AND MOLECULES DERIVING THEREFROM THAT BIND FRAGMENT TRVB5-1 OF THE β CHAIN OF HUMAN T-CELL RECEPTOR
WO2025054202A1 (en) 2023-09-05 2025-03-13 Sana Biotechnology, Inc. Method of screening a sample comprising a transgene with a unique barcode
EP4520334A1 (en) 2023-09-07 2025-03-12 Mnemo Therapeutics Methods and compositions for improving immune response
WO2025052001A1 (en) 2023-09-07 2025-03-13 Mnemo Therapeutics Methods and compositions for improving immune response
WO2025054347A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025059533A1 (en) 2023-09-13 2025-03-20 The Broad Institute, Inc. Crispr enzymes and systems
WO2025059414A1 (en) * 2023-09-15 2025-03-20 Singular Immune, Inc. Composition and method of use recombinant fusion protein to generate car-immune cells
CN121889164A (zh) 2023-09-26 2026-04-17 阿斯利康(瑞典)有限公司 包含抗steap2嵌合抗原受体t细胞的治疗组合
WO2025072571A1 (en) 2023-09-27 2025-04-03 Cellanome, Inc. Cell culture within microfluidic structures
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025083398A1 (en) 2023-10-16 2025-04-24 Cell Therapy Catapult Limited Co-culture
WO2025082603A1 (en) 2023-10-18 2025-04-24 Institut Curie Engineered immune cells overexpressing cd74 molecule
US12364777B2 (en) 2023-10-20 2025-07-22 Medicovestor, Inc. Homodimeric antibodies for use in treating cancers and methods of use
WO2025090985A1 (en) * 2023-10-27 2025-05-01 Duke University Compositions comprising chimeric antigen receptors targeting citrullinated vimentin and methods of use thereof
WO2025096305A1 (en) * 2023-10-30 2025-05-08 The Cleveland Clinic Foundation Chimeric antigen receptors with a tip co-stimulatory domain
AU2024369584A1 (en) 2023-10-30 2026-04-09 Allogene Therapeutics, Inc. Cells expressing anti-cd19 chimeric antigen receptors and methods of use thereof
WO2025096419A1 (en) 2023-10-31 2025-05-08 Lyell Immunopharma, Inc. T cells comprising a chimeric antigen receptor targeting transforming growth factor beta and a t cell receptor targeting a tumor antigen, and use thereof
WO2025096517A1 (en) 2023-11-01 2025-05-08 Kite Pharma, Inc. Factors for optimizing immunotherapy efficacy
WO2025097055A2 (en) 2023-11-02 2025-05-08 The Broad Institute, Inc. Compositions and methods of use of t cells in immunotherapy
WO2025096975A1 (en) 2023-11-02 2025-05-08 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods of enhancing immune cell therapies by runx2 modulation
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US12562256B2 (en) * 2023-11-07 2026-02-24 New York University Systems, methods and computer-accessible medium for identifying target pairs for CAR-T therapy
WO2025117544A1 (en) 2023-11-29 2025-06-05 The Broad Institute, Inc. Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
WO2025128434A1 (en) 2023-12-14 2025-06-19 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for the treatment of ven/aza resistant acute myeloid leukemia
WO2025129120A2 (en) 2023-12-15 2025-06-19 Port Therapeutics, Inc. Use of thermal bioswitches for treating autoimmune diseases
TW202526007A (zh) 2023-12-21 2025-07-01 美商凱特製藥公司 用於上調低密度脂蛋白受體（ｌｄｌ－ｒ）表現之系統及方法
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
US12600795B2 (en) 2023-12-26 2026-04-14 Medicovestor, Inc. Oligomeric IgG for immunotherapeutics and diagnostics
US12116410B1 (en) 2023-12-26 2024-10-15 Medicovestor, Inc. Methods of manufacturing dimeric antibodies
WO2025147545A1 (en) 2024-01-03 2025-07-10 Juno Therapeutics, Inc. Lipid nanoparticles for delivery of nucleic acids and related methods and uses
WO2025146286A1 (en) 2024-01-04 2025-07-10 Immunoscape Pte. Ltd. Human t cell receptors and uses thereof
WO2025151838A1 (en) 2024-01-12 2025-07-17 Sana Biotechnology, Inc. Safety switches to control in vitro and in vivo proliferation of cell therapy products
WO2025151923A1 (en) * 2024-01-17 2025-07-24 Newsouth Innovations Pty Limited Apparatus for production of engineered cells
WO2025158400A1 (en) 2024-01-24 2025-07-31 Yale University Compositions and methods of natural killer cell hyperboosts for enhancement of nk cell therapy
WO2025163107A1 (en) 2024-02-01 2025-08-07 Institut Gustave Roussy Immune cells defective for znf217 and uses thereof
US12240900B1 (en) 2024-02-02 2025-03-04 Medicovestor, Inc. Nucleic acids, vectors, and cells that encode antibodies and other proteins that bind folate receptor alpha
US12378314B1 (en) 2024-02-02 2025-08-05 Medicovestor, Inc. Proteins that bind folate receptor alpha including fully-human antibodies
US12258396B1 (en) 2024-02-02 2025-03-25 Medicovestor, Inc. Methods of using immunotherapeutics that bind folate receptor alpha
US20250297219A1 (en) 2024-02-08 2025-09-25 Kite Pharma, Inc. Methods for generating engineered lymphocytes with enriched t memory stem cells
US20250262300A1 (en) 2024-02-16 2025-08-21 Kite Pharma, Inc. Systems, methods, and kits for generating and administering engineered t cells and cd38 targeting compounds as a combination therapy
WO2025184421A1 (en) 2024-02-28 2025-09-04 Juno Therapeutics, Inc. Chimeric antigen receptors and antibodies specific for delta-like ligand 3 (dll3) and related methods
WO2025181329A1 (en) 2024-03-01 2025-09-04 Immunoscape Pte. Ltd. Human t cell receptors and uses thereof
WO2025188561A1 (en) 2024-03-04 2025-09-12 Kite Pharma, Inc. Predictive markers for immunotherapy
WO2025191300A1 (en) 2024-03-12 2025-09-18 Novartis Ag Rapcabtagene autoleucel for use in treating systemic lupus erythematosus
US20250361297A1 (en) 2024-03-12 2025-11-27 Adaptam Therapeutics, S.L. Anti- siglec-15 binding molecules and methods of use
WO2025191531A1 (en) 2024-03-15 2025-09-18 Takeda Pharmaceutical Company Limited Cd19 targeting car nk cells in treating systemic lupus erythematosus and lupus nephritis
WO2025199338A1 (en) 2024-03-20 2025-09-25 Arsenal Biosciences, Inc. Systems targeting slc34a2 and tmprss4 and methods of use thereof
WO2025199346A1 (en) 2024-03-20 2025-09-25 Arsenal Biosciences, Inc. Antigen binding proteins that bind tmprss4 and methods of use thereof
EP4624494A1 (en) 2024-03-29 2025-10-01 Institut Curie Her2 single domain antibody and uses thereof
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025231376A1 (en) 2024-05-03 2025-11-06 Kite Pharma, Inc. Chimeric receptors binding to cll-1 and methods of use thereof
US20250345431A1 (en) 2024-05-10 2025-11-13 Juno Therapeutics, Inc. Genetically engineered t cells expressing a cd19 chimeric antigen receptor (car) and uses thereof for allogeneic cell therapy
US20250376484A1 (en) 2024-05-21 2025-12-11 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
NL2037811B1 (en) 2024-05-29 2025-12-12 Univ Oslo Treatment for Cancer
WO2025250819A1 (en) 2024-05-31 2025-12-04 Kite Pharma, Inc. Tricistronic constructs for anti-gpc3 car
WO2025255030A1 (en) 2024-06-03 2025-12-11 Cornell University Interferon gamma responsive chimeric t cell costimulatory receptor
NL2037929B1 (en) 2024-06-11 2026-01-12 Prinses Maxima Centrum Voor Kinderoncologie B V Brain Organoid
WO2025259578A1 (en) 2024-06-11 2025-12-18 Kite Pharma, Inc. Methods for generating engineered lymphocytes
WO2026006682A1 (en) 2024-06-27 2026-01-02 Lentigen Technology, Inc. Chimeric antigen receptor therapies for treating cancer with il7fc armored car-t cells
WO2026006767A1 (en) 2024-06-28 2026-01-02 Dispatch Biotherapeutics, Inc. Tethered il-9/il-9r and related engineered cells and methods
WO2026015450A1 (en) 2024-07-06 2026-01-15 Tr1X, Inc. Cd4+ t cells expressing il-10 and chimeric antigen receptors and uses thereof
US20260009001A1 (en) 2024-07-08 2026-01-08 Kite Pharma, Inc. Systems and methods for applying mechanical force to living cells to generate a phenotypic response
WO2026020055A2 (en) 2024-07-18 2026-01-22 Juno Therapeutics, Inc. Methods for assessing exosomes in a cell composition and related uses
WO2026025092A1 (en) 2024-07-26 2026-01-29 Juno Therapeutics, Inc. Synthetic promoters for t cell expression
WO2026039365A1 (en) 2024-08-12 2026-02-19 Gilead Sciences, Inc. Kras modulating compounds
US20260108629A1 (en) 2024-08-14 2026-04-23 Kite Pharma, Inc. Vectors for production of therapeutic constructs
WO2026050426A2 (en) 2024-08-28 2026-03-05 Juno Therapeutics, Inc. Cd19-directed chimeric antigen receptor cell therapy for treating autoimmune and neurological diseases
WO2026047626A1 (en) 2024-08-30 2026-03-05 Inceptor Bio, Llc Compositions and methods involving immune cells engineered for binding bispecific antibodies for use in cell therapy
WO2026055342A1 (en) 2024-09-04 2026-03-12 Arsenal Biosciences, Inc. Synthetic pathway activators
WO2026062222A1 (en) 2024-09-20 2026-03-26 Institut Curie Novel protein isoforms and uses
WO2026069206A1 (en) 2024-09-25 2026-04-02 Takeda Pharmaceutical Company Limited Hypoimmunogenic modified gamma delta t cells
WO2026069200A1 (en) 2024-09-25 2026-04-02 Novartis Ag Treatment of neuroimmune diseases using a population of cd19 car-expressing cells

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
US4882282A (en) * 1985-08-16 1989-11-21 Immunex Corporation DNA sequences encoding bovine interleukin-2
US5906936A (en) 1988-05-04 1999-05-25 Yeda Research And Development Co. Ltd. Endowing lymphocytes with antibody specificity
US6303121B1 (en) 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
DE69123241T2 (de) 1990-12-14 1997-04-17 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
NZ241855A (en) 1991-03-07 1994-04-27 Gen Hospital Corp Use of therapeutic cells to obtain cellular response to infection, tumours or autoimmune-generated cells, cells with chimaeric receptors (with binding component and destruction signal), dna encoding the receptor, vectors and antibodies to receptor
US7049136B2 (en) 1991-03-07 2006-05-23 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
US6004811A (en) 1991-03-07 1999-12-21 The Massachussetts General Hospital Redirection of cellular immunity by protein tyrosine kinase chimeras
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
US8211422B2 (en) 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US7211259B1 (en) 1993-05-07 2007-05-01 Immunex Corporation 4-1BB polypeptides and DNA encoding 4-1BB polypeptides
ES2341631T3 (es) * 1993-09-16 2010-06-23 Indiana University Research And Technology Corporation Receptor humano h4-1bb.
AU694222B2 (en) 1994-05-02 1998-07-16 Bernd Groner Bifunctional protein, preparation and use
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
US6103521A (en) 1995-02-06 2000-08-15 Cell Genesys, Inc. Multispecific chimeric receptors
AU708339B2 (en) 1995-02-24 1999-08-05 General Hospital Corporation, The Redirection of cellular immunity by receptor chimeras
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
GB9526131D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
US5874240A (en) 1996-03-15 1999-02-23 Human Genome Sciences, Inc. Human 4-1BB receptor splicing variant
EP0937095A4 (en) 1996-10-25 1999-12-22 Cell Genesys Inc TARGETED CYTOLYSIS OF CANCER CELLS
GB9713473D0 (en) 1997-06-25 1997-09-03 Celltech Therapeutics Ltd Biological products
US20030060444A1 (en) 1997-06-25 2003-03-27 Celltech Therapeutics, Ltd. Cell activation process and reagents therefor
JP2001521008A (ja) * 1997-10-28 2001-11-06 ユニバーシティ・オブ・ブリティッシュ・コロンビア 哺乳類の中枢神経系ミエリンを一過的に変えて神経再生を促進する免疫組成物及びその使用方法
GB9722779D0 (en) * 1997-10-28 1997-12-24 Isis Innovation Human CD8 as an inhibitor of the cellular immune system
GB9809658D0 (en) 1998-05-06 1998-07-01 Celltech Therapeutics Ltd Biological products
JP2002524081A (ja) 1998-09-04 2002-08-06 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ 前立腺−特異的膜抗原に特異的な融合受容体およびその使用
WO2000023573A2 (en) 1998-10-20 2000-04-27 City Of Hope Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies
US7052906B1 (en) 1999-04-16 2006-05-30 Celltech R & D Limited Synthetic transmembrane components
CA2386270A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB9925848D0 (en) 1999-11-01 1999-12-29 Celltech Therapeutics Ltd Biological products
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
CA2391129A1 (en) * 1999-11-10 2001-05-17 The Uab Research Foundation Lentiviral vector transduction of hematopoietic stem cells
CA2406864A1 (en) 2000-02-24 2001-08-30 Life Technologies Corporation Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
IL136511A0 (en) * 2000-06-01 2001-06-14 Gavish Galilee Bio Appl Ltd Genetically engineered mhc molecules
AU2001275474A1 (en) 2000-06-12 2001-12-24 Akkadix Corporation Materials and methods for the control of nematodes
GB0025307D0 (en) 2000-10-16 2000-11-29 Celltech Chiroscience Ltd Biological products
AU2001297703B2 (en) * 2000-11-07 2006-10-19 City Of Hope CD19-specific redirected immune cells
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) * 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US7514537B2 (en) 2001-04-30 2009-04-07 City Of Hope Chimeric immunoreceptor useful in treating human gliomas
US20030171546A1 (en) 2001-04-30 2003-09-11 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US20030148982A1 (en) 2001-11-13 2003-08-07 Brenner Malcolm K. Bi-spcific chimeric T cells
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
US7446190B2 (en) * 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
JP3878522B2 (ja) * 2002-07-18 2007-02-07 株式会社日立製作所 ベンチュリ式燃料供給装置を備えたエンジンの空燃比制御方法及びその方法を備えた燃料制御装置
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
US7402431B2 (en) * 2004-03-01 2008-07-22 Immunovative Therapies, Ltd. T-cell therapy formulation
US8198020B2 (en) 2003-08-22 2012-06-12 Potentia Pharmaceuticals, Inc. Compositions and methods for enhancing phagocytosis or phagocyte activity
US20050113564A1 (en) * 2003-11-05 2005-05-26 St. Jude Children's Research Hospital Chimeric receptors with 4-1BB stimulatory signaling domain
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
AU2005250408B2 (en) 2004-05-27 2010-09-23 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
US7994298B2 (en) 2004-09-24 2011-08-09 Trustees Of Dartmouth College Chimeric NK receptor and methods for treating cancer
EP1827604B1 (en) 2004-12-10 2019-11-20 Peter MacCallum Cancer Institute Methods and compositions for adoptive immunotherapy
US7581948B2 (en) * 2005-12-21 2009-09-01 Johns Manville Burner apparatus and methods for making inorganic fibers
US7551486B2 (en) * 2006-05-15 2009-06-23 Apple Inc. Iterative memory cell charging based on reference cell value
US20100105136A1 (en) 2006-10-09 2010-04-29 The General Hospital Corporation Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
EP1916259A1 (en) * 2006-10-26 2008-04-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anti-glycoprotein VI SCFV fragment for treatment of thrombosis
US20080131415A1 (en) 2006-11-30 2008-06-05 Riddell Stanley R Adoptive transfer of cd8 + t cell clones derived from central memory cells
US20080311098A1 (en) * 2007-02-14 2008-12-18 Lapointe Rejean Compounds and methods for modulating the immune response against antigens
US7448191B2 (en) * 2007-02-14 2008-11-11 Deere & Company Mower deck lift system with transport lock
CA2584494A1 (en) * 2007-03-27 2008-09-27 Jeffrey A. Medin Vector encoding therapeutic polypeptide and safety elements to clear transduced cells
CA2682527C (en) 2007-03-30 2017-07-11 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes
WO2009091826A2 (en) * 2008-01-14 2009-07-23 The Board Of Regents Of The University Of Texas System Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
WO2009097140A1 (en) 2008-01-30 2009-08-06 Memorial Sloan-Kettering Cancer Center Methods for off -the -shelf tumor immunotherapy using allogeneic t-cell precursors
US8450112B2 (en) * 2008-04-09 2013-05-28 Maxcyte, Inc. Engineering and delivery of therapeutic compositions of freshly isolated cells
EP4032552B1 (en) * 2008-08-26 2023-10-04 City of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
CN101348525B (zh) * 2008-08-28 2011-11-16 南京医科大学 抗血吸虫单克隆抗体np11-4单链抗体及其制备方法、应用
WO2010085660A2 (en) * 2009-01-23 2010-07-29 Roger Williams Hospital Viral vectors encoding multiple highly homologous non-viral polypeptides and the use of same
US8465743B2 (en) 2009-10-01 2013-06-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
EP3467101A3 (en) 2010-09-08 2019-06-19 Baylor College of Medicine Immunotherapy of brain tumor using geneticially engineered gd2-specific t cells
CN108424462A (zh) 2010-10-27 2018-08-21 贝勒医学院 使t细胞重定向针对cd70阳性恶性肿瘤的嵌合cd27受体
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
ES2791716T3 (es) 2010-12-14 2020-11-05 Univ Maryland Células T que expresan al receptor de antígeno quimérico antietiqueta universal y métodos para el tratamiento del cáncer
WO2012127464A2 (en) 2011-03-23 2012-09-27 Gavish-Galilee Bio Applications Ltd Constitutively activated t cells for use in adoptive cell therapy
KR20140033029A (ko) 2011-04-01 2014-03-17 메모리얼 슬로안-케터링 캔서 센터 에이치엘에이 에이2에 의해 제공된 더블유티1 펩타이드에 특이적인 티 세포 수용체 유사 항체
CN107164330A (zh) 2011-04-08 2017-09-15 贝勒医学院 使用嵌合细胞因子受体逆转肿瘤微环境的影响
US20130071414A1 (en) 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
US9833476B2 (en) 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
EP3692794A1 (en) 2011-09-16 2020-08-12 Baylor College of Medicine Targeting the tumor microenvironment using manipulated nkt cells
WO2013059593A1 (en) 2011-10-20 2013-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd22 chimeric antigen receptors

Also Published As

Publication number Publication date
AU2020200767B2 (en) 2021-12-23
CN110452882A (zh) 2019-11-15
JP2022002516A (ja) 2022-01-11
AU2017203087B2 (en) 2019-06-20
EP2649086A4 (en) 2014-12-31
US20160194404A1 (en) 2016-07-07
MX2013006570A (es) 2013-08-26
EP3214091B1 (en) 2018-10-03
EP3214091A1 (en) 2017-09-06
US20180258391A1 (en) 2018-09-13
US20130288368A1 (en) 2013-10-31
KR102417796B1 (ko) 2022-07-07
AU2017203087A1 (en) 2017-06-08
FR19C1006I2 (fr) 2020-03-20
JP6293194B2 (ja) 2018-03-14
US20140106449A1 (en) 2014-04-17
HRP20182202T1 (hr) 2019-03-08
US20160130355A1 (en) 2016-05-12
ZA201304470B (en) 2014-08-27
EA201390847A1 (ru) 2013-12-30
JP5947311B2 (ja) 2016-07-06
AP2013006918A0 (en) 2013-06-30
CN106220739A (zh) 2016-12-14
ECSP13012739A (es) 2013-10-31
ES2700966T3 (es) 2019-02-20
MX385933B (es) 2025-03-18
SI2649086T1 (en) 2018-01-31
JP2018029595A (ja) 2018-03-01
CR20130269A (es) 2013-09-03
US8975071B1 (en) 2015-03-10
KR20250175001A (ko) 2025-12-15
KR20210059762A (ko) 2021-05-25
PH12013501201A1 (en) 2013-07-29
CO6801633A2 (es) 2013-11-29
US9464140B2 (en) 2016-10-11
US20150050729A1 (en) 2015-02-19
HUE036872T2 (hu) 2018-08-28
JP7426361B2 (ja) 2024-02-01
JP6588060B2 (ja) 2019-10-09
US9518123B2 (en) 2016-12-13
CN107699585A (zh) 2018-02-16
BR122021026169B1 (pt) 2023-12-12
IL226694B (en) 2020-10-29
KR102062407B1 (ko) 2020-01-03
US9102761B2 (en) 2015-08-11
US9481728B2 (en) 2016-11-01
US20170283775A1 (en) 2017-10-05
TR201820015T4 (tr) 2019-01-21
AU2017225161B2 (en) 2019-11-21
HK1243082B (en) 2019-09-13
HUE042207T2 (hu) 2019-06-28
HK1253052A1 (en) 2019-06-06
NL300967I1 (nl) 2019-02-20
KR20220101745A (ko) 2022-07-19
CN108103085B (zh) 2024-10-08
JP6943933B2 (ja) 2021-10-06
CA2820681C (en) 2018-10-23
US9101584B2 (en) 2015-08-11
MX2020005143A (es) 2020-08-17
LTC2649086I2 (lt) 2020-12-28
CA2820681A1 (en) 2012-06-14
AU2017225161C1 (en) 2021-07-29
SG10201510092QA (en) 2016-01-28
CL2013001645A1 (es) 2014-02-14
JP2024056708A (ja) 2024-04-23
NO2019007I1 (no) 2019-02-15
KR20230133410A (ko) 2023-09-19
US20140370017A1 (en) 2014-12-18
PT2649086T (pt) 2017-10-19
JP2020022456A (ja) 2020-02-13
NL300967I2 (nl) 2019-08-20
LUC00104I2 (https=) 2019-12-27
US8911993B2 (en) 2014-12-16
CY1119760T1 (el) 2018-06-27
HUS1900006I1 (hu) 2019-04-29
NZ612512A (en) 2015-03-27
MA34813B1 (fr) 2014-01-02
EP2649086A1 (en) 2013-10-16
US8906682B2 (en) 2014-12-09
WO2012079000A4 (en) 2012-08-23
KR102243575B1 (ko) 2021-04-22
KR20130124521A (ko) 2013-11-14
US9540445B2 (en) 2017-01-10
US9328156B2 (en) 2016-05-03
NO2019006I1 (no) 2019-02-15
LUC00104I1 (https=) 2019-02-21
FR19C1006I1 (https=) 2019-04-05
WO2012079000A1 (en) 2012-06-14
US20130309258A1 (en) 2013-11-21
PT3214091T (pt) 2019-01-11
CN108103085A (zh) 2018-06-01
KR102243575B9 (ko) 2023-05-24
DK3214091T3 (en) 2019-01-07
LT3214091T (lt) 2018-12-10
CY2019008I1 (el) 2019-11-27
JP2014507118A (ja) 2014-03-27
AU2011338200B2 (en) 2017-02-23
CN103492406A (zh) 2014-01-01
US20150093822A1 (en) 2015-04-02
EP3305798A1 (en) 2018-04-11
AU2020200767A1 (en) 2020-02-27
HUS1900007I1 (hu) 2019-04-29
JP2018029594A (ja) 2018-03-01
US20160208012A1 (en) 2016-07-21
MX347078B (es) 2017-04-10
US20150099299A1 (en) 2015-04-09
MY191313A (en) 2022-06-15
EP3660029A1 (en) 2020-06-03
LT2649086T (lt) 2017-11-10
NI201300051A (es) 2014-01-07
KR102417796B9 (ko) 2024-03-06
DK2649086T3 (en) 2017-09-18
SG190997A1 (en) 2013-07-31
GT201300150A (es) 2014-06-10
EA027153B1 (ru) 2017-06-30
US20150118202A1 (en) 2015-04-30
KR20200014343A (ko) 2020-02-10
EP2649086B1 (en) 2017-07-19
RS58100B1 (sr) 2019-02-28
LTPA2019503I1 (lt) 2019-03-12
CN103492406B (zh) 2022-07-26
US9499629B2 (en) 2016-11-22
EA201790175A1 (ru) 2017-09-29
AU2011338200A1 (en) 2013-07-04
BR112013014265B8 (pt) 2023-12-19
CY2019007I2 (el) 2019-11-27
JP6588514B2 (ja) 2019-10-09
BR112013014265A8 (pt) 2022-03-22
BR112013014265A2 (pt) 2017-12-19
AU2022201895A1 (en) 2022-04-07
US9102760B2 (en) 2015-08-11
SI3214091T1 (sl) 2019-02-28
ES2641870T3 (es) 2017-11-14
PL2649086T3 (pl) 2018-03-30
BR122021026173B1 (pt) 2023-12-05
AU2017225161A1 (en) 2017-11-09
BR112013014265B1 (pt) 2023-05-16
AU2020200767C1 (en) 2025-04-24
PE20140178A1 (es) 2014-02-20
RS56453B1 (sr) 2018-01-31
CY2019007I1 (el) 2019-11-27
US8916381B1 (en) 2014-12-23
PL3214091T3 (pl) 2019-03-29
US20130287748A1 (en) 2013-10-31
DOP2013000128A (es) 2014-03-16
US20160159907A1 (en) 2016-06-09
LTPA2019502I1 (lt) 2019-03-12
JP2016174607A (ja) 2016-10-06
MY169644A (en) 2019-04-24
EA035484B1 (ru) 2020-06-23

Similar Documents

Publication Publication Date Title
HRP20171577T1 (hr) Uporaba t stanica modificiranih himernim receptorom za antigen za liječenje karcinoma
Ruggeri et al. Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells
Marchini et al. Overcoming barriers in oncolytic virotherapy with HDAC inhibitors and immune checkpoint blockade
US20190175649A1 (en) Combination immune therapy and cytokine control therapy for cancer treatment
JP7590737B2 (ja) ＣＤ１ａ陽性癌の治療のためのＣＡＲ Ｔ細胞
Burroughs et al. Treosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases: a prospective multicenter trial
Pogue et al. Targeting attenuated interferon-α to myeloma cells with a CD38 antibody induces potent tumor regression with reduced off-target activity
IL284985B2 (en) Combined immunotherapy and cytokine control therapy for cancer treatment
RU2015153250A (ru) Cd19-специфический химерный антигенный рецептор и его применения
Kyriakidis et al. Invasive fungal diseases in children with hematological malignancies treated with therapies that target cell surface antigens: monoclonal antibodies, immune checkpoint inhibitors and CAR T-cell therapies
JP2017528462A5 (https=)
JP2018500014A5 (https=)
HRP20150400T1 (hr) Lijeäśenje pedijatrijske akutne limfoblastiäśne leukemije
HRP20210778T1 (hr) Neutralizacija inhibitornih putova u limfocitima
Crupi et al. Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer
Al-Ani et al. Drugs for multiple sclerosis activate natural killer cells: do they protect against COVID-19 infection?
Carew et al. Oncolytic reovirus inhibits angiogenesis through induction of CXCL10/IP-10 and abrogation of HIF activity in soft tissue sarcomas
RU2017145662A (ru) Моноклональные антитела и способы их применения
Jazowiecka-Rakus et al. Myxoma virus expressing LIGHT (TNFSF14) pre-loaded into adipose-derived mesenchymal stem cells is effective treatment for murine pancreatic adenocarcinoma
WO2016120331A1 (de) Agonistische anti-cd66cd66 antikörper für die antiviralen therapie
Chong et al. Essential role of NK cells in IgG therapy for experimental autoimmune encephalomyelitis
Gammelgaard et al. Targeting two distinct epitopes on human CD73 with a bispecific antibody improves anticancer activity
US9580504B1 (en) Pidilizumab monoclonal antibody therapy following stem cell transplantation
Looi et al. Revolutionizing the treatment for nasopharyngeal cancer: the impact, challenges and strategies of stem cell and genetically engineered cell therapies
EP3765519B1 (en) Anti-cxcr4 antibody combined with activated and expanded natural killer cells for cancer immunotherapy